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Non-standard abbreviations 
 
 
apoB   apolipoprotein B 
apoC-III  apolipoprotein C-III 
apoC-III0  apolipoprotein C-III containing no neuraminic acid residues 
apoC-III1  apolipoprotein C-III containing one neuraminic acid residue 
apoC-III2  apolipoprotein C-III containing two neuraminic acid residues 
ARCL  autosomal recessive cutis laxa 
B4GalT  β-1,4-galactosyltransferase 
C6ST  chondroitin 6-sulfotransferase 
CDG   congenital disorders of glycosylation 
CGN   cis Golgi network 
CMP   cytidine 5’-monophosphate 
COG   conserved oligomeric Golgi complex 
COP   coatomer protein 
Cosmc  core 1 β3-galactosyltransferase specific molecular chaperone 
DGC   dystrophin-glycoprotein complex 
DMRV  distal myopathy with rimmed vacuoles 
Dol-P  dolichol phosphate 
DTD   diastrophic dysplasia 
DTDST  diastrophic dysplasia sulfate transporter 
ECM   extracellular matrix 
EGF   epidermal growth factor 
ER   endoplasmic reticulum 
ERGIC  endoplasmic reticulum - Golgi intermediate compartment 
FKRP  fukutin related protein 
FTC   familial tumoral calcinosis 
Fuc   fucose 
Fru   fructose 
FUCT  GDP - Fuc transporter 
FUT   fucosyltransferase 
Gal   galactose 
GalNAc  N-acetylgalactosamine  
GalNT  N-acetylgalactosyltransferase 
GDI   Rab guanine nucleotide dissociation inhibitor 
GDP   guanidine 5’-diphosphate 
Glc   glucose 
GlcA   glucuronic acid (or glucuronate) 
GlcN6ST  GlcNAc-6-O-sulfotransferase 
GlcN   glucosamine 
GlcNAc  N-acetylglucosamine 
 
GNE/MNK  UDP-GlcNAc 2 epimerase/N-acetylmannosamine kinase 
GU   glucose units 
HIBM  hereditary inclusion body myopathy 
hLys   hydroxylysine 
HUS   hemolytic uremic syndrome 
IdoA   iduronate 
IEF   isoelectric focusing 
LARGE  N-acetylglucosaminyl-like protein 
Le   Lewis antigen 
LLO   lipid-linked oligosaccharide 
Lys   lysine 
Man   mannose 
ManNAc  N-acetylmannosamine 
MEB   muscle eye brain disease 
NeuAc  N-acetylneuraminic acid/sialic acid 
NP-HPLC  normal phase high-pressure liquid chromatography 
NST   nucleotide sugar transporter 
OTase  oligosaccharyltransferase 
PAPSS2  3’-phophoadenosine-5’-phosphosulfate synthase 2 
pp-GalNAc-T UDP-GalNAc: polypeptide N-acetylgalactosaminyl transferase 
sLe   sialyl Lewis antigen 
SNARE  soluble N-ethylmaleimide-sensitive fusion attachment protein receptor 
ST3Gal  CMP-N-acetylneuraminate-β-galactoside-α-2,3-sialyltransferase 
ST6GalNAc  CMP-N-acetylneuraminate-α-N-acetylgalactosamine-α-2,6-sialyltransferase 
TBG   thyroxine-binding globulin 
TEAA  triethylammonium acetate 
TGN   trans Golgi network 
TIEF   transferrin isoelectric focusing 
t-SNARE  tethering-SNARE 
TSR   thrombospondin type 1 repeats 
UDP   uridine 5’-diphosphate 
VLDL  very low density lipoprotein 
v-SNARE  vesicle-SNARE 
WWS  Walker Warburg syndrome 
Xyl   xylose 
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Introduction 
 
 
Glycosylation is the enzymatic addition of carbohydrates to proteins and lipids. This thesis will 
focus on protein glycosylation. Glycans are usually covalently linked to eCither the amide group 
of an asparagine residue (N-glycosylation, Figure 1A), to the hydroxy group of a serine, threonine 
or lysine residue (O-glycosylation, Figure 1B) or via a C-C bond to a tryptophan residue (C-
glycosylation, Figure 1C). The general introduction mainly describes the N-glycosylation process, 
whereas the O-glycosylation process is described in Chapter 3 of this thesis.  
 
 
 
 
 
 
 
History 
 
 
Figure 1. 
Protein – glycan linkages. A) N-linked glycan bond; an N-acetylglucosamine residue is attached to a nitrogen residue of 
asparagine. B) Example of an O-glycan bond; an N-acetylgalactosamine residue is attached to the oxygen residue of serine. 
C) C-glycan bond; a carbon residue from mannose is attached to a carbon residue of tryptophan. 
In 1984, Jaeken et al. were the first to describe a new syndrome in identical twin sisters with a 
deficient sialylation of plasma and cerebrospinal fluid transferrin1. Thirteen years later, a 
phosphomannomutase deficiency was found as the basis of the most frequent type of inborn 
error in the metabolism of protein N-glycosylation, named CDG-Ia (Congenital Disorders of 
Glycosylation type Ia2). Since then, several defects have been found in the biosynthesis of N-
glycans. The diseases in this pathway have collectively been referred to as CDG. At present, 18 
different CDG subtypes are known: CDG-Ia through -Il and CDG-IIa through –IIf (see Table 1 
and Figure 2)3,4. Furthermore, numerous congenital disorders in the O-glycosylation have been 
described, as summarized in Chapter 3. Most of these have not been included in the CDG 
nomenclature system. Examples are muscle-eye-brain disease5, familial tumoral calcinosis6 and 
the progeroid variant of Ehlers Danlos syndrome7 in which the biosynthesis of respectively O-
mannosylglycans, mucin-type O-glycans and glycosaminoglycans is deficient.  
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The general biosynthesis of protein-linked glycans 
 
 
The biosynthesis of protein-linked glycans can be subdivided into 4 stages (Figure 2). In the first 
stage, the biosynthesis of nucleotide sugars occurs in the cytoplasm of the cell. 
Monosaccharides used for the biosynthesis of nucleotide sugars derive from dietary sources and 
salvage pathways. Series of phosphorylation, epimerization, and acetylation reactions convert 
the monosaccharides into various high-energy nucleotide sugar donors. Specific nucleotides are 
used for each monosaccharide required in glycan biosynthesis: Uridine 5’-diphosphate (UDP) is 
linked to the monosaccharides galactose (UDP-Gal), glucose (UDP-Glc), N-acetylgalactosamine 
(UDP-GalNAc), N-acetylglucosamine (UDP-GlcNAc) and xylose (UDP-Xyl); guanidine 
5’diphosphate (GDP) is linked to mannose (GDP-Man) and fucose (GDP-Fuc) and cytidine 5’-
monophosphate (CMP) is linked to neuraminic acid (CMP-NeuAc). As observed in CDG-Ia and 
CDG-Ib, aberrant glycosylation can result from an insufficient availability of a specific nucleotide 
sugar.  
 
Table 1: Overview of the different CDG subtypes and their gene defects 
CDG type Gene, Protein EC Nr on Figure 2 
Ia PMM2, Phosphomannomutase 5.4.2.8 1 
Ib PMI, Phosphomannose isomerase 5.3.1.8 2 
Ic ALG6, Glucosyltransferase I 2.4.1.- 3 
Id ALG3, Mannosyltransferase VI 2.4.1.130 4 
Ie DPM1, Dol-P-Man synthase 2.4.1.83 5 
If LEC35, Dol-P-Man utilization protein - 6 
Ig ALG12, Mannosyltransferase VIII 2.4.1.130 7 
Ih ALG8, Glucosyltransferase II 2.4.1.- 8 
Ii ALG2, Mannosyltransferase II 2.4.1.132 9 
Ij DPAGT1, GlcNActransferase I 2.7.8.15 10 
Ik ALG1, Mannosyltransferase I 2.4.1.142 11 
Il ALG9, Mannosyltransferase VII 2.4.1.130 12 
IIa MGAT2, GlcNActransferase II 2.4.1.143 13 
IIb GLS1, Glucosidase I 3.2.1.106 14 
IIc SLC35C1, GDP-fucose transporter - 15 
IId B4GALT1, Galactosyltransferase 2.4.1.- 16 
IIe COG7, COG 7 - 17 
IIf SLC35A1, CMP-NeuAc transporter - 18 
 
The second stage represents the transport mechanisms that are responsible for the translocation 
of the activated monosaccharides into the lumen of the endoplasmic reticulum (ER) and the 
Golgi. In the ER, the nucleotide sugars bind to the cytosolic side of the membrane-bound lipid 
dolichol-phosphate (Dol-P). Subsequently, the nucleotide moiety is cleaved off. A hypothetical 
‘flippase’ then mediates the turnover of the Dol-P-monosaccharide complex from the cytoplasmic 
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leaflet to the lumenal leaflet of the ER. Abnormal glycosylation can result from a reduced Dol-P-
monosaccharide synthesis or transport as is seen in patients with CDG-Ie and CDG-If8,9. The 
primary defect in CDG-Ie is a deficiency of Dol-P-Man-synthase, and the primary defect in CDG-
If is a defect in the MPDU1 gene, known to be required for efficient use of Dol-P-Man and Dol-P-
Glc as donor substrates. In the Golgi, nucleotide sugars enter the lumen via specific nucleotide 
sugar transporters (NSTs). These NSTs are antiporters in which the nucleotide sugar entry into 
the ER/Golgi is coupled to the equimolar exit of the corresponding nucleoside monophosphate 
from the ER/Golgi lumen10. As observed in CDG-IIc, a deficiency of the GDP-Fuc transporter11 
and in CDG-IIf, a deficiency of the CMP-NeuAc transporter4, abnormal glycosylation can result 
from a reduced NST function.  
In the third stage, specific transferases attach the glycan in the ER and the Golgi. N- and O-
glycans are synthesized by the sequential action of a number of specific membrane-bound 
glycosyltransferases in a highly controlled fashion. The pathways of glycosylation are determined 
by the distinct substrate specificities of glycosyltransferases. Most CDG subtypes and O-
glycosylation disorders described to date are caused by deficiencies in glycosyltransferases.  
The last stage represents the Golgi traffic and Golgi integrity mechanisms. The Golgi apparatus 
exists of several cisternae organized in the form of a stack. Glycoproteins and also 
glycosyltransferases, for example, are transported to their destination via the cisternae and 
series of Golgi vesicles. Recently, it was discovered that a defect in subunit 7 of the COG 
complex, involved in Golgi traffic, caused abnormal glycosylation in 2 patients with CDG-IIe12. 
 
 
The biosynthesis of N-glycans 
 
 
The N-glycosylation pathway comprises the assembly and processing of glycans and extends 
over 3 subcellular compartments: the cytoplasm, the ER and the various Golgi compartments. 
The N-glycosylation biosynthesis routing has been excellently reviewed by Marquardt et al.13. In 
short, the assembly of N-glycans is initiated in the cytosol. Two specific cytosolic UDP-GlcNAc 
transferases deliver the first 2 GlcNAc monosaccharides to Dol-P (Figure 2). Biosynthesis is 
continued on the cytosolic side with the attachment of 5 consecutive Man-residues donated by 
the nucleotide sugar GDP-Man. The lipid bound heptasaccharide is then flipped to the ER lumen 
by the hypothetical flippase. In contrast to cytosolic glycan biosynthesis, luminal glycan 
biosynthesis uses Dol-P-bound saccharides as precursor. The Man5GlcNAc2-Dol-P is 
subsequently extended with 4 additional Man and 3 Glc residues donated by Dol-P-Man and Dol-
P-Glc respectively. This results in a Glc3Man9GlcNAc2-Dol-P structure (Figure 2). This lipid-linked 
oligosaccharide (LLO) is the substrate for the enzyme oligosaccharyltransferase (OTase). 
Defects in the assembly of this mature LLO-form are referred to as CDG type I.  
The processing of N-glycans starts with the removal of the Glc3Man9GlcNAc2 from Dol-P and its 
transfer to a nascent protein chain containing the consensus sequence Asn-X-Ser/Thr (X 
denotes any amino acid). This transfer is catalyzed by the OTase complex. Directly after the 
transfer of the N-glycan chain to the protein, the terminal glucose residues are removed by 2 
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membrane-bound glucosidases followed by the cleavage of the terminal-linked Man residues by 
several mannosidases. Several lectins recognizing terminal bound Man residues promote the 
transport of synthesized polypeptides to the Golgi apparatus. In the different Golgi compartments 
the glycoprotein can be further processed. Defects in the processing of N-glycans are referred to 
as CDG type II.  
In general, 3 protein-linked N-glycan types can be distinguished (Figure 3). The first type is the 
‘high mannose structure’, which is an N-glycan containing between 5 and 9 mannose residues 
(Figure 3A). The glycans attached to some proteins remain in this state when the glycoprotein 
moves through the various Golgi compartments to the cell surface. The second type is the ‘hybrid 
structure’, which is an N-glycan with 1 antenna of the complex type and 1 antenna of the high 
mannose type (Figure 3B). Hybrid structures are formed when Golgi mannosidases do not act 
after the addition of a single GlcNAc residue by GlcNAc-transferase I. The last N-glycan type is 
the ‘complex structure’, which is an N-glycan with antennae that are fully processed (Figure 3C). 
The complex type N-glycan is very heterogeneous. Variations are seen in the terminal residues 
and in the branching of N-glycans; besides the bi-antennary N-glycan, also tri-antennary and 
tetra-antennary N-glycans can be distinguished. Subsequently, N-glycans can be modified by 
addition of a bisecting GlcNAc residue, an N-glycan core fucose residue, fucosylation, or a 
polylactosamine epitope, which is a series of repeated Gal-GlcNAc residues.  
 
Figure 3. 
The three N-glycan types. 
A) ‘high mannose type’ B) 
‘hybrid type’ C) ‘complex 
type’. The common N-
glycan core structure is 
shaded. Because the two 
branching mannose 
residues in the core are in 
different linkages to the 
innermost mannose residue, 
these two branches are 
known as the 1-3 antennae 
and the 1-6 antennae of an 
oligosaccharide. 
 
In summary, N-glycans share a common core structure and their diversity results from the 
differential action of glycosidases and glycosyltransferases in the Golgi apparatus14. It is 
interesting that glycan structures are determined in this way and that there is no template 
available for their biosynthesis. While DNA forms the template for the sequence of amino acids in 
a protein, there is no such equivalent for the design of glycans. The sequence of 
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monosaccharides on a protein is determined by a number of factors, such as glycosyltransferase 
specificity and expression and the availability of monosaccharides. 
 
 
The biosynthesis of O-glycans 
 
 
The biosynthesis of O-glycans is initiated after the folding and oligomerization of proteins and 
can set off in the late ER or in one of the Golgi compartments15-18. Therefore, O-glycosylation 
mainly takes place in coil, turn and linker regions of proteins. In Chapter 3 of this thesis the 
biosynthesis of O-glycans is reviewed. In short, 7 different types of O-glycan attachments are 
known in man, classified on basis of the first sugar (GalNAc, Xyl, GlcNAc, Gal, Man, Glc, Fuc) 
bound to the serine, threonine or hydroxylysine residue of the protein. In man, the mucin-type O-
glycan (with GalNAc as the first sugar) and the glycosaminoglycans (GAGs; with Xyl as the first 
sugar) are by far the most common structures. The total amount of monosaccharide residues in 
mucin-type O-glycans may vary between 1 and about 10, whereas GAG chains are about 100 or 
more monosaccharides long (Figure 4). Mucin-type O-glycans and GAGs occur in various 
different forms. Mucin-type O-glycans, for example, can be further subdivided into 8 core 
structures depending on the second sugar(s) and / or sugar binding and further elongation of 
these core structures give rise to at least 50 different mucin-type O-glycan structures. The 
structures of the other 5 O-glycan types (starting with GlcNAc, Gal, Man, Glc, and Fuc) seem to 
show less variability and mostly occur in 1 conformation19,20.  
The O-glycosylation process differs from the N-glycosylation process in various aspects. N-linked 
glycans share a common protein-glycan linkage, have a common core structure and only few N-
glycan structures exist. This reflects a common biosynthetic pathway that only diverges in its late 
stages. In contrast, O-glycans have different protein-glycan linkages in which GalNAc, Xyl, Fuc, 
Man, Glc, GlcNAc and Gal can be attached to serine, threonine or hydroxylysine resulting in 
many different glycan types. A more detailed description of the biosynthesis of O-glycans is 
presented in Chapter3. 
 
 
Functions of glycans 
 
 
Various functions have been described for protein-linked glycans. The main general roles of 
glycans relate to protein structure and stability, recognition, modulation of the activity of enzymes 
and signaling molecules, and to protein expression and processing. 
Glycans can influence the secondary protein structure, as they can break the α-helicity of 
proteins, the tertiary protein structure, seen for example in the low density lipoprotein receptor-
related protein which becomes misfolded when N-glycosylation is blocked in cultured cells21, and  
 18 
Introduction and outline 
 
Figure 4. 
Proteoglycan bearing two 
heparan sulfate chains. The 
molecular mass of the GAGs is 
often higher than the mass of 
the protein itself. Heparan 
sulfate contains regions where 
the GlcNAc units maintain 
acetylated (NA-domain) that 
remain (almost) unmodified and 
regions with GlcNS units that 
are highly sulfated (S-domain).  
 
the quaternary protein structure, seen for instance in serum IgA1 that forms noncovalent self-
aggregates when carbohydrates are removed from the IgA1 molecule22. Subsequently, glycans 
maintain protein stability, heat resistance, hydrophilicity, and protease resistance by steric 
hindrance20. 
Another important function of glycans is to mediate recognition between proteins. Glycan 
structures can be substrates for non-enzymatic sugar binding proteins, known as lectins. By 
interacting with lectins, glycans influence the targeting of the proteins to which they are attached. 
Examples of glycan-mediated recognition of glycoproteins are ubiquitous. For instance, calnexin 
and calreticulin represent 2 lectins localized in the ER. The monoglucosylated glycan 
Glc1Man9GlcNAc2 localized on folding proteins acts as a substrate for these lectins, which in turn 
interact with the co-chaperone ERp57. ERp57 catalyzes the formation of disulfide bonds 
between cysteines in the folding protein, thereby facilitating the protein folding process23. When 
disulfide bridges are formed, the partially or fully folded protein is released from 
calreticulin/calnexin by removal of the terminal glucose residue by glucosidase II. Following 
release, the UDP-glucose:glycoprotein glucosyltransferase acts as a folding sensor by 
reglucosylating only partially folded proteins, and redirecting them to the chaparone system. This 
cycle is continued until proteins are correctly folded.  
For a number of signaling molecules, explicitly hormones and cytokines, and a relatively small 
number of enzymes, effects of glycosylation on their bioactivity have been described. In the 
anticoagulent human protein C inhibitor, for example, each N-linked glycan contributes to the 
activity of the protein. Some of its N-glycans increase the enzyme activity, while others have an 
inhibitory effect24.  
Finally, glycosylation is essential for the expression of particular proteins. The glucose 
transporter GLUT1 expression, for example, is induced 2-5 times when N-glycosylation is 
inhibited25. As glycans are involved in numerous processes it is inevitable that defects in the 
biosynthesis of N- or O-linked glycans result in clinical signs and symptoms.  
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Clinical features of glycosylation disorders 
 
 
Table 2 summarizes the most common symptoms of the known CDG defects known to date. In 
general, these very rare disorders present as neurological and multi-systemic diseases that 
affect nearly all organs and systems. A specific description of the clinical features for the different 
CDG subtypes is hardly possible either due to the overlap of the clinical presentation and/or the 
limited number of patients. The majority of patients with a CDG type I have the ‘classical CDG 
phenotype’ with common symptoms such as muscle hypotonia, central nervous system 
abnormalities, seizures, growth delay, feeding problems, coagulation defects and liver disease 
and frequently specific signs like abnormal fat distribution, a small cerebellum and inverted 
nipples that help with the early clinical diagnosis. The exception is CDG-Ib, which is a hepatic-
intestinal disease. The clinical spectrum of CDG type I is variable; ranging from a very severe 
multisystemic phenotype to a nonsymptomatic phenotype seen in a CDG-Ia patient26.  
In several CDG type II disorders the O-glycosylation is also affected. Examples are CDG-IIc and 
CDG-IIe11,12. CDG-IIf seems to be a congenital disorder in O-glycosylation as the N-glycosylation 
seems to be unaffected4. In CDG type II the ‘classical CDG symptoms’, such as muscular 
hypotonia, central nervous system abnormalities, seizures, coagulopathy and liver disease are 
combined with unique features such as hemorrhages and immune dysfunction. Looking at the 
clinical phenotypes of yet unsolved CDG type II patients other unique symptoms have been 
described like cutis laxa, deafness, blindness and urogenital anomalies27. In contrast to defects 
in the N-glycosylation, patients with O-glycosylation disorders described to date commonly have 
the involvement of only 1 organ or organ system and do not have the general symptoms 
suggestive for an inborn error of metabolism. For examples the reader is referred to Chapter 3 of 
this thesis. Most of the disorders of O-glycan biosynthesis described seem to have a very 
specific tissue expression, whereas N-glycans are ubiquitously expressed. 
 
 
Treatment 
 
 
CDG-Ib patients can be treated with oral mannose. CDG-Ib patients respond well to dietary 
supplements of Man as the sugar is transported into the cell and is directly phosphorylated to 
Man-6-P, bypassing the defect (Figure 2, defect nr. 256,31) . In some cases, CDG-IIc was treated 
succesfully with fucose, depending on the mutations the patients have53. For the other CDG 
defects no treatments have been described to date.  
Addition of Man to fibroblasts of CDG-Ia patients resulted in a correction of the LLO size and to a 
restoration of the depleted GDP-Man pools. Unfortunately, CDG-Ia patients do not respond to  
oral supplementation of Man; the clinical features of a CDG-Ia patient did not improve and also 
the biochemical features remain abnormal (low coagulation patterns and abnormal glycoprotein 
IEF patterns)57,58. 
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Table 2. Overview of the different CDG subtypes and their most common clinical features 
CDG 
type MIM 
Nr of 
patients Clinical features Ref 
Ia 212065 >500 Hypotonia, strabismus, cerebellar hypoplasia, coagulopathy, multi-organ involvement, inverted nipples, fat pads  2,28 
Ib 602579 ~20 Liver disease, coagulopathy, protein losing enteropathy  29,31 
Ic 603147 ~20 Hypotonia, strabismus, coagulopathy  28,32,33
Id 601110 4 Psycho-motor retardation, seizures, microcephaly  34,35 
Ie 608799 5 Psycho-motor retardation, seizures, hypotonia, microcephaly  8,36,37 
If 609180 4 Psycho-motor retardation, seizures, hypotonia, skin problems  9,38 
Ig 607143 5 Psycho-motor retardation, dysmorphy, failure to thrive  39-41 
Ih 608104 4 Dysmorphy, coagulopathy, oedema, ascites, cardiorespiratory problems, hypotonia, hypoalbuminaemia  42,43 
Ii 607906 1 Psycho-motor retardation, seizures, retarded myelinization, coagulopathy, poor vision  44 
Ij 608093 1 Psycho-motor retardation, seizures, hypotonia, microcephaly 45 
Ik 608540 4 Psycho-motor retardation, seizures, hypotonia, coagulopathy 46-48 
Il 608776 2 Psycho-motor retardation, seizures, hypotonia, hepatomegaly, microcephaly  3,49 
IIa 212066 4 Seizures, hypotonia, dysmorphy, coagulopathy, liver disease  28,50 
IIb 606056 1 Psycho-motor retardation, seizures, hypotonia, dysmorphy, liver disease, coagulopathy 51 
IIc 266265 5 Psycho-motor and growth retardation, hypotonia, dysmorphy, recurrent infections  11,52,53
IId 607091 1 Psycho-motor retardation, hypotonia, macrocephaly, coagulopathy 54,55 
IIe 608779 2 Psycho-motor retardation, seizures, hypotonia, dysmorphy, severe liver disease, coagulopathy, early death 12 
IIf  1 Hemorrhages, respiratory distress syndrome, opportunistic infections 4 
 
Unfortunately, Man-1-P cannot pass the plasma membrane, making it currently impossible to 
provide CDG-Ia patients with the missing intermediate. Recently, Eklund et al. synthesized 2 
membrane permeable acylated versions of Man-1-P and showed that both compounds had the 
ability to restore LLO size and correct N-glycosylation to control levels in CDG-Ia fibroblasts. 
Additionally, it was shown with one of the compounds that it also corrects LLO size in fibroblasts 
from a CDG-Ie patient and partially corrects LLO size in fibroblasts from a CDG-Ig patient, 
whereas it has no effect on fibroblasts from a CDG-Id and CDG-If patient. Thus, the hydrophic 
Man-1-P derivates may serve as potential therapeutics for some types of CDG-I59  
 
 
Diagnostic procedures 
 
 
Isoelectric focusing of transferrin 
 
Plasma transferrin isoelectric focusing (TIEF) is generally applied in the diagnosis of defects in 
the biosynthesis of N-glycans. Before TIEF is performed the protein has to be saturated with iron. 
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Transferrin is a plasma protein that contains 2 N-glycan structures (positioned at Asn 413 and 
611) of the ‘complex type’ with 2 or 3 antennae (figures 5A and 5B). Sialic acid, or neuraminic 
acid has a negative charge and is always positioned at the terminus of the N-glycan structure. 
The charge of the sialic acid residues contributes to the isoelectric point (IEP) of the protein. In 
human plasma the tetrasialotransferrin fraction is the most abundant form, corresponding with 
the transferrin isoform that contains 2 fully sialylated biantenarry N-glycans. Also the trisialo-, 
pentasialo and hexasialotransferrin isoforms can be observed in human plasma (Figure 5C, lane 
1). Children younger than 1 month can have a different transferrin isoform ratio that may mimick 
a CDG TIEF profile. A defect in the biosynthesis of N-glycans is picked up by abnormal quantities 
of the different transferrin isoforms.  
Transferrin IEF can also be used to distinguish between CDG type I and CDG type II defects 
(Figure 5C). Defects in the assembly of N-glycans result in unglycosylated proteins, thus in 
proteins that lack complete N-glycan structures. This results in the characteristic CDG type 1 
profile, with increased amounts of asialo- and disialotransferrin and decreased amounts of 
tetrasialo and pentasialotransferrin (Figure 5C, lane 2). Defects in the processing of N-glycans 
often lead to hyposialylation of proteins, thus in proteins lacking their terminal sialic acid 
residues. All profiles that are not a type 1 profile are classified as a CDG type 2 profile (Figure 
5C, lanes 3 and 4). N-glycosylation biosynthesis defects can be confirmed by performing IEF of 
thyroxine-binding globulin (TBG), another N-glycosylated plasma protein. 
There are some pitfalls of the transferrin IEF test. Not all CDG type II defects can be picked up 
with transferrin IEF. Patients with CDG-IIb, -IIc and CDG-IIf have a normal transferrin IEF profile. 
Polymorphisms in the protein part of transferrin can complicate the interpretation of transferrin 
IEF profiles. Polymorphisms can result in a different IEP of the protein and thus can have an 
influence on the TIEF profile. The double bands in Figure 5C, lanes 3 and 4 represent a 
frequently occurring polymorphism. Some of the rare polymorphisms result in a TIEF profile that 
easily may be misinterpreted as pathological and indicative for CDG. To exclude these false-
positive results transferrin should be incubated with neuraminidase. This enzyme catalyzes the 
 
Figure 5.  
N-glycosylation of transferrin. A) ‘tetrasialo 
transferrin’ B) ‘pentasialo transferrin’ C) 
isoelectric focusing of human plasma 
transferrin. Lane 1: normal TIEF profile, lane 
2: CDG type I TIEF profile, lane 3: CDG type II 
profile, lane 4: CDG type II profile. 
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hydrolysis of NeuAc residues from glycans. In a neuraminidase treated sample all transferrin 
isoforms migrate to the asialo position on TIEF, whereas a neuraminidase treated sample with a  
hetero-allelic polymorphism in transferrin gives 2 bands on TIEF. The paper of Weidinger et al. 
gives an overview of known polymorphisms and their influence on the electrophoretic behaviour 
of the protein60.  
Some patients secondarily have an abnormal biosynthesis of N-glycans. In samples of patients 
with galactosemia, fructosemia, alcohol abuse and severe liver disease TIEF can result in a CDG 
type 1 profile. TIEF performed on samples from HUS patients result in a CDG type 2 profile (see 
also ‘secondary glycosylation disorders’).  
 
Enzymatic measurements 
 
Phosphomannomutase (PMM) and Phosphomannose isomerase (PMI) activity, the enzymes 
deficient in patients with respectively CDG-Ia and –Ib, can be measured in fibroblasts or 
leukocytes61. Leukocytes seem to be more reliable than fibroblasts for PMM measurements, as 
high residual activity has been observed in the fibroblasts of some CDG-Ia patients, whereas 
PMM activity was always abnormal in leukocytes of these patients62.  
 
Lipid linked oligosaccharide analysis 
 
LLO analysis can be applied on patients with CDG type I who have normal PMM and PMI 
activities. The Dol-P bound oligosaccharides, or LLO’s, are released from the patients’ fibroblasts 
by chloroform/methanol/water extractions. Subsequently, the glycans are released from Dol-P by 
mild acid hydrolysis and analyzed with HPLC. The short LLO’s are released by a 
chloroform/methanol extraction and analyzed by thin layer chromatography63. The assembly of 
N-glycans is highly conserved in eukaryotic cells and therefore yeast mutants have been very 
useful in the identification of new N-glycosylation disorders in human. By comparing LLO 
structures of patients with those of yeast mutant strains, most CDG type I defects (CDG-Ic - Ie, -
Ig - Ii, -Ik, and –Il) have been elucidated64-66,36,40,42,44,47,3.  
 
Protein glycan structure analysis 
 
Protein glycan structure analysis can be applied on plasma samples from patients with a CDG 
type II or a defect in the biosynthesis of O-glycans. The determination of glycoprotein glycans 
requires their enzymatic or chemical release. Enzymatic release of N-glycans is accomplished by 
the endoglycosidases peptide N-glycosidase F and A, that catalyze the release of intact reducing 
N-glycans from the protein backbone. Two endo-α-N-acetylgalactosaminidases have been 
reported to facilitate O-glycan removal from proteins, although their specificity is narrowed to 
unsubstituted core 1 O-glycans67,68. A general endoglycosidase for release of all O-glycans, if 
any, remains to be discovered. Therefore, release of O-glycans is accomplished by chemical 
methods like reductive β-elimination, hydrazinolysis and nonreductive β-elimination69-71. Both N- 
and O-glycans are analyzed by methods like HPLC or mass spectrometry72,73.  
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Isoelectric focusing of apolipoprotein C-III 
 
Plasma apolipoprotein C-III (apoC-III) IEF can be applied in the diagnosis of defects in the 
biosynthesis of core 1 O-glycans. ApoC-III is a plasma protein that contains 1 core 1 O-glycan 
(positioned at Thr 94). The core 1 O-glycan can be elongated with 1 or 2 NeuAc residues (see 
also Figure 6, A-C). Three isoforms of the protein can be distinguished; apoC-III0, apoC-III1 and 
apoC-III2. The number in the isoform correlates with the number of NeuAc residues that is 
attached to the protein. As NeuAc has a negative charge it contributes to the IEP of the protein 
so that the 3 isoforms can be separated from each other with IEF. In human plasma the apoC-III1 
and apoC-III2 fractions are about equally distributed, whereas apoC-III0 is the minor fraction. In 
controls, the ratio of the different apoC-III isoforms is constant, although it changes with age. 
ApoC-III glycans in very young children carry more NeuAc residues than in adults. A defect in the 
biosynthesis of core 1 O-glycans can be picked up by an abnormal ratio of the different apoC-III 
isoforms. Just like in TIEF, polymorphisms in the protein part can alter the protein’s IEP and thus 
have an influence on the apoC-III IEF profile. To exclude these false-positive results the protein 
can be treated with neuraminidase.  
Some patients secondarily have an abnormal biosynthesis of core 1 O-glycans. In HUS patients, 
for example, apoC-III IEF can result in a hyposialylation profile (see also ‘secondary glycosylation 
disorders’).  
 
Figure 6. 
O-glycosylation of apolipoprotein C-III. A) 
‘ApoC-III0’ B) ‘ApoC-III1’ C) ‘ApoC-III2’ D) 
isoelectric focusing of human plasma 
apoC-III. Lane 1: normal apoC-III IEF 
profile, lane 2: abnormal apoC-III IEF 
profile, lane 3: abnormal apoC-III IEF 
profile. 
 
Prenatal diagnosis 
 
Prenatal diagnosis is only possible when the molecular defect is known in the index patient or 
when the mutations have been detected in the parents. Prenatal diagnosis on basis of transferrin 
IEF in fetal blood is not reliable74,75 and enzymatic measurements of PMM activities in cultured 
amniocytes or trophoblasts may give inconclusive data76.  
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Secondary glycosylation disorders 
 
 
Patients with classic galactosemia (galactose-1-phosphate uridyltransferase deficiency, EC 
2.7.7.12) have truncated N-glycans deficient in galactose. After treatment with a galactose-free 
diet the biosynthesis of N-glycans becomes normal. It is postulated that the accumulated Gal-1-P 
inhibits galactosyltransferase activity involved in N-glycosylation or that the defect has an effect 
on the formation of UDP-galactose77. The biosynthesis of core 1 O-glycans seems not to be 
affected as a patient with classic galactosemia (before dietary treatment) showed a normal apoC-
III IEF profile78. 
Also in patients with fructosemia (fructose 1-phosphate adolase deficiency, EC 5.3.1.8) an 
abnormal transferrin IEF pattern was found (a CDG type 1 pattern). After dietary treatment the 
biosynthesis of N-glycans becomes normal in fructosemia patients. It is found that the 
accumulated Fru-1-P is an inhibitor for the activity of phosphomannose isomerase, the enzyme 
that is deficient in CDG-Ia patients79,80.  
A third group with a secondary defect in the biosynthesis of N-glycans is individuals suffering 
from alcohol abuse. These persons show an abnormal transferrin pattern (a CDG type 1 
pattern)81. The biosynthesis of core 1 O-glycans is normal in individuals with alcohol abuse78. 
Also patients with severe liver disease (primary biliary cirrhosis and chronic active hepatitis) 
show an abnormal biosynthesis of N-glycans81. The biochemical mechanism behind this 
observation is unknown.  
Patients with Hemolytic Uremic Syndrome (HUS) attributable to Streptococcus pneumoniae also 
have a secondary glycosylation disorder. Transferrin IEF showed a hyposialylation pattern (a 
type 2 pattern) and also apoC-III IEF showed a hyposialylation profile. Streptococcus 
pneumoniae excretes neuraminidase, which catalyzes the hydrolysis of α2,3-, α2,6- and α2,8-
linked neuraminic acid (NeuAc) residues from glycoproteins, thus explaining the hyposialylation 
profiles found82,78.  
 
 
Objectives and outline of the thesis 
 
 
Objectives 
 
In the last decade, a lot of progress has been made in the understanding of the biosynthesis of 
protein-linked N-glycans, their role in the human body and the clinical and molecular aspects of 
biosynthesis defects in N-glycosylation. At the beginning of this study, the first few papers were 
published with basic/fundamental knowledge on protein-linked O-glycans. In the field of inborn 
errors of metabolism defects in protein-linked O-glycans was largely ignored. It was unknown 
what the influence was of congenital modified protein-linked O-glycans on health. The main 
objective of this thesis was to investigate the role of protein-linked mucin-type O-glycans in 
inborn errors of metabolism.  
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Outline 
 
In Chapter 2, we introduce the general mechanisms of protein O-glycan biosynthesis and share 
our current knowledge about diagnosis, clinical manifestations, and molecular genetic aspects of 
known protein O-glycan biosynthesis defects. The other chapters of this thesis are divided into 2 
parts. Part I deals with methodological studies that have been performed to improve the 
biochemical diagnosis of biosynthesis defects in protein-linked O-glycans (Chapters 3-5). Part II 
deals with studies that highlight the clinical aspects of defects in the biosynthesis of protein-
linked (N- and) mucin-type core 1 O-glycans (Chapters 6-8). Finally, Chapter 9 summarizes the 
studies presented in this thesis. 
 
Part I: Methodological studies 
 
In 2001, when the research described in this thesis was initiated, we developed a first approach 
to screen for biosynthesis defects in the most common protein O-glycan type in mammals. This 
was done by the apolipoprotein C-III IEF assay, which can be used to screen for defects in the 
biosynthesis in mucin-type core 1 O-glycans (Chapter 3). The study in Chapter 4 examines the 
use of transferrin IEF in combination with SDS-PAGE and IEF of apoC-III to provide a 
biochemical classification for CDG patients. This can be helpful to narrow down the options for 
the primary defect in patients with unsolved CDG and could lead to the definition of new CDG 
defects. Chapter 5 gives an overview of the use of the apoC-III IEF assay in laboratory 
diagnostics and summarizes conditions and diseases that primary or secondarily lead to 
abnormal apoC-III IEF profiles. 
 
Part II: Clinical studies 
 
Using the apoC-III IEF assay, new categories of patients could be identified with a congenital 
disorder of glycosylation. We found that 3 patients with cutis laxa syndrome and neurological 
symptoms had a combined deficiency in the biosynthesis of N- and mucin-type O-glycosylation. 
The clinical and biochemical characteristics of these cutis laxa patients are described in 
respectively Chapter 6 and Chapter 7. Furthermore, we investigated the role of N- and mucin-
type core 1 O-glycans in the pathogenesis of Sialuria in Chapter 8.  
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Abstract 
 
 
Background: Genetic diseases that affect the biosynthesis of protein O-glycans are a rapidly 
growing group of disorders. Because this group of disorders does not have a collective name, it 
is difficult to get an overview of O-glycosylation in relation to human health and disease. Many 
patients with an unsolved defect in N-glycosylation are found to have an abnormal O-
glycosylation as well. It is becoming increasingly evident that the primary defect of these 
disorders is not necessarily localized in one of the glycan specific transferases, but can likewise 
be found in nucleotide sugar biosynthesis, their transport to the endoplasmic reticulum 
(ER)/Golgi, and in Golgi trafficking. Already, disorders in O-glycan biosynthesis form a 
substantial group of genetic diseases. In view of the the number of genes involved in O-
glycosylation processes and the increasing scientific interest in congenital disorders of 
glycosylation, it is expected the number of identified diseases in this group will grow rapidly over 
the coming years. 
Content: We first discuss the biosynthesis of protein O-glycans from their building blocks to their 
secretion from the Golgi. Subsequently, we review 24 different genetic disorders in O-
glycosylation and 10 different genetic disorders that affect both N- and O-glycosylation. The key 
clinical, metabolic, chemical, diagnostic and genetic features are described. Additionally, we 
describe methods that can be used in clinical laboratory screening for protein O-glycosylation 
biosynthesis defects and their pittfalls. Finally, we introduce existing methods that might be 
useful for unraveling O-glycosylation defects in the future.  
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Introduction 
 
 
The human proteome, originating from expression of the protein-coding genes of the genome, 
comprises approximately 30 000 proteins1, a surprisingly low number, considering that the 
genome of the nematode Caenorhabditis elegans already comprises of 20 000 genes2. However, 
a higher order of complexity of protein products in humans arises from pretranslational events, 
such as alternative splicing, and posttranslational modifications, such as phosphorylation and 
glycosylation. Glycosylation, the enzymatic addition of carbohydrates to proteins or lipids, is the 
most common and most complex form of posttranslational modification. This is illustrated by the 
estimation that 1% of human genes are required for this specific process3. Furthermore, more 
than half of all proteins are glycosylated according to estimates based on the SwissProt 
database4. In humans, protein linked glycans can be divided into 3 categories: N-linked (linkage 
to the amide group of Asn), O-linked (linkage to the hydroxyl group of Ser, Thr or hydroxylysine 
(hLys)), and C-linked (linkage to a carboxyl group of Trp)5.  
Initially, the study of glycoproteins and their role in human congenital diseases focused on N-
linked glycans. The diseases in this pathway have collectively been referred to as congenital 
disorders of glycosylation (CDG). N-glycans share a common protein-glycan linkage and have a 
common biosynthetic pathway that diverges only in the late Golgi stage. Endoglycosidases are 
available that can cleave intact N-glycans from the protein backbone, making it relatively easy to 
study alterations of N-glycosylation in health and disease. In contrast, O-glycans are built on 
different protein glycan linkages and have extremely diverse structures; in addition, there is no 
endoglycosidase available for the release of intact O-glycans. However, methods for the 
chemical release of O-glycans have been developed and have enabled the generation of 
structural information of O-glycans, making it more feasible to study alterations in O-glycosylation 
in relation to health and disease. This review focuses on the biosynthesis of O-glycans and the 
human congenital disorders of O-glycosylation and their screening.  
 
 
Structures of O-linked glycans  
 
 
The O-glycosylation process produces an immense multiplicity of chemical structures. Each 
monosaccharide has 3 or 4 attachment sites for the linkage of other sugar residues and can form 
a glycosidic linkage in an α or β configuration, allowing glycan structures to form branches. 
Glycans therefore have a larger structural diversity in contrast to other cellular macromolecules 
such as proteins, DNA, and RNA, which form only linear chains. Theoretically, the 9 common 
monosaccharides found in humans could be assembled into more than 15 million possible 
tetrasaccharides, all of which would be considered relatively simple glycans6.  
The 7 different types of O-linked glycans found in humans are summarized in Table 1. O-Linked 
glycans are classified on the basis of the first sugar attached to a Ser, Thr or hLys residue of a 
protein. The mucin-type O-glycan, with N-acetylgalactosamine (GalNAc) at the reducing end, is 
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Table 1. Different types of O-linked glycans in humans 
Type of O-linked glycan Structure and peptide linkage Glycoprotein    Ref 
 
Mucin-type 
 
(R)-GalNAcα1-Ser/Thr 
 
secreted + plasma membrane  
 
7 
GAG (R)-GlcAβ1-3Galβ1-3Galβ1-4Xylβ1-Ser proteoglycans 8,9 
O-linked GlcNAc GlcNAcβ1-Ser/Thr nuclear and cytoplasmic  10 
O-linked Gal Glcα1-2 ± Galβ1-O-Lys collagens 11 
O-linked Man NeuAcα2-3Galβ1-4GlcNAcβ1-2Manα1-Ser/Thr α-dystroglycan 12 
O-linked Glc Xylα1-3Xylα1-3 ± Glcβ1-Ser EGF protein domains 13 
O-linked Fuc NeuAcα2-6Galβ1-4GlcNAcβ1-3 ± Fucα1-Ser/Thr 
Glcβ1-3Fucα1-Ser/Thr 
 
EGF protein domains 
TSR repeats 
13 
14 
 
the most common form in humans. In total, 8 mucin-type core structures can be distinguished, 
depending on the second sugar and its sugar linkage, of which core 1-6 and core 8 have been 
described in humans (summarized in Table 2)15. In addition to the 7 core structures, the Tn 
(GalNAcα1-Ser/Thr) and sialyl Tn (NeuAcα2-6GalNAcα1-Ser/Thr; where NeuAc is N-
acetylneuraminic acid) epitopes can be distinguished. The core structures can be further 
modified; for example, by the addition of an N-acetyllactosamine unit (Galβ1-4GlcNAc; where 
GlcNAc is N-acetylglucosamine), also seen on N-glycans. The N-acetyllactosamine unit may be 
branched by a GlcNAcβ1-6 residue or form repeating N-acetyllactosamine units, called poly N-
acetyllactosamine extensions. It can also attach to the blood group determinants (A, B and H) 
and the type 2 Lewis determinants (Lex, sialyl Lewisx (sLex), and Ley). N-acetyllactosamine 
elongations are seen mainly on core 2 O-glycans. Sugars occurring at the nonreducing termini 
include NeuAc, Fuc, GlcNAc and GalNAc. GlcNAc and Gal residues can be modified at position 
6 or at positions 3 and/or 6, respectively, by sulfation7, and NeuAc residues can be further 
modified at positions 4, 7, 8, and 9 with O-acetyl ester groups16. This gives rise to several 
hundreds of different mucin-type O-glycan structures, of which core 1 and 2 are most abundant15. 
 
Table 2. Diversity of mucin-type O-linked glycans 
Core Structure Human tissue Ref 
 
1 
 
Galβ1-3GalNAc 
 
most cells and secreted proteins 
 
15 
2 Galβ1-3(GlcNAcβ1-6)GalNAc all blood cells 17 
3 GlcNAcβ1-3GalNAc colon and saliva  18,19 
4 GlcNAcβ1-3(GlcNAcβ1-6)GalNAc mucin secreting cell types 17 
5 GalNAcα1-3GalNAc meconium 20 
6 GlcNAcβ1-6GalNAc ovarian tissue 21 
7 GlcNAcα1-6GalNAc -  
8 
 
Galα1-3GalNAc bronchia  22 
 
Another common type of O-glycosylation with large structural diversity involves the 
glycosaminoglycans (GAGs). Proteoglycans are proteins containing GAG chains. GAGs are 
attached to a Ser residue of a protein via the linker tetrasaccharide GlcAβ1-3Galβ1-3Galβ1-4Xyl, 
except for keratan sulfate, which is linked to proteins either through N- or core 1 O-glycans. 
GAGs are long, unbranched polysaccharides containing a disaccharide repeat that consists of 
either a GalNAc or GlcNAc residue combined with a glucuronic acid (GlcA) or a Gal residue. 
Three different types of GAGs can be distinguished on the basis of the composition of the 
disaccharide repeat: 1. dermatan sulfate and chondroitin sulfate (GlcA + GalNAc), 2. 
heparin/heparan sulfate (GlcA + GlcNAc) and 3. keratan sulfate (Gal + GlcNAc). GlcA in 
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dermatan sulfate and heparin/heparan sulfate can be epimerized to iduronate (IdoA). The 
heterogeneity of GAGs results from variable O-sulfation at defined locations23. An extra 
modification step occurs in heparin and heparan sulfate by the deacetylation and N-sulfation of 
GlcNAc residues. Regions in which the hexosamine units are acetylated remain (almost) 
unmodified and consist of disaccharide repeats with GlcA, whereas regions with deacetylated 
hexosamine units become highly sulfated and exist as disaccharide repeats with IdoA. Heparin is 
a highly and uniformly sulfated GAG, whereas heparan sulfate is highly sulfated only in defined 
blocks24.  
The structures of the other 5 O-glycan types seem to show less variability, and they occur mostly 
in 1 conformation. A frequently occurring O-linked glycan is the single GlcNAc linked to nuclear 
and cytosolic proteins. This posttranslational modification is more analogues to phosphorylation 
than to classical complex O-glycosylation, because it is a reversible process catalyzed by the 
enzymes O-GlcNAc transferase and O-GlcNAcase, respectively25 and the ‘normal glycosylation 
machinery’ is not implicated25,26.  
O-galactosyl glycans have been found only on collagen domains. Gal or Glcα1-2Gal residues are 
covalently linked to hLys residues found in collagens, but not all hLys residues become 
glycosylated. The collagen 3-dimensional structure depends upon the extent of this 
posttranslational modification. The quantities and types of O-galactosyl glycans vary 
considerably not only among the different types of collagen, but also among the same collagen 
type from different tissues and even the same collagen type from different areas of the same 
type of tissue27,28. 
O-mannosyl glycans are a less common type of protein modification, present on a limited number 
of glycoproteins in the brain, nerves, and skeletal muscle. The best known O-mannosyl 
glycosylated protein is α-dystroglycan, which is a skeletal muscle extracellular matrix protein12. 
To date, only the NeuAcα2-3Galβ1-4GlcNAcβ1-2Man structure has been found in humans. α-
Dystroglycan containing Galβ1-4(Fucα1-3)GlcNAcβ1-2Man has been found in sheep brain29,30 
and the O-mannosyl glycan HSO3-3GlcAβ1-3Galβ1-4GlcNAcβ1-2Man has been detected in rat 
brain31,30. Studies have also shown that mammalian N-acetylglucosaminyltransferase IX acts on 
the GlcNAcβ1,2-Manα1-Ser/Thr moiety, suggesting that 2,6-branched O-mannosyl glycan 
structures are formed in the brain32. It is therefore likely that structural diversity of O-mannosyl 
glycans will also be present in humans.  
O-glucosyl and O-fucosyl glycans are also rare types of protein glycosylation that have been 
found in the epidermal growth factor homology regions (EGF modules) of some human proteins. 
An EGF module is a common structural motif found in several secreted and cell-surface proteins 
that is often involved in mediating protein-protein interactions. The EGF repeat is typically 30-40 
amino acids long and is characterized by 6 conserved Cys residues participating in 3 disulfide 
bridges. Glc is linked to the Ser residue in proteins in the putative consensus sequence 
C1XSXPC2 (where C1 and C2 are the first and second conserved cysteines of the EGF module, S 
the modified Ser residue, and X can be any amino acid)33. O-Linked glc can be further elongated 
with 1 or 2 α1-3 linked xyloses and is found on proteins such as human factor VII, factor IX, and 
protein Z34,35. All O-fucosylated glycoproteins are modified with a single O-linked fuc residue 
(e.g., urinary-type plasminogen activator, tissue-type plasminogen activator, and coagulation 
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factors VII and XII) except for coagulation factor IX, which contains O-linked fuc that is elongated 
to the tetrasaccharide NeuAcα2-6Galβ1-4GlcNAcβ1-3Fucα1-Ser/Thr. Most O-fucose 
modifications on EGF repeats are found on the consensus site C2X3-5S/TC3 (where C2 and C3 are 
the second and third conserved cysteines of the EGF repeat, S/T the modified Ser/Thr residue 
and X can be any residue)34. A second type of O-fucosylation has been identified. On 
thrombospondin type 1 repeats (TSR), a disaccharide form of O-fucosyl glycans (Glcβ1-3Fucα1-
Ser/Thr) is found on the human extracellular matrix protein ‘thrombospondin-1’14. TSRs are found 
in many extracellular proteins. A single TSR repeat is ~60 amino acids long and is characterized 
by conserved Cys, Trp, Ser and Arg residues. The putative consensus sequence site for this 
modification is WX5CX2/3S/TCX2G34.  
 
O-glycan consensus sites 
 
For most O-glycosylation types a recognition consensus sequence for the attachment of the first 
sugar residue remains unknown. The exceptions are the O-glucose and O-fucose modifications 
in which putative consensus sites have been described (see above;and Refs33,34). The lack of a 
consensus sequence can arise from the coexistence of multiple transferases with overlapping 
but different substrate specificities, as seen, e.g., in mucin-type O-glycosylation, or is the result of 
a nonlimited consensus sequence, as seen, e.g., in O-GlcNAc modifications. Statistical studies 
yielded some general rules for mucin-type O-glycans and O-GlcNAc modifications, leading to the 
development of algorithms for the prediction of these 2 O-glycan types. These O-glycosylation 
prediction sites are available on the Internet. The NetOglyc 3.1 prediction server correctly 
predicts 76% of the glycosylated residues and 93% of the nonglycosylated residues in any 
protein36.  
 
 
The biosynthesis of O-glycans 
 
 
The main pathway for the biosynthesis of complex N- and O-linked glycans is located in the 
endoplasmic reticulum (ER) and Golgi compartments, the so-called secretory pathway. 
Glycosylation is restricted mainly to proteins that are synthesized and sorted in this secretory 
pathway, which includes ER, Golgi, lysosomal, plasma membrane, and secretory proteins. There 
is one exception; nuclear and cytosolic proteins can be modified with a single O-linked N-
acetylglucosamine25. Proteins synthesized by ribosomes and sorted in the secretory pathway are 
directed to the rough ER by an ER signal sequence in the N-terminus37,38. After protein folding is 
completed in the ER, these proteins move via transport vesicles to the Golgi complex. The 
biosynthesis of O-glycans is initiated after the folding and oligomerization of proteins either in the 
late ER or in one of the Golgi compartments39-42. Intriguingly, for the biosynthesis of glycans no 
template is involved; where DNA forms the template for the sequence of amino acids in a protein, 
there is no such equivalent for the design of glycans. The biosynthesis of glycans can be divided 
into 3 stages. In the first stage, nucleotide sugars are synthesized in the cytoplasm. In the 
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second stage, these nucleotide sugars are transported into the ER or the Golgi. In the third 
stage, specific glycosyltransferases attach the sugars to a protein or to a glycan in the ER or 
Golgi. An additional prerequisite for proper glycosylation is Golgi trafficking. Recently, it was 
discovered that a defect in a protein involved in Golgi traffic secondarily caused abnormal N- and 
O-glycans in 2 patients with CDG-IIe. For this reason, Golgi traffic will be discussed briefly in this 
section. 
 
Biosynthesis of nucleotide sugars 
 
Monosaccharides used for the biosynthesis of nucleotide sugars derive from dietary sources and 
salvage pathways. Glucose (Glc) and fructose (Fru) are the major carbon sources in human from 
which all other monosaccharides can be synthesized (Figure 1). Series of phosphorylation, 
epimerization, and acetylation reactions convert them into various high-energy nucleotide sugar 
donors (see Figure 1). Nucleotide sugar biosynthesis takes place in the cytosol, except for CMP-
NeuAc, which is synthesized in the nucleus43. 
As observed in patients with CDG-Ia and CDG-Ib, aberrant glycosylation results from insufficient 
availability of GDP-Man. The availability of nucleotide sugars is tightly regulated. UDP-GlcNAc, 
for example, inhibits glutamine-fructose-6P-transaminase, which catalyzes the first step in the 
biosynthetic pathway of UDP-GlcNAc44, and CMP-NeuAc inhibits UDP-GlcNAc-2-epimerase/N-
acetylmannosamine kinase (GNE/MNK), which catalyzes the first 2 biosynthetic steps of CMP-
NeuAc45. Although much is known about the nucleotide sugar biosynthesis pathways and their 
feedback regulators, the actual cytosol and Golgi steady-state concentrations of most nucleotide 
sugars are unknown at present. Furthermore, because of the interconnected pathways of 
nucleotide sugar metabolism, the result of an individual enzyme deficiency is difficult to predict.  
Several steps in the biosynthesis of nucleotide sugars require ATP; therefore, the metabolic state 
of the cell influences the availability of the nucleotide sugars. The tight regulation of the 
biosynthesis of nucleotide sugars means that alterations in a single nucleotide sugar can 
significantly impair glycosylation. 
 
Transport processes to generate monosaccharide donors in the ER/Golgi 
 
The nucleotide sugars are biosynthesized in the cytosol, and their monosaccharides must be 
translocated into the lumen of the ER and/or Golgi before they can be used for the glycosylation 
process. Because nucleotide sugars cannot cross the membrane lipid bilayer, specific transport 
mechanisms are responsible for their translocation. Two transport mechanisms for the 
generation of monosaccharide donors in the ER/Golgi can be distinguished, shown in Figure 2. 
The first mechanism is the entrance of Man and Glc through binding to the lipid carrier dolichol 
phosphate (Dol-P). To date, this transport system has been described only in the ER. Cytosolic 
Dol-P-Man- and Dol-P-Glc-synthases link GDP-Man and UDP-Glc to the cytosolic site of Dol-P 
by cleaving off the nucleotide moiety. A hypothetical ‘flippase’ then mediates the turnover of the 
Dol-P-monosaccharide from the cytoplasmic leaflet to the lumenal leaflet of the ER. 
Subsequently, the monosaccharides can be used by ER located glycosyltransferases (see also 
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Figure 1.  
Schematic overview of the biosynthesis of nucleotide sugars. Not all intermediate steps are shown. Circled monosaccharides 
are obtained from dietary sources and/or salvage pathways. Gray stars indicate reactions that require ATP. Neu-9P, N-
acetylneuraminic acid 9-phosphate; ManNAc-6P, N-acetylmannosamine 6-phosphate; ManNAc, N-acetylmannosamine; 
GalNAc-1P, N-acetylgalactosamine 1-phosphate; GlcNAc-1P and GlcNAc-6P, N-acetylglucosamine 1-phosphate and 6-
phosphate, respectively; GlcN-6P, glucosamine 6-phosphate; Fru-6P, fructose 6-phosphate; Man-6P and Man-1P, mannose 
6-phosphate and 1-phosphate, respectively; Fuc-1P, fucose 1-phosphate; Glc-6P and Glc-1P, glucose 6-phophate and 1-
phosphate, respectively; Gal-1P, galactose 1-phosphate. 
 
Figure 2, A)46. As observed in patients with CDG-Ie who are deficient for Dol-P-Man-synthase 
and in patients with CDG-If who have mutations in the MPDU1 gene, known to be required for 
efficient use of Dol-P-Man and Dol-P-Glc as donor substrates, abnormal glycosylation results 
from a diminished Dol-P-monosaccharide transport47,48. In CDG-If patients, it was observed that 
the mannosylation of N-glycans, glycosylphosphatidylinotisol (GPI) anchors and C-mannosyl 
glycans was defective. Although O-mannosylation was not studied, it is likely that this is also 
aberrant in these patients.  
The second mechanism is the transport of nucleotide sugars through specific nucleotide sugar 
transporters (NSTs). NSTs belong to the solute carrier family 35 and reside in the Golgi and/or 
ER membranes with their C- and N-terminal regions exposed to the cytosol. These NSTs are 
antiporters in which the nucleotide sugar entry into the ER/Golgi is coupled to the equimolar exit 
of the corresponding nucleoside monophosphate from the ER/Golgi lumen49. The nucleotide 
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moiety of the nucleotide sugar is the recognition feature required for initial binding to the NST, 
whereas the attached monosaccharide finally determines whether the entire nucleotide sugar is 
translocated. After entrance of the nucleotide sugar into the ER/Golgi lumen, a 
glycosyltransferase will transfer the monosaccharide to a glycan by cleaving off the nucleotide 
part. The nucleoside diphosphates are converted to dianionic nucleoside monophosphates (used 
for the antiporter) and inorganic phosphate by a nucleoside diphosphatase. It is postulated that 
inorganic phosphate exits the ER/Golgi lumen via a specific transporter (see also Figure 2, B)49. 
Nucleoside di- and monophosphates can inhibit the nucleotide sugar transport process and the 
activity of glycosyltransferases.  
Some NSTs transport more than one substrate, for example, the UDP-Gal/UDP-GalNAc 
transporter (hereafter referred to as UDP-Gal transporter)50, the UDP-GlcA/UDP-GalNAc/UDP-
GlcNAc transporter (hereafter referred to as UDP-GlcA transporter)51,52, and the recently 
described UDP-Xyl/UDP-GlcNAc transporter (hereafter referred to as UDP-Xyl transporter)53. In 
contrast, the CMP-NeuAc54, GDP-Fuc55 and UDP-GlcNAc transporters56 are monospecific.  
In general, the transport of a nucleotide sugar occurs in the organelle in which the corresponding 
glycosyltransferase is localized. Some nucleotide sugars enter only the lumen of Golgi vesicles, 
others enter the lumen of ER derived vesicles and a few enter both. It has been shown that the 
CMP-NeuAc, the GDP-Fuc, the UDP-GlcNAc and the UDP-Xyl transporters have a strict Golgi 
membrane localization49,56,53, whereas the UDP-GlcA transporter is localized in the ER 
membrane51. Experiments investigating the intra-organelle availability of nucleotide sugars have 
shown that UDP-Xyl and UDP-Glc can also be found in the ER, whereas UDP-GlcA and UDP-
Glc can be found in the Golgi49, suggesting that the corresponding NSTs are yet to be identified.  
Galactosylceramide is galactosylated by a galactosyltransferase (UDP-galactose:ceramide 
galactosyltransferase) found exclusively in the ER, whereas the UDP-Gal transporter has mainly 
a Golgi localization. This galactosyltransferase is produced only in specialized cells, such as 
myelinating cells, spermatogonia and in various epithelial cell types. The question of how an ER-
resident glycosyltransferase could function without a source of substrate was answered by 
showing that the galactosyltransferase forms a complex with the UDP-Gal transporter. This led to 
in the presence of a fraction of the UDP-Gal transporter in the ER. It is not clear whether this is 
attributable to the retention of the UDP-Gal transporter by the galactosyltransferase or to 
recycling of the UDP-Gal transporter through the cis-Golgi. In this way, a biosynthetic pathway 
can be established only when required57. Recently, a second active mechanism has been found 
for the ER localization of the UDP-Gal transporter. The UDP-Gal transporter is produced in 2 
splice forms UGT1 and UGT2. UGT1 has a strict Golgi localization, whereas UGT2 shows a dual 
localization in both ER and Golgi caused by a dilysine motif KVKGS in its C-terminus58. 
As observed in the case of patients with CDG-IIc who have a deficient GDP-Fuc transporter59 
and in a patient with CDG-IIf who has a deficient CMP-NeuAc transporter60, abnormal 
glycosylation results from a diminished NST function. In addition, in Chinese hamster ovary 
(CHO) lec8 and lec2 cells, defective in UDP-Gal and CMP-NeuAc transport, respectively, 70%-
90% of the glycans lacked that particular monosaccharide49. It was also shown that the 
nucleotide sugar transport process depends on the continuous production of nucleoside 
monophosphates. Abeijon et al. showed that in vitro transport of GDP-Man into the Golgi is  
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Figure 2.  
Schematic overview of the nucleotide sugar transport mechanisms. A) Man (M) is transferred from GDP-Man to Dol-P. The 
Dol-P-Man ‘flips’ over the ER membrane, where Man is attached to the glycan by a specific mannosyltransferase (ManT). B) 
UDP-GalNAc is transported into the lumen of the ER/Golgi with equimolar exit of dianionic nucleoside monophosphate 
(UMP P2-). GalNAc is attached to the protein by a specific ppGalNAc-transferase, thereby simultaneously cleaving off the 
nucleoside diphosphate. This is converted to UMP2- and inorganic phosphate (Pi) by a lumenal nucleoside diphosphatase. 
Inorganic phosphate is postulated to exit the ER lumen via a specific transporter. 
 
severely decreased in a S. cerevisiae guanosine diphosphatase null mutant. All glycoproteins 
and glycolipids showed impaired mannosylation61. This results indicates that NSTs are critical 
components of glycosylation pathways. 
 
Transfer of nucleotide sugars to the glycan 
 
O-glycans are assembled by the sequential action of several specific, membrane-bound  
glycosyl-, O-acetyl- and sulfotransferases in a highly controlled fashion7. The pathways of O-
glycosylation are determined by the distinct substrate specificities of glycosyltransferases, 
sulfotransferases and O-acetyltransferases. Transferases involved in O-glycan biosynthesis are 
localized mainly in the Golgi. Although many of these enzymes catalyze similar reactions, there 
is a surprisingly limited sequence homology among different classes. The Golgi 
glycosyltransferases described to date are all type II transmembrane proteins, with a short N-
terminal cytoplasmic domain, a single hydrophobic membrane-spanning domain, and a large C-
terminal catalytic domain localized in the lumen of the Golgi.  
Chapter 2 
 
The activity of glycosyltransferases can be influenced by different factors. It is known, for 
example, that some of the glycosyltransferases require divalent cations, such as Mn2+ and/or 
Mg2+ for optimal action. In contrast to the reactions involving UDP- and GDP-nucleotide sugars, 
the biosynthetic steps involving CMP-NeuAc do not require these cations62. Petrova et al. 
showed that divalent cations react strongly with the nucleotide sugar in solution thus altering its 
conformation63. 
Furthermore, it was recently discovered that human core 1 β3-galactosyltransferase (core 1 β3-
Gal-T), which is involved in the formation of core 1 (and core 2) mucin-type O-glycans, requires a 
molecular chaperone for its functioning. This molecular chaperone is called core 1 β3-Gal-T-
specific molecular chaperone (Cosmc) and is an ER-localized type II transmembrane protein that 
appears to be required for the proper folding of the core 1 β3-Gal-T enzyme. In the absence of 
functional Cosmc, core 1 β3-Gal-T is degraded in the proteosome64. This raises the question of 
whether additional chaperones specific for other glycosyltransferases exist.  
A third factor that might influence glycosyltransferase activity is the structure of the protein 
substrate. It is thought that the protein structure contains information for the action of specific 
transferases. This is seen, for example, in proteoglycans, in which the core protein dictates 
whether it will receive a heparan sulfate or a chondroitin sulfate chain65, or in lysosomal 
enzymes, in which GlcNAc-phosphotransferase recognizes subtle motifs in the secondary 
structure and selectively phosphorylates the N-glycans on proteins that should reach the 
lysosome66,67. However, how proteins are recognized by glycosyltransferases remains largely 
unknown. Finally, glycosyltransferase activity can be dependent on heterocomplex formation. O-
mannosyltransferase activity, for example, is generated only when the genes POMT1 and 
POMT2 (both encoding mannosyltransferases) are coexpressed68.  
Golgi transferases can recognize a single sugar residue, a sugar sequence or a peptide moiety 
leading to variable specificity. With very few exceptions, each type of transferase is regio- and 
stereospecific. Glycosyltransferases involved in the linkage of monosaccharides to the protein 
backbone and those involved in the core processing of mucin-type O-glycans are specific and 
not involved in other classes of glycoconjugates, whereas most glycosyltransferases involved in 
the elongation, branching, and termination of glycans are not specific for one glycoconjugate 
class. For example, the ubiquitous α2,6 sialyltransferase ST6Gal I recognizes the N-
acetyllactosamine unit and catalyzes the formation of an α2,6 linkage to terminal N-
acetyllactosamine structures found on N-glycans, O-glycans and glycosphingolipids, whereas the 
β1,4-galactosyltransferase Gal-T1 galactosylates any terminal GlcNAc residue.  
The attachment of UDP-GalNAc in an α-linkage to the hydroxyl residue of serine or threonine in 
mucin-type O-glycans is a complex and as yet not fully understood process. This transfer is 
catalyzed by specific UDP-GalNAc: polypeptide N-acetylgalactosaminyl transferases (pp-
GalNAc-Ts, EC 2.4.1.41). The mammalian family of pp-GalNAc-Ts comprises 15 members, the 
fifteenth being discovered only recently69,70. It is estimated that at least 24 unique human pp-
GalNAc-Ts exist on basis of sequence homology70. The different pp-GalNAc-Ts have 
overlapping, but different specificities and are tissue-specific7,70. It seems that mucin-type O-
glycosylation proceeds in a hierarchical manner, because some of the characterized pp-GalNAc-
Ts glycosylate only peptides that are already partly glycosylated70. Currently, no consensus 
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sequence has been formulated because every pp-GalNAc-T has its own specific attachment site. 
Only serines and threonines that are exposed on the protein surface will be glycosylated, as O-
glycosylation is a post-folding event. Therefore, O-glycosylation takes place mainly in coil, turn, 
and linker regions. Furthermore, all attachment sites have a high serine, threonine and proline 
content36.  
The biosynthesis of GAG structures differs from the ‘small O-linked glycans’ in 2 significant ways: 
1) the transferases required are all specific and not involved in other glycoconjugate classes, with 
the exception of chondroitin 6-sulfotransferase, keratan sulfate Gal-6-sulfotransferase, and the 
GlcNAc 6-O-sulfotransferase that also sulfates N-acetyllactosamine extensions71 and 2) the 
mechanism of GAG chain elongation. Chondroitin/dermatan sulfate and heparin/heparan sulfate 
are synthesized on the common tetrasaccharide linker (GlcAβ1-3Galβ1-3Galβ1-4Xyl). 
Chondroitin/dermatan sulfate is synthesized when GalNAc is transferred to the linkage region, 
whereas heparin/heparan sulfate is synthesized if GlcNAc is added first. It has been 
demonstrated that the human exostoses-like family (EXTL1, -2, and -3) is responsible for the 
heparin/heparan sulfate chain initiation with the attachment of the first and second GlcNAc 
residues, and that the exostoses enzymes extosin-1 and -2 are the copolymerases that elongate 
the GAG chain with [GlcAβ1-4GlcNAcα1-4]n23. Recently, chondroitin GalNAc transferases I and II 
and chondroitin synthetase were discovered72-74. Chondroitin GalNAc transferases I and II are 
responsible for the initiation of the chondroitin/dermatan sulfate GAG chain with the attachment 
of the first few GalNAc residues to the linker region, whereas chondroitin synthetase acts as a 
copolymerase and is responsible for the elongation of chondroitin/dermatan sulfate with 
[GalNAcβ1-4GlcAβ1-3]n. 
 
Golgi traffic 
 
The Golgi apparatus consists of several cisternae, starting from the nucleus with the cis-Golgi-
network, through the cis-, medial-, and trans-Golgi compartments, and ending with the trans-
Golgi network, which are organized in the form of a stack. The Golgi position and organization 
within a cell is sustained largely through the combined efforts of a complex cytoskeletal matrix 
composed of microtubules, an actin-spectrin network and intermediate filaments. The interaction 
between these filament systems and Golgi membranes is mediated by mechanochemical 
enzymes, such as dyneins, kinesins, myosins, dynamin and different structural proteins75.  
A schematic overview of the transport route from ER through the different Golgi compartments is 
shown in Figure 3 [for reviews, see Refs.76,77]. The journey of proteins between these 
compartments starts with the exit from 100-200 export sites on the ER in COPII-coated vesicles. 
Coatamer proteins (COPs) recognize transport signals present in the cytoplasmic tail of cargo 
membrane proteins for their incorporation in COPII vesicles. Three classes of ER export signals 
have been described to date. Most type I membrane proteins have a diacidic or dihydrophobic 
motif, and the type II glycosyltransferases have a [RK](X)[RK] motif proximal to the 
transmembrane domain78. Signals that direct soluble cargo into ER-derived vesicles are less well 
defined. It is thought that soluble proteins are exported from the ER in 2 ways: 1) through a 
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Figure 3.  
Schematic overview of Golgi traffic mechanisms. 1) Cargo proteins and v-SNAREs are incorporated into a COPII coated 
vesicle. COPII coat assembly is mediated by Sar1-GTP. The coated COPII vesicles are subsequently budded from the ER 
membrane. 2) The COPII vesicle becomes uncoated and tethers to the ERGIC by a Rab protein and a tethering factor. The v- 
and t-SNAREs assemble into a 4-helix bundle. This trans-SNARE complex promotes fusion of the vesicle with ERGIC, where 
cargo is transferred to 3), in which ER proteins and misfolded proteins are transported back to the ER via COPI coated 
vesicles. 4) Cargo remains in a Golgi compartment for further processing. Glycosyltransferases are transported via COPI 
coated vesicles to their specific Golgi compartments. CGN, cis-Golgi network; TGN, trans-Golgi network. 
 
coated vesicles. The ERGIC elements are transported to and fused with the cis-Golgi network. 
From here, both anterograde and retrograde transport is mediated via COPI-coated vesicles. 
Three major protein families regulate vesicle transport. The ARF and Sar1 family GTPases are 
involved in COPI and COPII vesicle formation, which starts with the activation of ARF and Sar1 
by a nucleotide exchange factor into ARF-GTP and Sar1-GTP. ARF-GTP and Sar1-GTP recruit 
many additional components for the synthesis of the vesicle coat. Subsequently, the Rab family 
GTPases mediate vesicle targeting. The mammalian Rab protein family includes at least 63 
isoforms. All cytosolic Rab proteins form a complex with the Rab guanine nucleotide dissociation 
inhibitor chaperone, which transports the Rab proteins to the membrane of specific Golgi 
compartments, where they become activated to the GTP state. Activated Rabs mediate vesicle 
motility and the tethering of transport intermediates to their target membranes. The third family 
consists of SNARE proteins, which direct vesicle fusion. Each type of transport vesicle carries a 
specific vesicle-SNARE (v-SNARE), which binds to a tethering-SNARE (t-SNARE) on the target 
membrane, producing the trans-SNARE complex. After fusion, the cargo is transferred to that 
specific compartment76,77. 
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The Golgi is a very dynamic organelle; it has the capacity to transform in response to specific 
stimuli or cellular changes. For example, the Golgi or any Golgi-like structures fragment into 
numerous tubular and vesicular structures when cells undergo mitosis: the ER export sites 
disappear, the Golgi integral membrane proteins are trapped in the ER, and Golgi peripheral 
proteins are retargeted to the ER or cytoplasm. After mitosis is completed, the Golgi is readily re-
formed by outgrowth from the ER and fusion of the tubular and vesicular structures80. 
Until recently, the Golgi was seen as a static organelle. In this model, Golgi enzymes are 
retained within one Golgi cisterna, and cargo (the proteins that are transported to and processed 
in the Golgi) are transported through the different Golgi compartments in the anterograde 
direction via COPI vesicles. However, at present, the cisternal maturation model is favored. It is 
now believed that cargo remains in one cisterna and that this Golgi compartment traffics in the 
anterograde direction, whereas the Golgi enzymes traffic backward by COPI vesicles. This model 
is based on the experimental observations that cargo indeed remains in a specific cisterna and 
that COPI vesicles are enriched with Golgi enzymes81,82.  
Given the sequential and competing nature of glycosyltransferases, the precise localization of 
these enzymes within the Golgi is of great importance. It is thought that glycosyltransferases are 
arranged in an assembly line in the Golgi, where early-acting transferases are localized in the 
cis-Golgi, intermediate acting transferases in the medial-Golgi, and ‘terminating’ transferases in 
the trans-Golgi. A signal targeting glycosyltransferases to a specific Golgi localization has not yet 
been described. Studies have indicated that glycosyltransferases from a certain Golgi 
compartment form high-molecular-mass complexes. The presence of multi-enzyme complexes is 
likely to be functionally relevant in the regulation of glycosylation and contribute to the 
maintenance of the steady-state localization of the Golgi glycosyltransferases83. When Nilsson et 
al. re-directed a Golgi resident glycosyltransferase to the ER, another Golgi enzyme also was 
retained in the ER. Not all glycosyltransferases form complexes; in particular, those found in the 
trans-Golgi network seem to be unbound. Another factor that is likely to play a role in the 
targeting of glycosyltransferases is the thickness of the lipid bilayer, which increases en route to 
the plasma membrane. The fact that Golgi proteins have shorter transmembrane domains than 
do plasma membrane proteins suggests that cisternae of a specific compartment can 
accommodate glycosyltransferases with a transmembrane domain of matching length. However, 
it has been shown that some soluble forms of glycosyltransferases, which have lost their 
transmembrane domain, are retained in the Golgi probably as a result of being associated in 
complexes82,81. It is likely that more independent signals act together to mediate efficient Golgi 
localization. 
 
Conserved oligomeric Golgi complex and its role in Golgi traffic 
 
Recently, 2 patients were identified to have a defect in subunit 7 of the conserved oligomeric 
Golgi complex (COG7); the patients were classified as CDG type IIe84. The mammalian COG 
complex contains 8 subunits, of which COG1 through -4 form lobe A and COG5 through –8 form 
lobe B with COG4 as core component linking the 2 lobes85.  
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Mutations in COG subunits (COG1 through -8) of CHO, yeast, and Drosphila melanogaster 
sperm cells have been shown to affect structure and function of the Golgi, producing defects in 
glycoconjugate biosynthesis, intracellular protein sorting, protein secretion, and in some cases, 
cell growth. In the recessive COG1 and COG2 CHO null mutants, for example, the Golgi showed 
an abnormal morphology with dilated cisternae and pleiotropic defects in a number of medial- 
and trans-Golgi-associated reactions affecting N-linked, O-linked, and lipid-linked 
glycoconjugates86. The COG complex thus seems to play a role in determining and maintaining 
Golgi structure and morphology. Furthermore, COG works in concert with COPI. Their function is 
to retrograde transport several Golgi resident proteins to the appropriate Golgi compartment 
where they reside. Evidence came from the work of Oka et al.87, who investigated the 
consequences of the loss and overexpression of COG on a set of Golgi resident type II 
transmembrane proteins, including members of the SNARE, Rab, and golgin protein families. 
The expression and localization of some proteins were COG-dependent, whereas for others this 
was not the case. The COG-sensitive proteins are referred to as ‘GEARs’.  
 
 
Functions of O-linked glycans 
 
 
Various functions have been described for O-linked glycans. Only the main roles are given here; 
for details, the reader is referred to other reviews7,88. In general, O-linked glycans have been 
found to function in protein structure and stability, immunity, receptor-mediated signaling, 
nonspecific protein interactions, modulation of the activity of enzymes and signaling molecules, 
and protein expression and processing. The biological roles of oligosaccharides appear to span 
the spectrum from those that are trivial to those that are crucial for the development, growth, 
function, or survival of an organism. A particular glycan may mediate diverse functions at distinct 
locations at specific times within a single organism89.  
Just like N-glycans, O-glycans can influence the secondary protein structure: the glycan can 
break the α-helicity of peptides90; can have a role in the tertiary protein structure [seen, e.g., on 
the porcine filamentous-shaped submaxillary mucin, in which release of an O-glycan leads to a 
globular shape91]; and in the quaternary protein structure and protein aggregation [seen, e.g., in 
ovine submaxillary mucin, which only forms aggregates when it is O-glycosylated92]. 
Subsequently, O-linked glycans maintain protein stability, heat resistance, hydrophilicity, and 
protease resistance by steric hindrance7.  
Additionally, mucin-type O-glycans are important for the binding of water. Mucins are proteins 
that are heavily glycosylated with mucin-type O-glycans and are often present at outer surfaces 
lacking an impermeable layer, such as the surfaces of the digestive, genital, and the respiratory 
system tracts. These mucins bear clusters of sialylated glycans, which produce regions with a 
strong negative charge. This gives mucins the capacity to bind large amounts of water and form 
mucus. The gels observed in nasal secretions, for example, are formed by secreted MUC2 
polypeptides linked together to form long, cross-linked polymers holding water. The primary 
function of these viscous mucin solutions and gels is to form a protective coating with 
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antibacterial properties93. Like mucin-type O-glycans, GAGs bind large volumes of water via the 
strong negative charge of the sulfate groups, providing resilience or resistance to compression 
rather than lubrication or reduction of friction. GAGs are found in extracellular matrices. In 
structural tissues, such as the cartilage of joints, GAGs can act as shock breakers by the slow 
reduction of its water content under high pressure.  
Another important function of O-linked sugars is to mediate recognition between proteins. Glycan 
structures can be substrates for nonenzymatic sugar-binding proteins, known as lectins. By 
interacting with lectins, glycans influence the targeting of the proteins to which they are attached. 
Examples of glycan-mediated recognition of glycoproteins are ubiquitous. For example, selectins 
and galectins, representing 2 classes of lectins located in the leukocyte-vascular system, bind to 
carbohydrate epitopes that induce cellular signaling, which in turn influences many crucial 
cellular processes, including cell growth, apoptosis, endocytosis, cell-cell interactions, cell-matrix 
interaction, matrix network assembly, and oocyte fertilization94. Additionally, sialylated O-
mannosyl glycan serves as binding ligand for laminin in the dystroglycan complex, which is 
important in muscle and brain development30. Moreover, O-linked glycans are known to have an 
effect on the immunologic recognition; for example, the ABO blood group antigens and 
recognition of glycopeptides by the MHC complex or by antibodies95.  
Subsequently, it is known that GAGs have a role in nonspecific protein interactions. Cell surface 
proteoglycans, for example, adhere soluble polypeptide growth factors through electrostatic 
interactions mediated by their GAGs, preventing the growth factors from diffusing. GAG 
interactions increase and stabilize concentration gradients of growth factors88.  
The effects of O-linked glycosylation on the bioactivity of many signaling molecules, particularly 
hormones and cytokines, and a relatively small number of enzymes, have been described. In 
most cases, the influence is not very strong (a difference of 2- or 3-fold), but rather provides a 
fine regulation mechanism. Effects leading to both an increase and a decrease in biological 
activity have been described. For example, a mucin-type O-linked glycan decreases the 
biological activity of interleukin-596, whereas it induces a higher enzymatic activity of human 
lactase phlorizin hydrolase97. The influence of unusual carbohydrate modifications on the activity 
of signaling molecules appears to be often crucial and specific. For example, O-fucose on 
urinary-type plasminogen activator was shown to be required for activation of its receptor, and 
the presence of O-fucosyl glycans seems to be required for proper Notch function34. Another 
example is the dynamic O-GlcNAc modification that seems to have an important role in a variety 
of signaling pathways, such as transcriptional regulation, proteasome-mediated protein 
degradation, insulin, and cellular stress signaling. Recently, it was found that O-GlcNAc 
modulates the activity of critical intermediates involved in the regulation of neutrophil motility98. 
Some very specific GAG structures are known to act as co-receptors, allowing activation of the 
primary receptor necessary for the activation of growth factors. The fibroblast growth factor, for 
example, must interact with the heparan sulfate chain of the proteoglycan syndecan to activate 
the primary fibroblast growth factor receptor99.  
Finally, O-linked glycosylation is essential for the expression and processing of particular 
proteins. Glycophorin A, for example, is a heavily glycosylated protein present on the surface of 
human erythrocytes. It has been shown that O-linked sugars are necessary for cell surface 
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expression of this glycoprotein100. The influence of O-glycans in the processing of proteins is, for 
example, seen in pro-insulin-growth-factor-II, which is cleaved into IGF-II only when Thr75 
contains an O-linked sugar101. As O-glycans are involved in numerous processes, it is inevitable 
that defects in O-glycan biosynthesis might lead to severe abnormalities for cellular functioning.  
 
 
Congenital disorders in the biosynthesis of O-glycans in humans 
 
 
CDG form a group of autosomal recessive metabolic disorders caused by defects in the 
biosynthesis of protein-linked glycans. To date, mainly genetic defects in N-glycan biosynthesis 
have been classified as CDG. The division of CDG into types I and II is based on the location of 
the defect in the N-glycan biosynthetic pathway. CDG-I includes all defects in the early N-glycan 
pathway in the cytoplasm or the ER and covers all steps until the transfer of the glycan to the 
protein. CDG-II includes all defects localized in the processing of N-glycans on the glycosylated 
protein. These are situated mainly in the Golgi compartment. At present, most defects in the 
biosynthesis of protein O-linked glycans are not included in this CDG classification and still have 
‘popular’ names and / or ‘biochemical’ names that are informative about the nature of the 
disease. Some O-glycosylation disorders affect only a particular O-glycan type, certain disorders 
affect more O-glycan types, and others also affect the biosynthesis of other glycoconjugates. It is 
becoming increasingly evident that the primary defect of these disorders is not necessarily 
localized in one of the glycan-specific transferases, but can likewise be found in the biosynthesis 
of nucleotide sugars, their transport to the ER/Golgi, and in Golgi trafficking. The clinical 
variations within a disorder and among the different inborn errors of O-glycan metabolism are 
enormous. Defects can lead to a severe autosomal recessive multisystem syndrome with 
neurologic involvement, whereas some defects, for example those in persons with the Bombay 
blood group or the Lewis-null blood group, do not produce a clinical phenotype. As O-
glycosylation biosynthesis is a very complex process with an enormous number of genes 
involved, it is obvious that the disorders described to date are just the tip of the iceberg. This 
novel area of inborn errors of metabolism still needs further exploration.  
This section discusses the clinical, molecular genetic, laboratory, and biochemical aspects of the 
known congenital disorders in the biosynthesis of O-glycans. The human congenital disorders 
that affect the biosynthesis of protein O-linked glycans are summarized in Table 3A, whereas the 
human congenital disorders with a defect affecting the biosynthesis of both N- and O-glycans are 
summarized in Table 3B. Both parts of Table 3 also list the group(s) who first discovered the 
genetic defects in the disorders.  
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Table 3A. Human congenital disorders of O-glycosylation 
Name OMIM Gene O-glycan type Ref. 
 
Defects in mucin-type O-glycan biosynthesis 
Familial Tumoral Calcinosis 211900 GALNT3 mucin-type 102 
 
Defects in GAG biosynthesis 
Progeroid variant of Ehlers Danlos 130070 B4GALT7 GAG 103 
Multiple exostoses syndrome type I 133700 EXT1 heparan/heparin sulfate 104 
Multiple exostoses syndrome type II 133701 EXT2 heparan/heparin sulfate 105 
Multiple exostoses syndrome type III 600209 EXT3 heparan/heparin sulfate 106 
 
Defects in GAG sulfation 
Macular Corneal Dystrophy 217800 CHST6 keratan sulfate 107 
Spondylo epiphyseal dysplasia type Omani 608637 CHST3 chondroitin sulfate 108 
Achondrogenesis type 1B 600972 DTDST sulfated GAGs 109 
Atelosteogenesis type II 256050 DTDST sulfated GAGs 110 
Diastrophic Dysplasia 222600 DTDST sulfated GAGs 111 
Multiple Epiphyseal Dysplasia 4 226900 DTDST sulfated GAGs 112 
Spondylo epimetaphyseal dysplasia type Pakistany 603005 ATPSK2 sulfated GAGs 113 
 
Defects in O-galactosyl glycan biosynthesis 
Ehlers Danlos syndrome type VI 225400 PLOD O-linked Gal 114 
 
Defects in O-mannosyl glycan biosynthesis 
Walker Warburg 236670 POMT1 or POMT2 
or FCMD or FKRP O-linked Man 
115-
118 
Limb-girdle muscular dystrophy type 2K 609308 POMT1 O-linked Man 119 
Muscle-eye-brain disease 253280 POMGNT1 or FKRP O-linked Man 118,120 
 
Putative defects in O-mannosyl glycan biosynthesis 
Fukuyama type congenital muscular dystrophy 253800 FCMD O-linked Man? 121 
Congenital muscular dystrophy type 1C 606612 FKRP O-linked Man? 122 
Limb-girdle muscular dystrophy type 2I 607155 KKRP O-linked Man? 123 
Congenital muscular dystrophy type 1D 608840 LARGE O-linked Man? 124 
 
Defects in O-glycan sialylation 
Hereditary inclusion body myopathy 600737 GNE sialylated O-linked glycans 125 
Distal myopathy with rimmed vacuoles 605820 GNE sialylated O-linked glycans 126 
Sialuria 269921 GNE sialylated O-linked glycans 127 
Congenital disorder of glycosylation type IIf 
 
- SLC35A1  sialylated O-linked glycans 60 
 
 
DEFECTS IN MUCIN-TYPE O-GLYCAN BIOSYNTHESIS 
 
 
UDP-GalNAc transferase 3 (polypeptide N-acetylgalactosaminyltransferase 3) deficiency 
 
The GALNT3 gene encodes UDP-GalNAc transferase 3 (GalNT3, EC 2.4.1.41), which transfers 
UDP-GalNAc to Thr/Ser of a protein backbone. GALNT3 is expressed in organs that contain 
secretory epithelial glands. It is highly expressed in human pancreas, skin, kidney, and testis and 
weakly expressed in prostate, ovary, intestine, and colon128. Patients with familial tumoral 
calcinosis (FTC) can have mutations in the GALNT3 gene. 
Familial tumoral calcinosis 
FTC is an autosomal recessive progressive metabolic disorder that manifests with massive 
calcium deposits in the skin and subcutaneous tissues and unresponsiveness to parathyroid 
hormone129. At present, FTC is the only syndrome with an isolated defect in mucin-type O-glycan 
biosynthesis102. The syndrome can be treated with phosphate-binding antacids (aluminium 
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hydroxide) and a low-phosphorus diet combined with calcium deprivation, which reduces and 
prevents the recurrence of calcific mass130. 
Laboratory findings 
Hyperphosphatemia has been described accompanied by inappropriately normal or increased 
concentrations of parathyroidhormone and 1,25-dihydroxyvitamin D3, 2 essential regulators of 
phosphate metabolism. Serum calcium is within reference values, and 25-hydroxycholecalciferol 
is decreased102.  
Diagnosis 
Recently, immunostaining with a monoclonal antibody against GalNT3 revealed that the protein 
was absent in a frozen skin biopsy from a patient with FTC, whereas GalNT3 was strongly 
expressed in the epidermis of a healthy individual. This suggests that immunostaining of skin 
biopsy samples for GalNT3 might be a useful tool in the diagnosis of this disorder131. The 
diagnosis can be confirmed at the molecular genetic level102.  
 
 
DEFECTS IN GAG BIOSYNTHESIS 
 
 
β-1,4-Galactosyltransferase 7 deficiency 
 
The B4GALT7 gene encodes β-1,4-galactosyltransferase 7 (B4GalT7, EC 2.4.1.133), which 
transfers Gal to the Xyl-Ser linkage in the linker region of proteoglycans103. B4GALT7 is 
expressed in human heart, pancreas, liver, and to a lesser extent, in placenta, kidney, brain, 
skeletal muscle, and lung. Patients with the autosomal recessive progeroid variant of Ehlers-
Danlos syndrome have mutations in the B4GALT7 gene. 
Progeroid variant of Ehlers-Danlos syndrome 
To date, 5 patients have been described with the progeroid variant of Ehlers-Danlos. 
Characteristic clinical features are a premature aging phenotype with a loose, elastic skin, failure 
to thrive, joint laxity, psychomotor retardation, hypotonia, and macrocephaly. Because 
proteoglycans are important structural components of the extracellular matrix of connective 
tissue, these patients suffer from skin, cartilage, and bone problems.  
Laboratory findings 
Thyroid, kidney, and liver function test results are within reference values. Urine organic acids, 
amino acids, mucopolysaccharides, and oligosaccharides were all within reference values. In 
addition, nitroprusside test results, chromosomal studies, serum creatine kinase concentrations, 
and growth hormone concentrations were all normal132.  
Diagnosis 
This disorder can be diagnosed at the enzyme level by use of an assay for galactosyltransferase 
I in human fibroblasts133. Mutations can be found in the corresponding gene103.  
 
 52 
Defects in protein O-glycan biosynthesis 
 
Deficiencies of extosin-1, -2, and -3 
 
The EXT1 and EXT2 genes encode the proteins extosin-1 and -2 (EC 2.4.1.224/2.4.1.225), 
respectively, which oligomerize with the copolymerases responsible for the elongation of the 
heparin and heparan sulfate chains. The exact function of extosin-3 is not known. The EXT 
genes are ubiquitously expressed in human tissue. Patients with hereditary multiple exostoses 
(HME) have a mutated EXT1, EXT2, or EXT3 gene. 
Hereditary Multiple exostoses (type I, II, and III) 
HME is a genetically heterogeneous autosomal dominant disorder characterized by the 
development of multiple cartilage-capped benign bone tumours (exostoses) located mainly on 
the long bones. This disorder is often accompanied by skeletal deformities and short stature. In 
many cases, the exostoses transform to malignant tumours. Mutations in EXT1 and EXT2 
account for 44% - 66% and 30% of the HME patients, respectively, whereas EXT3 appears to be 
the minor locus106. For a review on hereditary multiple exostoses, please see the article by 
Wicklund et al.134.  
Laboratory findings 
No laboratory findings have been reported that may aid in diagnosis.  
Diagnosis 
Genetic confirmation of the diagnosis can be obtained by mutation analysis in EXT1, EXT2, and 
EXT3104-106. 
 
 
DEFECTS IN GAG SULFATION 
 
 
N-acetylglucosamine-6-O-sulfotransferase deficiency 
 
The CHST6 gene encodes human GlcNAc-6-O-sulfotransferase (EC 2.8.2.-) that transfers 
sulfate to the 6-O position of GlcNAc and Gal residues in poly-N-acetyllactosamine extensions in 
keratan sulfate. GlcNAc-6-O-sulfotransferase is produced in human cornea, brain, spinal cord, 
and trachea. Macular corneal dystrophy (MCD) is caused by distinct mutations in the gene 
CHST6. 
Macular Corneal Dystrophy (types I and II) 
MCD is a progressive autosomal recessive disease in which minute, gray, punctuate opacities in 
the cornea lead to bilateral loss of vision. Onset of clinical signs occurs in the first decade of life. 
Most patients have painful attacks with photophobia, foreign body sensations and recurrent 
corneal erosions. MCD is characterized by nonsulfated (MCD type I) or low-sulfated (MCD type 
II) keratan sulfate107. 
Laboratory findings 
MCD patients have an accumulation of GAGs in corneal fibroblasts135,136. Keratan sulfate in 
serum and cartilage is nonsulfated or low-sulfated137,138. The defect is thus not restricted to cells 
in the cornea. No abnormalities have been described in the total amount of urinary GAGs or in 
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GAG subfractions. In addition, the electrophoretic migration of urinary GAG subfractions was 
normal. 
Diagnosis 
In earlier days, histopathologic diagnosis of MCD was based on the fact that GAG deposits stain 
positively with Hale’s colloidal iron, alcian blue, periodic acid-Schiff, and metachromic dyes139. 
Currently, MCD can be diagnosed with an ELISA that makes use of a monoclonal antibody 
specific for a sulfated epitope on keratan sulfate140. The subdivision of MCD into types I and II is 
based on the results of this ELISA. The diagnosis can be confirmed at the molecular genetic 
level107.  
 
Chondroitin 6-sulfotransferase 1 deficiency 
 
The CHST3 gene encodes chondroitin 6-sulfotransferase 1 (EC 2.8.2.17), which catalyzes the 
sulfation of the 6-O position of GalNAc residues in chondroitin sulfate chains. CHST3 is widely 
expressed in adult tissues. It is expressed in the human heart, placenta, skeletal muscle, and 
pancreas, but also in various immune tissues such as the spleen, lymph nodes, and thymus. 
Recently, it was found that mutations in the CHST3 gene cause autosomal recessive 
spondyloepiphyseal dysplasia (SED), Omani type108. 
Spondylo epiphyseal dysplasia type Omani 
Patients with SED Omani type are normal in length at birth but show growth retardation later, and 
are short in stature in adulthood (110-130 cm). Severe progressive kyphoscoliosis, severe 
arthritic changes with joint dislocations, rhizomelic limbs, genu valgum, cubitus valgus, mild 
brachydactyly, camptodactyly, and microdontia occur in this disease141.  
Laboratory findings 
Laboratory investigations revealed hematological indices and biochemical results within 
reference values, normal results for routine metabolic investigations, and normal karyotype. 
Urinary excretion of mucopolysaccharides was normal. Thyroid function was normal, and growth 
hormone, insulin-like growth factor 1, follicle-stimulating hormone, and prolactin concentrations 
were within reference values141.  
Diagnosis 
Chondroitin 6-sulfotransferase 1 activity can be measured in human fibroblasts108. Mutations can 
be found in the corresponding gene108. 
 
Diastrophic dysplasia sulfate transporter deficiency 
 
The DTDST gene (also called SLC26A2) encodes the diastrophic dysplasia sulfate transporter 
(DTDST), which is a sulfate/chloride antiporter. The primary source of sulfur for the sulfation 
pathway of proteoglycans is free SO42-, which is transported to the cytoplasm mainly by DTDST. 
Mutations in the sulfate transporter lead to undersulfation of the GAGs. DTDST is ubiquitously 
expressed. Mutations in the DTDST gene are the cause of diastrophic dysplasia (DTD), 
achondrogenesis type 1B (ACG-1B), atelosteogenesis type II (AO-II), and multiple epiphyseal 
dysplasia 4 (EDM4). The clinical features in the DTDST skeletal dysplasia family range from a 
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relatively mild condition to severe conditions incompatible with life and are subdivided into the 4 
syndromes listed above. The disorders have autosomal recessive inheritance. The severity of the 
phenotype correlates with the underlying DTDST mutation; mutations leading to stop codons or 
transmembrane domain substitutions mostly lead to the most severe phenotype (ACGB1), 
whereas other structural or regulatory mutations usually lead to one of the less severe 
phenotypes142. The classification of DTD, AO-II, or EDM4, and thus of the severity of the disease, 
depends on residual sulfate uptake capacity and the extent of proteoglycan undersulfation143. For 
a review, see the article by Rossi and Superti Furga144. 
Achondrogenesis type 1B  
ACGB1 is among the most severe skeletal disorders in humans. The disease is characterized by 
severe hypodysplasia of the spine, of the rib cage, and of the extremities. ACGB1 is always 
lethal immediately after and sometimes even before birth142.  
Atelosteogenesis type II 
AO-II is a lethal chondrodysplasia caused by collapse of the airways, resulting from abnormalities 
in the tracheal, laryncheal, and bronchial cartilage. Phenotypically, AO-II is the severe variant of 
DTD. In addition to the clinical features described for DTD, AO-II is characterized by severe and 
progressive kyphosis, horizontal sacrum, and a gap between the first and the second toes145. 
Diastrophic dysplasia 
DTD is a skeletal dysplasia associated with short stature [adult height, 100-140 cm146], joint 
contractures, cleft palate, scoliosis, bilateral clubfeet, and characteristic clinical signs such as the 
so-called ‘hitchhiker thumb’ and cystic swelling of external ears. Phenotypic variability is 
wide147,144.  
Multiple Epiphyseal Dysplasia 4 
Patients with EDM4 have a condition with clubfoot, scoliosis, mild finger deformity, and mildly 
short or normal stature, but without palatal clefting, ear swelling, or thumb deviation148.  
Laboratory findings 
Histochemical studies revealed that cartilage proteoglycans of ACGB1 patients were 
quantitatively reduced and do not stain with toluidine blue. Impaired synthesis of sulfated 
proteoglycans was observed in fibroblast cultures of an ACGB1 patient149. There have been no 
published studies on the quantitative excretion or the composition of urinary GAGs, the catabolic 
products of proteoglycans. 
Diagnosis 
Sulfate transport within cells can be measured in human fibroblasts150. The diagnosis of DTDST 
deficiency can be confirmed at the molecular genetic level109-112. 
 
3’-Phosphoadenosine 5’-phosphosulfate synthase 2 deficiency  
 
The ATPSK2 gene encodes the enzyme 3’-phosphoadenosine 5’-phosphosulfate synthase 2 
(PAPSS2, EC 2.7.1.25/EC 2.7.7.4)113. PAPSS2 is a bifunctional enzyme that activates 
cytoplasmic SO42- into a high-energy form in 2 enzymatic steps: 1) its ATP-sulfurylase uses ATP 
and SO42- to synthesize adenosine 5’-phosphosulfate (APS) and 2) its APS kinase catalyzes the 
phosphorylation of APS to 3’-phosphoadenosine 5’-phosphosulfate (PAPS). PAPS is the 
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universal sulfate donor for posttranslational protein sulfation. Defective PAPSS2 thus leads to 
undersulfation of GAGs. PAPSS2 is expressed in human cartilage. In a large Pakistani family, 
comprising 8 generations, a mutation was found in the ATPSK2 gene that leads to SED, 
Pakistany type. 
Spondylo epimetaphyseal dysplasia type Pakistany 
The clinical features of SED, Pakistany type, include short stature evident at birth; short, bowed 
lower limbs; a mild, generalized brachydactyly, kypohoscoliosis, an abnormal gait, and early-
onset degenerative joint disease in the hands and knees. Radiographs showed delayed 
epiphyseal ossification, especially of the hips and knees, and platyspondyly. Inheritance of the 
disease is autosomal recessive151.  
Laboratory findings 
No laboratory findings have been reported that may lead aid in diagnosis151. 
Diagnosis 
PAPSS2 activity can be measured in human liver biopsy samples152. Diagnosis can be confirmed 
at the molecular genetic level113. 
 
 
DEFECTS IN O-GALACTOSYL GLYCAN BIOSYNTHESIS 
 
 
Lysyl hydroxylase-1 deficiency  
 
The PLOD gene encodes lysyl hydroxylase-1 (EC 1.14.11.4). Lysyl hydroxylase-1 catalyzes the 
formation of hLys in collagens and other proteins with collagen-like amino acid sequences by the 
hydroxylation of Lys residues. hLys serves as attachment site for O-galactosyl glycans and is 
essential for the formations of collagen cross-links, contributing to collagen structure and stability. 
Lysyl hydroxylase-1 deficiency indirectly leads to an O-glycosylation defect. The function of the 
O-galactosyl glycans is unclear, although it is suggested that they may play a role in recognizing 
and activating collagen receptors in the cell membrane153. Subsequently, it has been shown that 
there is a relationship between cross-link content and the degree of collagen glycosylation154. 
Lysyl hydroxylase is produced in human liver, heart, lung, skeletal muscle, brain, and placenta155. 
Patients with Ehlers-Danlos syndrome type VIa have mutations in the PLOD gene. 
Ehlers-Danlos syndrome type VIa 
Patients with Ehlers-Danlos VIa are characterized clinically by neonatal kyphoscoliosis, 
generalized joint laxity, skin fragility, and severe muscle hypotonia at birth. Arterial rupture has 
caused death in some patients 156. The inheritance of the syndrome is autosomal recessive.  
Laboratory findings 
Urinary amino acids were within reference values. Amino acid analysis of dermal collagen shows 
a marked decrease in hLys content157.  
Diagnosis 
The activity of lysyl-protocollagen hydroxylase can be measured in cultured skin fibroblasts157. 
The diagnosis can be further confirmed by mutation analysis in the corresponding gene114. 
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DEFECTS IN O-MANNOSYL GLYCAN BIOSYNTHESIS 
 
 
O-Mannosyl glycan biosynthesis disorders are characterized by an abnormal α-dystroglycan 
glycosylation. α-Dystroglycan is an essential component of the dystrophin-glycoprotein complex, 
which is produced in human tissues such as muscle, brain, nerve, and heart. The dystrophin-
glycoprotein complex is a multimeric transmembrane complex, providing a tight connection 
between the cytoskeleton and the extracellular matrix. Dystroglycan is generated from a single 
gene (DAG1) and is subsequently cleaved into 2 subunits: transmembrane β-dystroglycan and 
peripheral α-dystroglycan. In muscle, the intracellular side of transmembranic β-dystroglycan 
binds to a variety of cytoplasmic molecules, such as dystrophin, which in turn interacts with the 
cytoskeleton of cells. The extracellular side of β-dystroglycan binds noncovalently to α-
dystroglycan, which in turn binds to extracellular matrix proteins such as laminin158,159. Different 
mammalian glycan sequencing studies have revealed that α-dystroglycan is heavily glycosylated 
with O-linked Man chains (~70%) and to a lesser extent with mucin-type O-glycans (~30%), 
which mediate protein-protein interactions160,161. For the screening of defects in O-mannosyl 
glycan biosynthesis, the immunohistochemical staining of α-dystroglycan is used on muscle 
biopsies of patients. At present, α-dystroglycan is the only known substrate for this type of 
glycosylation in mammals. Often the monoclonal antibodies VIA4-1 and IIH6, which recognize an 
unknown carbohydrate epitope in α-dystroglycan, are used. Antibodies against the core 
structures of α- and β-dystroglycan serve as controls in such experiments162. 
 
Protein O-mannosyltransferase deficiency 
 
Coexpression of the POMT1 and the POMT2 genes is necessary for the enzymatic activity of 
protein O-mannosyltransferase (EC 2.4.1.109; Ref.68). Mannosyltransferase catalyzes the 
attachment of Man residues to Thr/Ser amino acids of a protein. POMT1 is highly expressed in 
human testis, heart, and pancreas, whereas expression is lower in kidney, skeletal muscle, brain, 
placenta, lung, and liver. Walker-Warburg Syndrome (WWS) and limb-girdle muscular dystrophy 
type 2K (LGMD2K) can be caused by mutations in the POMT1 gene. POMT2 is highly expressed 
in testis, with expression lower in most tissues. Recently, it was discovered that mutations in the 
POMT2 gene also cause WWS163. 
Walker-Warburg Syndrome 
In 20% of WWS patients, a mutation is found in the POMT1 gene. The incidence of POMT2 
mutations is in the same range as that of POMT1163. The phenotype seen in the WWS patients 
with a POMT2 mutation is indistinguishable from that of patients with POMT1 mutations. Patients 
with this rare autosomal recessive disorder have a life expectancy of <3 years (mean, 0.8 years). 
WWS patients have malformations of the muscle, eye, and brain. Typical brain anomalies include 
hydrocephalus, cerebellar hypoplasia, absent corpus callosum and cerebellar vermis, 
cobblestone cortex, and fusion of the hemispheres. Additionally, WWS patients can have 
numerous eye anomalies, such as cataracts, microphthalmia, persistent hyperplastic primary 
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vitreous, and Peters anomaly. WWS patients have little motor activity because of severe muscle 
dystrophy164. For a review, see van Reeuwijk et al.164. 
Limb-girdle muscular dystrophy type 2K  
Patients with LGMD2K have a progressive muscle weakness involving the proximal muscles of 
the shoulder and pelvic girdles. These patients also have a slow, progressive limb-girdle 
muscular dystrophy, a mild microcephaly, and severe mental retardation, but normal brain 
imaging. Onset of the autosomal recessive disorder is in the first decade of life119,165.  
Laboratory findings 
In both WWS and LGMD2K patients, serum creatine kinase was increased and staining of α-
dystroglycan by the VIA4-1 and/or IIH6 monoclonal antibodies was abnormal119,166,167. Decreased 
staining of the laminin α2-chain (merosin) has been observed in WWS, although patients have 
been reported with normal amounts of merosin168,169. 
Diagnosis 
The activity of protein O-mannosyltransferase can be measured in human kidney cells68. The 
diagnosis of POMT1 deficiency can be confirmed by mutation analysis of the gene115,119. 
 
O-mannosyl-β1,2-N-acetylglucosaminyltransferase-1 deficiency 
 
The POMGNT1 gene encodes the enzyme O-mannosyl-β1,2-N-acetylglucosaminyltransferase-1 
(EC 2.4.1.101). This enzyme catalyzes the second step, the linkage of a GlcNAc residue to 
protein-bound Man, in the O-mannosyl glycan core structure. The enzyme O-mannosyl-β1,2-N-
acetylglucosaminyltransferase-1 appears to be present in all tissues. Muscle-eye-brain disease 
(MEB) is caused mainly by mutations in the POMGNT1 gene. 
Muscle-eye-brain disease 
MEB is a muscular dystrophy/neuronal migration disorder with a phenotype similar to, but less 
severe phenotype than, that of WWS patients. The life expectancy of MEB patients is 10-30 
years166. Clinically, MEB is differentiated from WWS mainly on the basis of the presence of a 
normal or thin corpus callosum and of pronounced cerebellar cysts, which are both absent in 
WWS patients166. The inheritance of the disorder is autosomal recessive. For a review, see 
Diesen et al.170. 
Laboratory findings 
MEB patients have increased serum creatine kinase and abnormal staining of α-dystroglycan by 
VIA4-1 and/or IIH6 monoclonal antibodies166,171. Staining of the laminin α2-chain (merosin) is 
generally normal171. 
Diagnosis 
The activity of O-mannosyl-β1,2-N-acetylglucosaminyltransferase-1 can be measured in human 
muscle biopsies172. The diagnosis can be further confirmed by molecular genetic analysis in the 
corresponding gene120. 
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PUTATIVE DEFECTS IN O-MANNOSYL GLYCAN BIOSYNTHESIS 
 
 
Fukutin deficiency 
 
The FCMD gene encodes the protein fukutin. The function of fukutin is not known, but it is 
suggested to be a glycosyltransferase173. Fukutin is produced in many parts of the body, with the 
highest amounts in the brain, heart, pancreas, and skeletal muscle. Fukuyama-type congenital 
muscular dystrophy (FCMD) and WWS can be caused by mutations in the FCMD gene. 
Deficiencies in fukutin are putative defects in O-mannosyl glycan biosynthesis. These 
deficiencies might be reclassified depending on the function of fukutin. 
Fukuyama-type congenital muscular dystrophy 
FCMD is an autosomal recessive disorder in which patients manifest with generalized muscle 
weakness, severe hypotonia, mental retardation, and brain malformations. Brain malformations 
are very similar to those reported in WWS and MEB and include cerebral and cerebellar 
micropolygyria, hydrocephalus, fibroglial proliferation of the leptomeninges, focal 
interhemispheric fusion, and hypoplasia of the corticospinal tracts174,175. Compared with MEB and 
WWS patients, the eye involvement in patients with Fukuyama type congenital dystrophy is more 
variable, ranging from myopia to retinal detachment, persistent vitreous bodies, persistent 
hyaloid artery, or microphthalmia176. For a review, see Toda et al.177. 
Walker-Warburg Syndrome 
Severe mutations in the FCMD gene lead to WWS116,117.  
Laboratory findings 
In both FCMD and WWS patients, serum creatine kinase was increased. Subsequently, 
abnormal staining of α-dystroglycan by the VIA4-1 and/or IIH6 monoclonal antibodies and 
decreased staining of laminin α2-chain were observed in all cases investigated178,179,168. 
Diagnosis 
As the function of fukutin is unknown at present, the diagnosis can be confirmed only at the 
molecular genetic level116,121. 
 
Deficiencies in fukutin-related protein 
 
The FKRP gene encodes the fukutin-related protein (FKRP), the function of which is undefined at 
present. FKRP is expressed in skeletal muscle, placenta, and heart and weakly in brain, lung, 
liver kidney, and pancreas. FKRP is predicted to be a tissue-specific glycosyltransferase involved 
in the O-mannosylation of α-dystroglycan122. Mutations in the FKRP gene with autosomal 
recessive inheritance have been found in congenital muscular dystrophy type 1C (MDC1C), 
LGMD2I, WWS, and MEB118, but also in asymptomatic cases180. Deficiencies in FKRP are 
putative defects in O-mannosyl glycan biosynthesis. These deficiencies might be reclassified 
depending on the function of FKRP. 
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Congenital muscular dystrophy type 1C 
The onset of the characteristic clinical features of MDC1C occurs at birth or within the first 6 
months of life; these features include severe weakness and wasting of the shoulder-girdle 
muscles, hypertrophy and weakness of the leg muscles with an inability to walk, and a severe 
restrictive pulmonary disease leading to respiratory failure in the second decade of life. 
Cardiomyopathy has been observed in several patients122. The brain is not always involved in 
this disorder. Severe mutations can lead to structural cerebellar changes181 or more extensive 
structural brain and eye involvement similar to that seen in MEB and WWS124. 
Limb-girdle muscular dystrophy type 2I 
In LGMD2I, the age at onset of clinical signs ranges from 6 months to 40 years. The disorder 
presents as hypotonia, weakness in the hip and shoulder-girdle muscles, and hypertrophy of the 
calf muscles. The spectrum ranges from infants with early presentation and a Duchenne-like 
disease course, including cardiomyopathy, to milder phenotypes with a long-term outcome. 
Moreover, these patients lack structural brain or eye involvement123,182.  
Walker-Warburg Syndrome and Muscle-eye-brain disease 
Recently, a patient diagnosed with WWS and a patient diagnosed with MEB were found to have 
a mutated FKRP gene118. 
Asymptomatic carriers for homozygous FKRP mutations 
De Paula et al.180 investigated 86 Brazilian LGMD genealogies and identified 4 persons with 
novel homozygous FKRP gene mutations who were asymptomatic.  
Laboratory findings 
In patients with the 4 disorders, serum creatine kinase was increased. In all MDC1C cases 
investigated, staining of α-dystroglycan by VIA4-1 and/or IIH6 monoclonal antibodies was 
abnormal, and staining of laminin α2-chain was decreased, whereas the LGMD2I cases studied 
showed a variable decrease in VIA4-1 and/or IIH6 staining and often (but not always) a laminin 
α2-chain deficiency was found122,123,183.  
Diagnosis 
As the function of FKRP is unknown at present, the diagnosis can be confirmed only at the 
molecular genetic level122,123,118. 
 
N-acetylglucosaminyltransferase-like protein deficiency 
 
The LARGE gene encodes the N-acetylglucosaminyltransferase-like protein (LARGE), a 
homolog of mammalian β1,3-N-acetylglucosaminyltransferase. The gene is ubiquitously 
expressed, with the highest expression in the heart, brain, and skeletal muscle184. Mutations in 
the LARGE gene have been found in a patient with MDC1D. Barresi et al. showed that gene 
transfer of LARGE not only restores the α-dystroglycan function in a LARGE-deficient mouse and 
in an MDC1D patient, but also in patients with FCMD, MEB, WWS, LGMD2I, and other 
glycosyltransferase-deficient muscular dystrophies185. Kanagawa et al.186 showed that the N-
terminal domain of α-dystroglycan serves as an intracellular recognition site for LARGE, which 
initiates subsequent functional glycosylation of α-dystroglycan. The glycosylation is essential for 
ligand binding and cell surface laminin/perlecan organization. Thus, LARGE is the key 
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determinant of the functional expression of α-dystroglycan186. Recently, it was shown that 
LARGE is localized in the Golgi, where it stimulates glycosylation. In a patient with MDC1D, 
LARGE was mislocalized and thus failed to have an effect on α-dystroglycan glycosylation187. 
Inducing LARGE expression or activity could be an attractive target for the design of therapeutics 
for glycosyltransferase-deficient congenital muscular dystrophies185. LARGE deficiency is a 
putative defect in O-mannosyl glycan biosynthesis. This deficiency might be reclassified 
depending on the function of LARGE. 
Congenital muscular dystrophy type 1D 
One patient with MDC1D was identified with a compound heterozygous mutation in the LARGE 
gene124. The LARGE-deficient patient presented with congenital muscular dystrophy, profound 
mental retardation, white matter changes, and subtle structural brain abnormalities124. 
Laboratory findings 
The MDC1D patient has increased serum creatine kinase. In addition, staining of α-dystroglycan 
by VIA4-1 and/or IIH6 monoclonal antibodies was abnormal, whereas staining of the laminin α2-
chain was normal124.  
Diagnosis 
Because the function of LARGE is unknown at present, the diagnosis can be confirmed only at 
the molecular genetic level124. 
 
 
DEFECTS IN O-GLYCAN SIALYLATION  
 
 
UDP-N-acetylglucosamine 2 epimerase/N-acetylmannosamine kinase deficiency 
 
The GNE gene encodes the enzyme GNE/MNK (EC 5.1.3.14/EC 2.7.1.60). GNE/MNK is a 
bifunctional enzyme that catalyzes the first 2 steps of the biosynthesis of the nucleotide sugar 
CMP-NeuAc. GNE/MNK activity is highest in the liver and placenta, and it is also found in the 
heart, brain, lung, kidney, skeletal muscle, and pancreas. Although CMP-NeuAc is incorporated 
in both N- and O-glycans, it seems that defects in GNE/MNK influence only the sialylation of O-
linked glycans and not of N-glycans188. Mutations in GNE/MNK have been described in 
hereditary inclusion body myopathy (hIBM), in distal myopathy with rimmed vacuoles (DMRV), 
and in sialuria.  
Hereditary inclusion body myopathy and distal myopathy with rimmed vacuoles 
Patients with hIBM and DMRV (also known as Nonaka myopathy) have biallelic missense 
mutations in the epimerase and/or kinase domains of the GNE gene. hIBM and DMRV are 
autosomal recessive forms of inclusion body myopathy that typically cause progressive, severe, 
noninflammatory muscle disease, leading to myopathic weakness and atrophy of the limb 
muscles. The quadriceps, however, is nearly always spared. The syndromes manifest in early 
adult life. For a review, see Darvish189. 
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Laboratory findings 
Histologically, the muscle fibers degenerate and form rimmed vacuoles in hIBM and DMRV, 
especially in the atrophic areas190,191. Creatine kinase was within reference values or moderately 
increased192,193. In most hIBM patients investigated, hypoglycosylation of α-dystroglycan was 
found with the VIA4-1 and/or IIH6 monoclonals, whereas staining of the laminin α2-chain was 
normal194,195. Arachis hypogaea peanut agglutinin lectin, which recognizes unsialylated core 1 O-
glycans, reacts strongly with sarcolemmal glycoproteins and with α-dystroglycan in DMRV 
patients, but not in controls. The sialic acid content of O-glycans was decreased to 60%-80% of 
control values in DMRV patients196.  
Sialuria 
Sialuria, formerly called French-type sialuria, is an autosomal dominant inborn error of 
metabolism in which the feedback control mechanism in the biosynthesis of CMP-NeuAc is lost. 
This is caused by mutations in codons 263 to 266 of GNE197, resulting in the lack of feedback 
inhibition of this enzyme by CMP-NeuAc. To date, 7 patients have been reported with sialuria; 
presenting clinical features included mild psychomotor delay, coarse face, recurrent upper 
respiratory tract infections, and hepatomegaly197.  
Laboratory findings 
Highly increased concentrations of urinary free sialic acid (NeuAc) and of fibroblast free sialic 
acid have been found in patients with sialuria198,199. Hypersialylated core 1 O-glycans were 
observed, whereas the sialylation of N- glycans was normal (Wopereis S; this thesis).  
Diagnosis 
The epimerase and the kinase activities can both be measured in human lymphoblastoid cells200, 
and total GNE activity can be measured in human leukocytes201. The diagnosis can be confirmed 
by molecular genetic approaches125-127. 
 
Golgi CMP-sialic acid transporter deficiency 
 
The SLC35A1 gene encodes the Golgi CMP-NeuAc transporter, which is responsible for the 
transport of cytoplasmic CMP-NeuAc into the Golgi. The SLC35A1 gene is likely to be 
ubiquitously expressed. Recently, a patient classified as having CDG-IIf was found to have 
mutations in the SLC35A1 gene.  
Congenital disorder of glycosylation type IIf  
The CDG-IIf patient presented initially with a spontaneous massive bleeding of the posterior 
chamber of the right eye and cutaneous hemorrhages. The clinical phenotype worsened to more 
severe hemorrhages, respiratory distress syndrome, and opportunistic infections. Because of 
graft-vs-host disease after bone marrow transplantation, the patient died at the age of 37 
months60.  
Laboratory findings 
The patient had macrothrombocytopenia, neutropenia and complete lack of sialyl Lex antigen on 
polymorphonuclear cells. Severe thrombocytopenia and abnormalities of the megakaryocyte 
morphology were found, including small mononuclear or hyposegmented megakaryocytes, 
vacuolated cells and abnormal fragmentation of megakaryocyte cytoplasm into large platelet 
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masses. Coagulation and enzyme activities of α1,3-fucosyl- and α2,3-sialyltransferase were all 
normal60. Unsialylated core 1 O-glycans were detected with peanut agglutinin lectin staining. 
Plasma N-glycosylated proteins appeared to have a normal sialylation pattern apparent from the 
normal plasma transferrin isoform profile60. 
Diagnosis 
The activity of the Golgi CMP-NeuAc transporter can be determined by cloning of the human 
cDNA alleles into a recombinant adeno-associated virus for gene complementation of lec2-
deficient cells. Lec2-deficient cells are commercially available CHO cells that have a deficient 
Golgi CMP-NeuAc transporter60. CMP-NeuAc transporter activity can also be determined in 
human fibroblasts84. The diagnosis can be confirmed by mutation analysis in the SLC35A1 
gene60. 
 
 
Congenital disorders of glycosylation affecting the biosynthesis of N- and O-
glycans 
 
 
Deficiencies in fucosyltransferase 1 and 2 
 
The FUT1 and FUT2 genes encode fucosyltransferase 1 (FUT1) and 2 (FUT2), respectively (EC 
2.4.1.69). FUT1 and -2 catalyze the addition of Fuc to a Gal residue in an α1,2 linkage, which is 
also known as the H determinant and is the essential precursor for the A and B antigens. The A, 
B, and H blood group determinants are linked to the N-acetyllactosamine unit or to Galβ1-
3GlcNAc structures of N- and mucin-type O-glycans, found on erythrocytes or on secreted 
proteins in saliva and other secretions. It is thought that FUT1 and FUT2 are expressed in a 
tissue-specific manner, with the expression is restricted to cells of mesodermal or endodermal 
origin. Human FUT2 is expressed in the small intestine, colon and lung, whereas which tissues 
express human FUT1 is unknown at present. Individuals with the Bombay, para-Bombay and 
non-secretor blood groups have mutations in the FUT1 or FUT2 gene. 
Bombay, para-Bombay and non-secretor blood groups 
The para-Bombay blood group is caused by a deficient FUT1202, whereas the non-secretor blood 
group is caused by a deficient FUT2203. The Bombay blood group can be caused by either a 
deficient FUT1 or a deficient FUT2204. Inheritance of the 3 conditions is autosomal recessive. 
Individuals with deficiencies in one of the FUT enzymes have no clinical phenotype.  
Laboratory findings 
Individuals with the Bombay blood group lack the H determinant in all tissues, and individuals 
with the para-Bombay blood group synthesize H determinants in soluble form but not on 
erythrocytes. Individuals with the non-secretor blood group lack the H determinants in soluble 
form, but still have their erythrocyte antigens. 
Diagnosis 
The diagnosis of FUT1 or FUT2 deficiency can be confirmed by mutation analysis of the 
genes202-204. 
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Galactoside 3(4)-fucosyltransferase deficiency 
 
The FUT3 gene encodes a galactoside 3(4)-fucosyltransferase (FUT3; EC 2.4.1.65). FUT3 can 
use both type 1 and type 2 carbohydrate chains as substrate, producing either an α1,3 or α1,4 
linkage of Fuc to the Gal residue. Type 1 Lewis determinants (Lea and Leb) are linked to Galβ1-
3GlcNAc structures of N-and mucin-type O-glycans, whereas the type 2 Lewis determinants (Lex, 
sLex, and Ley) are linked to the N-acetyllactosamine unit of N- and mucin-type O-glycans. FUT3 
is highly expressed in the stomach, colon, small intestine, lung, and kidney and to a lesser extent 
in the salivary glands, bladder, uterus, and liver. Individuals with a Lewis-negative blood group 
have mutations in the FUT3 gene. 
Lewis-null (Lea-/b-) blood group 
Individuals with the Lewis-null blood group have no clinical phenotype205. Inheritance is 
autosomal recessive.  
Laboratory findings 
Persons with a Lewis-negative blood group do not have the type 1 Lewis determinants. Because 
other fucosyltransferases (FUT4, FUT6, FUT7, or FUT9) catalyze the Fuc α1,3 and α1,4 linkage 
to Gal residues of type 2 glycans, the Lex, sLex and Ley determinants are expressed in persons 
with mutated FUT3. 
Diagnosis 
The diagnosis of FUT3 deficiency can be confirmed by mutation analysis in the gene205. 
 
Table 3B. Human combined congenital disorders of N- and O-glycosylation 
Name OMIM Gene Glycan type Ref 
 
Bombay blood group  
 
211100 
 
FUT1 or FUT2 
 
A, B, H blood group determinants 
 
204 
Para-Bombay bloodgroup 211100 FUT1 A, B, H blood group determinants 202 
Non-secretor bloodgroup  182100 FUT2 A, B, H blood group determinants 203 
Lewis negative bloodgroup 111100 FUT3 Lea and Leb determinants 205 
Congenital disorder of glycosylation type IIc 266265 FUCT1 fucosylated N- and mucin-type O-glycans 55,59
Congenital disorder of glycosylation type IId 607091 B4GALT1 N-acetyllactosamine unit 206 
Congenital disorder of glycosylation type IIe 608779 COG7 N- + O-glycans 84 
Chylomicron retention disease 246700 SARA2 N- glyans, O-glycans? 207 
Anderson disease 607689 SARA2 N- glyans, O-glycans? 207 
Chylomicron retention disease with 
Marinesco-Sjögren syndrome 
 
607692 SARA2 N- glyans, O-glycans? 207 
 
Golgi GDP-fucose transporter deficiency 
 
The FUCT1 gene encodes a FUCT. The FUCT is likely to be ubiquitous and has a strict Golgi 
localization. Fuc is present in both N-linked and mucin-type O-linked glycoproteins, mainly as a 
constituent of N-glycans, the antigenic determinants Lea, Leb, Lex, sLex, Ley, and the blood group 
determinants A, B, and H linked to the N-acetyllactosamine unit. Additionally, Fuc is present in O-
fucosyl glycans. Patients with CDG-IIc, formerly called leukocyte adhesion deficiency type II, 
have mutations in the FUCT1 gene. 
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Congenital disorder of glycosylation type IIc 
CDG-IIc is a rare autosomal recessive syndrome characterized by recurrent infections, typical 
dysmorphic features, and severe growth and psychomotor retardation. In some cases, CDG-IIc 
can be treated with Fuc, depending on the nature of the mutation208. 
Laboratory findings 
Patients with CDG-IIc have neutrophilia, the Bombay blood group, the Lewis-negative blood 
group, and a lack of sLex on polymorphonuclear cells. Cell binding to E- and P-selectin is 
severely impaired209. Mutations in FUCT lead to a lack of Fuc residues in N- and mucin-type O-
glycans, whereas the biosynthesis of O-fucosyl glycans is normal210. This is explained by the fact 
that protein O-fucosyltransferase 1, responsible for O-fucosylation of proteins, is localized in the 
ER211. Plasma of patients with CDG-IIc gives normal results with transferrin isoelectric focusing 
(IEF). 
Diagnosis 
The activity of Golgi FUCT can be determined in human fibroblasts212. The diagnosis can be 
confirmed at the molecular genetic level in the corresponding gene59,55. 
 
UDP-Gal:β-GlcNAc β-1,4-galactosyltransferase 1 deficiency 
 
The B4GALT1 gene encodes B4GalT1 (EC 2.4.1.38), which catalyzes the binding of UDP-Gal in 
a β1,4 linkage to GlcNAc residues. B4GalT1 is ubiquitous, but it is found only at very low 
concentrations in the fetal and adult brain. B4GalT1 is involved in the formation of the N-
acetyllactosamine unit. CDG-IId is caused by mutations in the B4GALT1 gene. 
Congenital disorder of glycosylation type IId 
To date, only 1 patient with CDG-IId has been described, and in that patient, only the N-glycans 
were studied206. However, in B4GALT1-knockout mice, both N- and O-glycans from erythrocyte 
membrane glycoproteins were found to have abnormal structures213. It may be anticipated that 
O-glycan biosynthesis is also impaired in patients with CDG-IId. The child with CDG-IId has 
mental retardation, macrocephaly due to a Dandy-Walker malformation with progressive 
hydrocephalus, myopathy and blood clotting defects214. The inheritance is autosomal recessive.  
Laboratory findings 
The patient has increased serum creatine kinase, prolonged activated partial prothrombin time, 
and an abnormal plasma transferrin pattern by IEF206. Apolipoprotein C-III (apoC-III) IEF results 
are normal in this patient, which is as expected because B4GalT1 is not involved in the 
biosynthesis of core 1 O-glycans215,216. 
Diagnosis 
B4GalT1 activity can be determined in human fibroblasts206. The diagnosis can be confirmed by 
mutation analysis of the corresponding gene206. 
 
Conserved oligomeric Golgi complex subunit 7 deficiency 
 
The COG7 gene encodes subunit 7 of the COG complex. It is thought that the COG complex has 
a role in the regulation, compartmentalization, transport, and activity of several Golgi enzymes. It 
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is not known in which human tissues COG 7 is located, but it is likely to be a ubiquitous protein. 
CDG-IIe is caused by mutations in the COG7 gene. 
Congenital disorder of glycosylation type IIe 
To date, only 2 siblings have been described with CDG-IIe presenting with perinatal asphyxia 
and dysmorphia, including low set dysplastic ears, micrognathia, a short neck, and loose, 
wrinkled skin. Generalized hypotonia, hepatosplenomegaly, and progressive jaundice developed 
shortly after birth. Both siblings developed severe epilepsy and died from recurrent infections and 
cardiac insufficiency within the first 10 weeks of life84.  
Laboratory findings 
Multiple lysosomal enzymes were increased and coagulation factors were decreased in the 
serum of the 2 CDG-IIe patients. Transferrin and apoC-III both showed an abnormal IEF 
patterns, and peanut agglutinin lectin staining was increased in the fibroblasts. Increased 
amounts of CMP-NeuAc were detected, whereas total amounts of serum NeuAc were 
decreased. The transport rate of the CMP-NeuAc and UDP-Gal NSTs were reduced to 30% of 
reference values. The activities of the core 1 galactosyltransferase and the α2,3-sialyltransferase 
acting on mucin-type O-glycans were decreased. Peripheral blood indices, serum electrolytes, 
urea, and creatinine were within reference values, whereas the liver enzymes and bilirubin were 
increased in serum. Metabolic investigations of urine from these patients showed increased 
amounts of galactitol, Gal and Tyr metabolites, but no succinylacetone in one of the patients. 
Urinary organic acids, oligosaccharides, and mucopolysaccharides were within reference 
ranges84,217.  
Diagnosis 
The COG subunits can be identified in human fibroblasts with rabbit polyclonal antibodies against 
the different COG subunits84,86. The diagnosis can be confirmed at the molecular genetic level in 
the corresponding gene84. 
 
GTP-binding protein SAR1b deficiency 
 
The SARA2 gene encodes the GTP-binding protein SAR1b (SAR1b-GTPase; EC 3.6.5.2). This 
enzyme is involved in the ER-to-Golgi transport of proteins, where it has a function in protein 
cargo selection and in the assembly of the coat of COPII vesicles. Sar1b is present in many 
tissues, including the small intestine, liver, muscle, and brain. Mutations in the SARA2 gene lead 
to chylomicron retention disease (CMRD), Anderson disease and CMRD with Marinesco-Sjögren 
syndrome. CMRD, Anderson disease, and CMRD with Marinesco-Sjögren syndrome are all 
autosomal recessive disorders.  
Chylomicron retention disease and Anderson disease 
Phenotypically, CMRD and Anderson disease present as a malabsorption syndrome with severe 
diarrhea with steatorrhoea, failure to thrive, and growth retardation. Mild neurological 
disturbances occur, including mental deficiency, loss of deep tendon reflexes, decreased 
vibratory sensation, axonal neuropathy, mild deficits of color perception, nystagmus, and action 
tremor. There is little acanthocytosis218,219. The distinction between CMRD and Anderson disease 
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has been made on the basis of the apparent differences between the partitioning of chylomicrons 
and of lipid droplets between membrane-bound and cytosolic compartments. 
Chylomicron retention disease with Marinesco-Sjögren syndrome 
Two brothers have been diagnosed with the Marinesco-Sjögren syndrome combined with CMRD. 
Marinesco-Sjögren syndrome is a rare form of cerebellar ataxia associated with congenital 
cataracts, mental deficiency, brisk tendon reflexes, skeletal anomalies and cerebellar atrophy220.  
Laboratory findings 
Apoprotein B is absent in the intestine and liver of patients with CMRD. Chylomicrons cannot be 
synthesized, and VLDL and LDL are undetectable in the plasma. Patients have low blood 
cholesterol and a deficiency in fat-soluble vitamins221. [14C]Mannose incorporation is evidently 
decreased in the total protein fraction of chylomicrons in CMRD patients compared with controls, 
pointing toward deficient N-glycan biosynthesis222. Unfortunately, the effect of Sar1b-GTPase 
deficiency on O-glycosylation has not been studied, but it is likely to be abnormal as well. 
Diagnosis 
The diagnosis of this disorder can be confirmed by mutation analysis of the SARA2 gene207. 
 
 
Clinical summary of congenital defects in O-glycosylation 
 
 
The first individuals who were found to have a defect in the biosynthesis of O-linked glycans 
were diagnosed with known clinical syndromes, such as multiple exostoses, the progeroid form 
of Ehlers-Danlos, and WWS. In these patients, the gene defect was discovered earlier than the 
underlying abnormality in the biochemical pathway. In most of these syndromes, there is genetic 
heterogeneity, and not all forms are familial. For example, only 10% of the patients with multiple 
exostoses have the hereditary form of the syndrome, and only 20% of the patients with WWS 
have a defect in the POMT1 gene. 
Defects in the biosynthesis of protein-linked O-glycans lead to a highly heterogeneous group of 
diseases. The majority of patients with “classical CDG” have a defect in N-glycan biosynthesis. 
They have common symptoms such as muscle hypotonia, central nervous system abnormalities, 
growth delay, feeding problems, coagulation defects, and liver disease, and frequently show 
specific signs such as abnormal fat distribution and inverted nipples, which help with the early 
clinical diagnosis. In contrast, patients with O-glycosylation disorders commonly have 
involvement of only one organ or one organ system and do not have the general symptoms that 
are suggestive for an inborn error of metabolism. For example, patients with a defect in the 
biosynthesis of GAGs often have cartilage problems leading to skeletal malformations, whereas 
patients with a defect in the biosynthesis of O-mannosyl glycans present with abnormalities in the 
musculo-cerebral system. Most of the disorders of O-glycan biosynthesis seem to have very 
specific tissue expression, whereas N-glycans are expressed ubiquitously. Another remarkable 
difference between N- and O-glycan deficiencies is that N-glycan deficiencies generally have 
recessive inheritance, whereas in some of the O-glycan biosynthesis diseases, such as sialuria 
and HME, inheritance is autosomal dominant.  
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Mucin-type O-glycans are more or less an exception among the O-glycans because they are 
expressed ubiquitously. Intriguingly, GalNTs, which are responsible for the attachment of the first 
GalNAc residue to the protein, are tissue specific. This becomes obvious in patients with FTC 
(GalNT3 deficiency), who present only with massive calcium deposits in the skin and 
subcutaneous tissues. These are the tissues in which the activity of this specific transferase is 
particularly high. Most of the other transferases involved in the biosynthesis of mucin-type O-
glycans, such as galactosyl- and sialyltransferases, have a broad tissue expression. It is 
therefore to be expected that defects in mucin-type O-glycosylation that are not localised in one 
of the tissue-specific GalNTs will produce a phenotype in which more than one organ/organ 
system is involved.  
Patients with combined defects in protein N- and O-glycosylation often have a phenotype that is 
a mixture of the features of inborn errors in combination with congenital malformations. For 
example, patients diagnosed with CDG-IIe (COG7 deficiency) have a phenotype with central 
nervous system involvement, hypotonia, and hepatopathy combined with severe congenital heart 
malformations, limb malformations, and skin abnormalities. This new group of metabolic 
diseases, presenting with combined defects in N- and mucin-type O-glycosylation, is growing 
continuously. In most cases described to date, the genetic background is not yet known. 
Wopereis et al.216 showed in a recent investigation that 75% of the 12 CDG-IIx patients examined 
also had abnormal biosynthesis of core 1 O-glycans. Clinically, these patients presented with 
widely variable clinical features ranging from a patient with only hepatic dysfunction to patients 
having a unique phenotype with congenital cutis laxa and congenital brain malformations in 
association with skeletal anomalies216.  
In summary, the phenotypes of patients with a congenital defect in O-glycosylation are a 
continuum. This ranges from patients who have a defect in the biosynthesis of O-glycans 
affecting only a few proteins and therefore have only 1 or 2 tissues involved (for example, 
patients with a defect in O-mannosyl glycan biosynthesis), to patients who have a defect in the 
biosynthesis of O-glycans disturbing many proteins and thus have more than 1 organ/organ 
system involved (probably defects in the biosynthesis of mucin-type O-glycans not localized in a 
GalNT), to patients who have combined defects in the biosynthesis of N- and O-glycans, who 
have a typical multisystem disease (for example patients with CDG-IIe).  
 
 
Screening methods for unravelling biosynthesis defects in O-glycosylation 
 
 
Most of the congenital defects in the biosynthesis of O-glycans have been found by genetic 
approaches. O-Glycans are very complex and heterogeneous structures because of their 
variable composition, linkage, and branching. In view of the estimated number of genes involved 
in O-glycosylation processes, it is likely that the currently described congenital disorders of O-
glycosylation form only a small part of a much larger group of defects. This area of inborn errors 
of metabolism still needs further research, beginning with the development of screening 
techniques to identify defects in the biosynthesis of the various types of O-glycans.  
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N-Linked glycans have a common protein-glycan linkage and a common biosynthetic pathway 
that diverges only in the late stages. There thus is limited variability in the design of plasma 
protein N-glycans. This explains the success of transferrin IEF as a screening method to identify 
defects in N-glycan biosynthesis. It will, however, be impossible to screen for all defects in O-
glycan biosynthesis with just one assay. Recently, a first approach to screen for defects in the 
biosynthesis of the abundant mucin-type core 1 O-glycan has been developed. An IEF assay of 
apoC-III was used for this purpose215 (Figure 4). ApoC-III is a plasma protein with a single core 1 
O-glycan at position Thr94. Three isoforms of apoC-III (apoC-III0, apoC-III1, and apoC-III2) can be 
distinguished. They differ in the number of NeuAc residues attached to the O-glycan core.  
 
Figure 4.  
The plasma apoC-III isoforms (apoC-
III0, apoC-III1, and apoC-III2) and their 
mucin-type core 1 O-glycan structures 
after isoelectric focusing. Lane 1, 
control; lanes 2 and 3, examples of 
patients with an abnormal biosynthesis 
in mucin-type core 1 O-glycans.  
 
Because NeuAc has a negative charge, it is possible to separate the 3 isoforms by IEF. In 
normal human plasma, apoC-III1 is the most abundant form, accounting for ~50%, followed by 
apoC-III2 with ~45%, whereas apoC-III0 accounts for ~5% of total apoC-III. The ratio of the 3 
isoforms in normal human plasma varies with age as the degree of apoC-III sialylation 
decreases. When the biosynthesis of core 1 O-glycans is disturbed, an abnormal apoC-III 
isoform ratio is found215. In combination with transferrin IEF, this technique has been useful for 
the detection of combined defects in N- and O-glycosylation223,216. In addition, apoC-III IEF 
profiling should be capable of identifying most diseases in which mucin-type core 1 O-glycan but 
not N-glycan biosynthesis is affected. Familial tumoral calcinosis, the only genetically defined 
defect in the biosynthesis of mucin-type O-glycans at present, may turn out to be an exception. 
ApoC-III IEF profiling has not yet been performed in this disease. It is expected to give a normal 
result as GalNT3, the defective enzyme in FTC, is not expressed in liver tissue, where apoC-III is 
synthesized102.  
For the screening of defects in O-mannosyl glycan biosynthesis, immunohistochemical staining 
of α-dystroglycan with the monoclonal antibodies VIA4-1 and IIH6 is used on muscle biopsy 
specimens from patients. VIA4-1 and IIH6 recognize a carbohydrate epitope on α-dystroglycan. 
At present, α-dystroglycan is the only known substrate for this type of glycosylation in 
mammals162. Some pitfalls of this technique are that it is not clear which carbohydrate epitope(s) 
is recognized by the antibodies and that batches of the same antibody differ in quality. In the 
report by Huizing et al.194, for example, batches of VIA4-1 and IIH6 antibodies were found to give 
variable results. It is known that α-dystroglycan carries O-mannosyl glycans as well as mucin-
type O-glycans and N-glycans160,161. Thus, abnormal staining of α-dystroglycan may occur in 
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biosynthesis defects of N- or mucin-type O-glycan biosynthesis. For future diagnostics, the 
challenge is to find a secreted protein with 1 or 2 O-mannosyl glycans attached to it. This would 
allow the development of a less invasive screening technique using plasma samples to detect 
defects in O-mannosyl glycan biosynthesis.  
In general, it would be advantageous to have a technique that can give an overview of all O-
glycans present in a sample. The development of such a holistic approach is hampered by the 
fact that it is difficult to remove all O-glycans from their protein backbone. A general 
endoglycosidase for release of all O-glycans remains to be discovered. Alternatively, a chemical 
cleavage method, such as hydrazinolysis or (non)reductive β-elimination may be useful. O-
Glycan profiles have been published for the human glycoproteins glycophorin A, serum and 
secretory IgA, and neutrophil gelatinase B224. A future challenge will be to test such methods on 
human blood samples, isolated cells, or biopsy material. A first study on profiling of total plasma 
O-glycans described alterations in the glycans of patients with Sialuria (Wopereis S; this thesis). 
Similarly, no screening method is available to identify defects in GAG biosynthesis. Substantial 
amounts of GAGs occur physiologically in urine. These GAGs derive mainly from limited 
proteolysis of proteoglycans from the glomerulus, the renal tubule, and the urinary tract. They are 
released into the extracellular environment without passing the lysosomes and end up in urine 
having the same sugar structure as in vivo. The largest proportion of urinary GAG is chondroitin 
sulfate (62%-77%), whereas heparan sulfate accounts for ~25% and dermatan sulfate for only 
~5%225. The mucopolysaccharidoses, a group of inborn errors in GAG catabolism, can be 
diagnosed by measuring increased urinary GAG’s. Reliable quantitative methods for urinary 
GAGs, such as dimethyl-methylene blue assay are available226. Theoretically, patients with 
defects in the GAG biosynthesis pathway would be expected to have decreased GAG excretion 
in the urine. As the assays for urinary GAG measurement have been developed for diagnosing 
mucopolysaccharidoses, most published studies have concentrated on the upper reference 
range limit. Most laboratories using this assay therefore do not have a lower reference limit and 
would disregard any abnormally low value. Another limitation of this approach to finding GAG 
biosynthesis disorders is the age dependancy of urinary GAG excretion. Patients older than 15 
years of age excrete only limited amounts of GAGs in the urine. The lower reference limit would 
thus be close to zero. This approach would therefore allow the identification of only patients 
younger than 15 years with GAG biosynthesis defects.  
Because chondroitin sulfate is the main GAG constituent in the urine, defects in chondroitin 
sulfate biosynthesis may be found by measuring urinary GAGs. It may require dedicated 
methods to measure urinary GAG subspecies to detect defects of heparan sulfate and dermatan 
sulfate biosynthesis. New ways may be found by studying the GAG composition in tissue 
samples. This may be accomplished by releasing the GAGs from the proteoglycans or by 
applying mass spectrometric techniques to peptide digests. 
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Abstract  
 
 
Background: Defects in the biosynthesis of N-glycans may be found by isoelectric focusing (IEF) 
of plasma transferrin. No test is available to demonstrate O-glycan biosynthesis defects.  
Methods: We used isoforms of apolipoprotein C-III (apoC-III) as a marker for the biosynthesis of 
core 1 mucin-type O-glycans. Plasma samples from patients with primary defects and secondary 
alterations in N-glycan biosynthesis were studied by apoC-III isofocusing.  
Results: Age-related reference values for apoC-III were determined. Plasma samples from 
patients with the primary congenital disorders of glycosylation (CDG) types Ia–Ic, Ie, If, IIa, and IId 
all showed a normal apoC-III isofocusing profile. Plasma from 2 patients with CDG type IIx were 
tested: one showed a normal apoC-III distribution, whereas the other showed a hypoglycosylation 
profile. In plasma from patients with hemolytic uremic syndrome (HUS), a hypoglycosylation profile 
was obtained. 
Conclusions: IEF of apoC-III is a rapid and simple technique that may be used as a screening 
assay for abnormalities in core 1 mucin-type O-glycans. Evidence that a patient in this study has a 
primary genetic defect affecting both N- and O-glycosylation provides the first example of an inborn 
error of metabolism affecting the biosynthesis of core 1 mucin-type O-glycans. Our data narrow the 
options for the position of the primary defect in this patient down to a step in the biosynthesis, 
activation, or transfer of galactose or N-acetylneuraminic acid to both N- and O-glycans. Circulating 
neuraminidase excreted by Streptococcus pneumoniae caused the high percentage of asialo 
apoC-III in 2 HUS patients. 
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Introduction 
 
 
In 1987, Jaeken et al.1 were the first to describe an inborn error of metabolism in the biosynthetic 
pathways of protein N-glycosylation. During the last decade, several defects were found in the 
biosynthesis of N-glycans. The diseases in this pathway have been collectively referred to as 
congenital disorders of glycosylation (CDG)2, formerly called carbohydrate-deficient glycoprotein 
syndrome2,3. The use of transferrin isofocusing on plasma and serum has been pivotal in 
detecting patients suffering from the various forms of the syndrome. At present, 13 different 
diseases in N-glycan biosynthesis are known: CDGIa through -Ih and CDGIIa through -IId4,5,6. A 
few inherited diseases have been found in the biosynthesis of O-linked glycans, mainly by genetic 
approaches. Examples are muscle–eye–brain disease and Walker–Warburg syndrome, in which 
the defect is situated in the biosynthesis of O-mannose-based glycans7,8. The biochemical 
hallmark in CDGIIc patients is hypofucosylation of both N- and O-glycosylated proteins. This 
disease is the first identified in which both N- and O-glycosylation is affected9,10. 
 
Figure 1.  
Glycan biosynthesis can be 
divided into 3 stages. Stage 
1, monosaccharides are 
synthesized in the 
cytoplasm and activated as 
nucleotide sugars. Stage 2, 
nucleotide sugars enter the 
ER bound to dolichol 
phosphate (Dol-P). Specific 
antiporters carry them to the 
lumen of the Golgi. Stage 3, 
the sugars are attached to 
the glycan by specific 
glycosyltransferases. 
 
The biosynthesis of N-glycans as well as O-glycans can be divided into 3 stages (see Figure 1). 
In the first stage, biosynthesis and activation of monosaccharides occurs. In the second stage, 
nucleotide sugars enter the endoplasmic reticulum (ER) bound to dolichol phosphate. Nucleotide 
sugars enter the lumen of the Golgi via specific antiporters. In the third stage, specific 
transferases attach the glycan in the ER and the Golgi. In mammals, 6 different types of O-
glycans are known, classified on the basis of the first sugar attached to the serine or threonine 
residue of the protein11. The mucin-type O-glycan, starting with N-acetylgalactosamine (GalNAc), 
is most common in humans. In total 8 core structures can be distinguished depending on the 
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second sugar(s) and/or sugar binding11,12,13. Further biosynthetic steps finally give rise to at least 
50 different O-glycan structures, of which core 1 and 2 are most abundant14,15. In brain and 
neural tissue, core 1 is most common16. The synthesis of core 2 mucin-type O-glycans requires 
the conversion of unsubstituted core 1 mucin-type O-glycans by a N-acetylglucosamine (GlcNAc) 
transferase17,18. 
In this study, we developed a test that may be used to demonstrate defects in the biosynthetic 
pathway of core 1 mucin-type O-glycans. The test uses the isoforms of apolipoprotein C-III 
(apoC-III). This protein carries a single O-glycan at Thr-94 and is not N-glycosylated19. The 
protein is rather stable and is readily detectable in human plasma. Human apoC-III antibodies are 
commercially available. This study is a step in the development of a biochemical approach to find 
defects in the biosynthesis of O-glycans. To our knowledge it is the first report describing a 
patient with an inborn error of metabolism affecting core 1 mucin-type O-glycan biosynthesis. 
 
 
Patients and Methods 
 
 
Patients 
 
We analyzed 15 different plasma samples from patients with secondary N-glycosylation 
alterations [hemolytic uremic syndrome (HUS), n = 2; galactosemia, n = 1; alcohol abuse, n = 
12]. In addition, we studied 21 different plasma samples from patients with primary CDG [CDGIa, 
n = 8; CDGIb, n = 1; CDGIc, n = 8; CDGIe, n = 1; CDGIf, n = 1; CDGIIa, n = 1; CDGIId, n = 1]. 
CDGI includes all defects starting from the assembly of dolichol to the transfer of the 
oligosaccharide to the protein. CDGII includes all defects that are localized in the processing of 
glycans on the protein. 
We also analyzed plasma samples from 2 patients with an as yet unidentified primary defect in N-
glycan biosynthesis. The patients had been classified as CDGII on the basis of their repeatedly 
abnormal transferrin isofocusing profile. Patient A is a child of healthy nonrelated German 
parents. He first presented at the age of 13 years. Until that time, he had been healthy and well 
and had reached his age-related milestones appropriately. Probably as a result of a 
thromboembolic complication or aspiration, he suffered from a sudden respiratory arrest, was 
resuscitated, and needed long-term ventilation. The intensive care period was complicated by a 
severe derangement of coagulation attributable to very low antithrombin III (<10%; reference 
interval, 70–130%), protein C (25%; reference interval, 70–130%), and factor XI (11%; reference 
interval, 70–130%). Recurrent arrhythmia was documented by electrocardiogram. Brain imaging 
showed slightly dilated ventricles. In the later course, the patient developed seizures with 
moderate neurologic sequelae and showed recurrently increased transaminases and 
abnormalities of the clotting factors. 
Patient B was born to consanguineous parents with several mentally retarded relatives. The 
neonatal period and early infancy were normal. In the course of an infection at 6 months of age 
she presented with neurologic regression mimicking Leigh disease. The child had infection-
triggered episodes with encephalopathy on 2 other occasions. At 6 years of age she had 
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microcephaly, mental retardation, strabismus, pseudoptosis, and a cerebellar syndrome. She 
could not walk without support, but she was able to make psychomotor progress. Brain magnetic 
resonance imaging showed brainstem and cerebellar atrophy. The other clinical data are as 
follows: failure to thrive, epicanthus, and small hands and feet with hypoplasia of the first phalanx 
of some fingers and toes. She also has frequent stomatitis, although immunologic studies did not 
show abnormalities. Increased creatine kinase and transaminase concentrations were observed 
during the acute phases in the disease. In such periods the coagulation pattern was abnormal, 
with protein C and protein S deficiency and decreased prothrombin time and coagulation factors. 
A detailed clinical description has been published [case 4 in Ref.20]. Both children had an 
abnormal isoelectric focusing (IEF) pattern with an increase of hypoglycosylated transferrin 
isoforms. 
 
Samples and sample preperation 
 
The VLDL pool was isolated by ultracentrifugation, and lipids were extracted by ethanol–acetone 
(1:1 by volume) and stored in the freezer to sediment the VLDL apoproteins. Identification of the 
apoC-III isoprotein bands was as published in the literature21. 
After centrifugation for cell separation, plasma samples were stored without delay at -80 °C until 
analysis. Samples used for the apoC-III isoform reference interval for the age group 0–1 year 
were from healthy babies at an age of 6 months (further use of leftover plasma volumes from a 
study on calcium homeostasis for which written informed consent was obtained). Samples used 
for the apoC-III isoform reference interval for the age group 1–18 years were from healthy 
volunteers (further use of leftover plasma from relatives of patients for routine microsatellite 
studies after informed consent). Samples used for the apoC-III isoform reference interval for the 
age group >18 years were obtained from healthy volunteers (Dutch blood bank donors after 
written informed consent). Their plasma samples showed no abnormalities when tested for N-
glycosylation (transferrin IEF). Plasma samples were diluted 10-fold in saline for IEF of apoC-III.  
 
ApoC-III isofocusing 
 
Dry IEF gels for the PhastSystem (cat. no. 17-0677-01; Amersham Pharmacia Biotech) were 
rehydrated for at least 1.5 h at room temperature in a solution of 8 mol/L urea and 60 mL/L 
Pharmalyte, which contained Pharmalyte 4.2–4.9 and Pharmalyte 3.5–5.0 (Amersham Pharmacia 
Biotech) in a ratio of 2:1. The gel was prefocused for 75V · h at 2000 V. After 0.5 µL of the 10-fold 
diluted plasma was applied to the gel, IEF was continued for 495 V · h22. 
 
Western blot procedure 
 
Proteins were blotted onto a nitrocellulose membrane (cat. no. 12806-200-200BLF; Sartorius) by 
diffusion for 1 h at 60 °C. Nonspecific sites on the nitrocellulose membrane were blocked with 50 
g/L nonfat dried milk dissolved in phosphate-buffered saline (PBS) containing 5 mL/L Tween 20. 
The membrane was washed in PBS containing 0.5 mL/L Tween 20. The primary rabbit anti-
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human apoC-III antibody (cat. no. 0650-1707; ANAWA Biomedical Services & Products) was 
diluted 1000-fold in 15 g/L bovine serum albumin dissolved in PBS containing 5 mL/L Tween 20. 
The secondary goat anti-rabbit horseradish peroxidase-conjugated antibody (cat. no. 1858415; 
Pierce Perbio Biotechnology) was diluted 5000-fold in the same solution. We than added 0.125 
mL of Western blotting detection reagents [electrochemiluminescence (ECL) reagent; cat. no. 
RPN 2134; Amersham Pharmacia Biotech] per cm2 of membrane. A chemiluminescent reaction 
occurs between horseradish peroxidase and the luminol in the ECL reagents, producing light 
emission. The blot was placed against an autoradiography film (Hyperfilm ECL; cat. no. RPN 
1681 H; Amersham Pharmacia Biotech) and exposed for different time intervals. The film was 
developed on a Kodak RP X-Omat Processor (Model M6B) and scanned with the Image master 
Labscan, Ver. 3.00 (Amersham Pharmacia Biotech). Isoforms of apoC-III were quantified by 
Image master 1D gel analysis, Ver. 4.10, software (Amersham Pharmacia Biotech). 
 
Neuraminidase treatment 
 
Neuraminidase can remove the negatively charged terminal sialic acid residues from N- and O-
linked glycans. After incubation with neuraminidase, all apoC-III isoforms migrate to the position 
of apoC-III0. Polymorphisms in the apoC-III protein can be identified by abnormal mobility of the 
protein on IEF after neuraminidase treatment. For that purpose neuraminidase (cat. no. 107590; 
Boehringer Mannheim; 1 g/L in 0.1 mol/L Tris, pH 7.0) and human plasma are incubated in a ratio 
of 3:2 overnight at room temperature. 
 
 
Results 
 
 
Human plasma apoC-III isofocusing 
 
Isofocusing of human plasma apoC-III shows the 3 isoforms apoC-III0, apoC-III1, and apoC-III2 
(see Figure 2). Theoretically, nonglycosylated apoC-III, apoC-III with only GalNAc, or apoC-III 
with GalNAc-Gal could contribute to the apoC-III0 fraction. It was not possible to distinguish the 
nonglycosylated apoC-III or apoC-III with only GalNAc from the asialo form by IEF (Figure 2).  
 
Figure 2.  
ApoC-III isoforms in human plasma 
and their structures.
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The isoelectric points of the 3 isoforms were in the pI range 4.5–5.1, which is in accordance with 
data in the literature23,24. The apoC-III isoform profile of the VLDL pool is shown in lane 10 of 
Figure 4. apoC-III1 and apoC-III2 are the major isoforms occurring in plasma (~55% and 40%, 
respectively), whereas only trace amounts of apoC-III0 are present. ApoC-III is a stable protein; 
identical apoC-III isoform distribution patterns were found for a fresh plasma sample and the 
same sample stored frozen at -80 °C for 1 week. No other protein bands were visible in the pI 
range 4–5.3, illustrating the specificity of the antibody used. 
The linearity of the assay was assessed by dilution experiments. Samples had to be diluted to 
determine the full range at which the assay was linear (Figure 3A). Exposure time of the blot for a 
10-fold diluted plasma sample on the radiography film showed a linear response until at least 60 
seconds of exposure (Figure 3B). 
 
 
 
 
 
 
 
 
 
 
 
Reproducibility 
 
The between-run reproducibility was assessed by performing the test on the same plasma 
sample on 6 different days. Results for the 3 isoforms, expressed as mean (SD) as a percentage 
of total apoC-III, were 4.5 (0.4)%, 59.1 (1.9)%, and 36.4 (1.9)% for apoC-III0, apoC-III1, and 
apoC-III2, respectively. 
 
Reference intervals 
 
The reference values for each age group are shown in Table 1. We found no statistically 
significant influence of gender (data not shown). ApoC-III0 was significantly lower in the age 
group 0–1 year than at older ages. ApoC-III1 and apoC-III2 are equally represented in this 
youngest age group, whereas at older ages, apoC-III1 becomes the most predominant isoform in 
most individuals. 
 
Table 1. Reference intervals for plasma apolipoproteinC-III isoforms in healthy volunteers expressed as percentage of total 
apolipoproteinC-III 
ApoC-III0
 
ApoC-III1
 
ApoC-III2Age, 
(year) n Mean ± SD  Range Mean ± SD Range Mean ± SD Range 
 
0-1    
 
17 
 
3.7 ± 1.9 
 
0.0 – 8.1 
 
47.2 ± 6.4 
 
34.0 – 58.5 
 
49.1 ± 5.9 
 
39.9 – 61.8  
1-18  17 5.1 ± 2.7 0.0 – 11.6 53.2 ± 9.1 33.1 – 66.9 41.6 ± 8.3 27.4 – 60.0 
> 18   
 
29 8.5 ± 4.1 2.6 – 18.9 55.5 ± 6.5 42.9 – 69.2 36.0 ± 7.2 23.2 – 50.0 
Figure 3.  
Linearity of the area under the curve for 
apoC-III1, the most prominent isoform in 
human plasma, as a function of exposure 
time. (A), undiluted plasma; (B), 10-fold 
diluted plasma. Sample volume for A and B
was 0.5 µL. 
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ApoC-III polymorphism 
 
Isofocusing of a plasma sample from one specific blood donor showed 4 apoC-III isoforms 
(Figure 4, lane 9). After treatment with neuraminidase, plasma from other blood donors showed 1 
band in the position of apoC-III0 (Figure 4, lane 7). The plasma sample of this specific blood 
donor showed bands of equal intensity at the positions of apoC-III0 and apoC-III1 (Figure 4, lane 
8). This is evidence for a polymorphism in the apoC-III protein that makes the net charge of the 
protein more negative. 
 
Patient groups 
 
Patients with primary CDG 
Plasma samples from patients with CDGIa, -Ib, -Ic, -Ie, -If, -IIa, and -IId showed a normal apoC-III 
isoform distribution (data not shown). 
 
Patients with secondary N-glycosylation alterations 
Plasma samples from 2 patients in the acute phase of HUS attributable to Streptococcus 
pneumoniae showed increased apoC-III0 (18% and 23%, respectively; reference interval, 0.0–
11.6%). 
Plasma samples from patients who abused alcohol (n = 12) or had classic galactosemia before 
dietary treatment (n = 1) showed a normal apoC-III isoform distribution (see Figure 4).  
 
Patients with unidentified CDG 
Figure 4 shows the apoC-III IEF analysis of 2 patients with unidentified CDG. Patient A has been 
classified as CDGIIx on the basis of his transferrin isofocusing profile, which showed increased 
asialo-, monosialo-, and disialotransferrin and decreased tetrasialotransferrin. Thyroxine-binding 
globulin (TBG), another N-glycosylated plasma protein, also showed an abnormal isofocusing 
profile, confirming the generalized character of the defect in N-glycan biosynthesis in this patient. 
Plasma from this patient showed a normal apoC-III isoform distribution (Figure 4, lane 1). Patient 
B has also been classified as CDGIIx. Transferrin isofocusing showed that he has increased 
monosialo- (8.6%; reference interval, 0.0–2.6%), disialo- (22.7%; reference interval, 1.6–6.1%), 
and trisialotransferrin (28.8%; reference interval, 2.5–15.6%) and decreased tetrasialotransferrin 
(32.6%; reference interval, 51.2–72.2%).  
Figure 4.  
Isofocusing profile of plasma apoC-III isoforms. 
Lane 1, patient A (CDGIIx); lane 2, patient B 
(CDGIIx); lane 3, control; lane 4, galactosemic 
patient; lane 5, alcohol abuser; lane 6, HUS 
patient; lane 7, plasma from blood donor 1 after 
neuraminidase treatment; lane 8, plasma from 
blood donor 2 (with apoC-III protein 
polymorphism) after neuraminidase treatment; 
lane 9, plasma from blood donor 2 (with apoC-III 
protein polymorphism) before neuraminidase 
treatment; lane 10, VLDL pool. 
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TBG isoforms were also abnormal in this patient. Plasma from this patient showed increased 
apoC-III0 (36.9%; reference interval, 0.0–11.6%) and decreased apoC-III2 (5.6%; reference 
interval, 27.4–60.0%; Figure 4, lane 2). Apparently the genetic defect in this patient affects N-
glycan biosynthesis as well as mucin-type core 1 O-glycan biosynthesis. 
 
 
Discussion 
 
 
Isofocusing of apoC-III is a simple and rapid technique that allows quantitative determination of 
the 3 apoC-III isoforms. apoC-III isoforms from plasma may be used as markers for the 
biosynthesis of core 1 of mucin-type O-glycans. This glycan type is widely expressed throughout 
the human body and is abundant in the nervous system; it is considered the most common type 
of O-glycan. Core 2 mucin-type O-glycans are synthesized from unsubstituted core 1 mucin-type 
O-glycans. A biosynthesis defect in unsubstituted core 1 O-glycans will also affect the synthesis 
of core 2 mucin-type O-glycans. Alterations in mucin-type O-glycan structure have been found in 
relation to cancer15. Recently evidence was found for inborn errors of metabolism in the 
biosynthesis of O-glycans. Defects were found in mannosylated O-glycan biosynthesis in the 
Walker–Warburg and muscle–eye–brain syndromes7,8 and in fucosylation of both N- and O-
glycans in CDGIIc9,10. As yet there is no evidence for inborn errors in the biosynthesis of mucin-
type O-glycans. 
In this study we tested 2 patients with a firmly established but as yet unidentified N-glycan 
biosynthesis defect. We found an abnormal plasma transferrin isoform distribution in both patients 
on several occasions. These patients have a so-called type 2 pattern with asialo-, monosialo-, 
and disialotransferrin isoforms overrepresented. This pattern predicts a defect in the Golgi part of 
N-glycan biosynthesis. Both also have an abnormal TBG isoform distribution. Because the 
primary defect in these patients has not been identified, both were diagnosed as CDG type IIx. In 
this study patient A showed a normal apoC-III isoform profile, whereas patient B showed a 
hypoglycosylation profile (Figure 4, lanes 1 and 2). From this we can conclude that the underlying 
defect causing the disease will be different in the 2 patients. Because apoC-III is not N-
glycosylated, it may be concluded that in patient B the O-glycan biosynthesis of the core 1 mucin-
type O-glycan is disturbed as well. After CDGIIc this is the second inherited disease affecting the 
biosynthesis of both N- and O-glycans. It may be the first example of a patient with an inborn 
error of metabolism affecting the core 1 mucin-type O-glycans. The primary defect in this patient 
remains unidentified, but it must be situated in 1 of the 3 biosynthetic stages indicated in Figure 1. 
Gal and N-acetylneuraminic acid (NeuAc) are the only sugars implicated in the biosynthesis of 
both N-glycans and core 1 mucin-type O-glycans; therefore, it is very likely that the genetic defect 
in patient B is situated in 1 of the 3 biosynthetic stages of Gal or NeuAc. 
Many of the transferases involved in O-glycan biosynthesis are potentially N-glycosylated 
themselves25. It is therefore an option that O-glycan biosynthesis would be secondarily affected in 
patients with a primary defect in N-glycan biosynthesis. However, the apoC-III profiles of patients 
with defined primary defects in N-glycan biosynthesis (CDGIa-, -Ib, -Ic, -Ie, -If, -IIa, and -IId) were 
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all fully normal. It is therefore highly unlikely that the O-glycan abnormality in patient B is 
secondary to a defect in N-glycan biosynthesis. 
Patient A had a normal apoC-III isoform profile and an abnormal transferrin isoform profile. As a 
consequence, it is unlikely that the primary defect in this patient is situated in the biosynthesis, 
activation, or transport to the Golgi of Gal or NeuAc. It seems more likely that the defect in this 
patient is situated in the pathways for the N-glycan-specific sugars Man, Glc, or GlcNAc. In 
addition, it may implicate the transferases that transfer Gal or NeuAc to the N-glycan because 
these enzymes are thought to be N-glycan specific. Our data suggest that apoC-III isoform testing 
may be a helpful step in the elucidation of the primary defect for the relatively large cohort of 
CDG type Ix and IIx cases present in the Euroglycan database that serves as a register for CDG 
patients26. A preliminary study on this group showed that 12 of 25 cases had an abnormal apoC-
III isoform profile in addition to their abnormal transferrin isoform distribution. 
In this study we also tested diseases and conditions leading to secondary N-glycan 
abnormalities. Among these are galactosemia, alcohol abuse, and HUS. A patient with classic 
galactosemia attributable to deficiency of galactose-1-phosphate uridyltransferase showed a 
normal apoC-III isofocusing profile before dietary treatment. The defect leads to the accumulation 
of galactose 1-phosphate. Transferrin hypoglycosylation in these patients may be attributable to 
direct inhibition of galactosyltransferase activity by the accumulated galactose 1-phosphate or to 
an effect on the formation of UDP-galactose, the donor-substrate in the reaction27. Core 1 mucin-
type O-glycan biosynthesis also requires the availability of UDP-galactose in the Golgi. Because 
the apoC-III O-glycan could be normally synthesized, our data suggest that the abnormal N-
glycans of plasma transferrin probably are not attributable to decreased availability of UDP-
galactose. The ß-1,4-galactosyltransferase (EC 2.4.1.38) involved in N-glycosylation differs from 
the ß-1,3-galactosyltransferase (EC 2.4.1.122) involved in O-glycan biosynthesis of apoC-III28. 
Our findings suggest that galactose 1-phosphate inhibits ß-1,4-galactosyltransferase but not ß-
1,3-galactosyltransferase in galactosemic patients. 
Secondary transferrin hypoglycosylation has been observed in HUS29 and in chronic alcohol 
abuse30,31. Plasma apoC-III was hypoglycosylated in the acute phase of S. pneumoniae-
associated HUS in 2 patients. S. pneumoniae excretes neuraminidase, which catalyzes the 
hydrolysis of α2–3-, α2–6-, and α2–8-linked NeuAc residues from glycoproteins and 
oligosaccharides. The presence of neuraminidase activity in the plasma of patients with S. 
pneumoniae-associated HUS explains the abnormal isoform pattern of N-glycosylated proteins in 
the acute phase of the disease29. The high percentage of apoC-III0 in plasma can be explained as 
a loss of sialic acid residues from the termini of apoC-III isoforms as a result of the action of 
circulating neuraminidase. 
Plasma samples from 12 patients with chronic alcohol abuse showed a normal apoC-III 
isofocusing profile. It is widely accepted that chronic ethanol consumption leads to 
hypoglycosylated plasma transferrin. The mechanism behind this N-glycan abnormality is still not 
well understood. Flahaut et al.32 showed that the abnormal transferrin isofocusing profile is the 
result of the loss of an entire N-linked oligosaccharide and of an alteration in terminal sialylation. 
It has been suggested that ethanol intake alters the biosynthesis and/or transfer of the dolichol–
oligosaccharide intermediates, leading to loss of the entire N-linked oligosaccharide. Alteration of 
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terminal sialylation is suggested to be the result of decreased activity of sialyltransferase in the 
Golgi. Conversely, it has been suggested that ethanol consumption enhances the activity of 
sialidase, which can remove the terminal sialic acid residues from glycans. Because 
sialyltransferases involved in O- and N-glycosylation are specific, our data show that this latter 
hypothesis is less likely. 
It is quite likely that the negative change in pI in the protein found in a healthy volunteer was 
caused by a heterozygous polymorphism of apoC-III. Three polymorphisms have been described 
for apoC-III33,34. The observed charge heterogeneity could also result from causes such as 
phosphorylation, acetylation, and sulfation of the protein. The presence of such pI changes may 
hamper the interpretation of apoC-III isoform profiles. However, incubation with neuraminidase 
followed by isofocusing is an easy test to show that the abnormal profile in such cases derives 
from a variation in the protein part of the molecule and is not caused by an O-glycan abnormality. 
Further investigations on the biosynthesis of O-glycans are of great importance. O-glycan 
biosynthesis is very complex, with many different end products. It is very likely that further work in 
this field will solve the molecular basis of various human diseases or syndromes. 
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Abstract 
 
 
Defects in the biosynthesis of N- and core 1 O-glycans may be found by isoelectric focusing 
(IEF) of plasma transferrin and apolipoprotein C-III (apoC-III). We hypothesized that IEF of 
transferrin and apoC-III in combination with sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) of apoC-III may provide a classification for congenital disorders of 
glycosylation (CDG) patients. We analyzed plasma from 22 patients with 8 different and well-
characterized CDG subtypes and 19 cases with unsolved CDG. Transferrin IEF (TIEF) has been 
used to distinguish between N-glycan assembly (type 1 profile) and processing (type 2 profile) 
defects. We differentiated two different CDG type 2 TIEF profiles: The “asialo profile” 
characterized by elevated levels of asialo- and monosialotransferrin and the “disialo profile” 
characterized by increased levels of disialo- and trisialotransferrin. ApoC-III IEF gave two 
abnormal profiles (“apoC-III0” and “apoC-III1” profiles). The results for the 8 established CDG 
forms exactly matched the theoretical expectations, providing a validation for the study approach. 
The combination of the 3 electrophoretic techniques was not additionally informative for the 
CDG-Ix patients as they had normal apoC-III IEF patterns. However, the CDG-IIx patients could 
be further subdivided into 6 biochemical subgroups. The robustness of the methodology was 
supported by the fact that 3 patients with similar clinical features ended in the same subgroup 
and that another patient, classified in the “CDG-IIe subgroup”, turned out to have a similar defect. 
Dividing the CDG-IIx patients in 6 subgroups narrows down drastically the options for the primary 
defect in each of the subgroups and will be helpful to define new CDG type II defects. 
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Introduction 
 
 
Congenital Disorders of Glycosylation (CDG) form a group of autosomal recessive metabolic 
disorders caused by defects in the biosynthesis of protein-linked glycans. Until now, genetic 
defects mainly in the N-glycan biosynthesis have been classified as CDG. At present, 18 
genetically distinct types of CDG have been described; CDG-Ia through –Il and CDG-IIa through 
–IIf1-3. Transferrin isoelectric focusing (TIEF) is generally used as a screening for defects in the 
biosynthesis of N-linked glycans4. The division of CDG into type I and type II is based on the 
location of the defect in the N-glycan biosynthetic pathway. CDG-I includes all defects in the 
early N-glycan pathway in the cytoplasm or in the endoplasmic reticulum (ER) and covers all 
enzymatic steps to the transfer of the glycan to the protein. A defect in this part of the N-glycan 
biosynthetic pathway results in a typical CDG type 1 TIEF profile with increased amounts of 
asialo and disialo transferrin. CDG-II includes all defects involved in the processing of N-glycans 
on the glycosylated protein. These are mainly situated in the Golgi compartment. A defect in this 
part of the N-glycan biosynthetic pathway results in an abnormal TIEF profile for CDG subtypes  
-IIa, -IId and -IIe. CDG subtypes -IIb, -IIc and -IIf do not result in a hyposialylation of transferrin 
and give normal TIEF profiles. In plasma, transferrin IEF of patients with CDG type II is different 
from that of patients with CDG type I. This allows a preliminary assignment of cases to the CDG I 
or II group and thus to the underlying organelle where the defect is located.  
Isoelectric focusing (IEF) of apolipoprotein C-III (apoC-III) has recently been described as a new 
screening assay for defects in the biosynthesis of core 1 O-glycans5. In mammals, the most 
common form of O-glycosylation is the mucin-type of O-glycosylation in which glycans are 
attached to the protein via an N-acetylgalactosamine (GalNAc) residue. This mucin-type O-
glycosylation can be subdivided into 8 core structures based on the second sugar(s) and/or 
sugar-linkage. The core 1 O-glycan, with Galβ1-3GalNAcα-(Ser/Thr) as the core, is the most 
common subtype and occurs on many membrane and secreted proteins, especially in mucus, 
brain and other neural tissue6-8. Recently, the first genetic defect in the biosynthesis of mucin-
type O-glycans has been described. Mutations in N-acetylgalactosaminyltransferase 3 (GALNT3) 
cause familial tumoral calcinosis (FTC)9. Other inborn errors of metabolism that affect O-
glycosylation are defects in proteoglycan biosynthesis (the progeroid variant of Ehlers Danlos 
syndrome10 and the multiple exostoses syndrome11) and defects in the biosynthesis of O-
mannosyl glycans (Muscle-Eye-Brain disease12 and Walker Warburg syndrome13).  
Nucleotide sugars, enzymes and transporters involved in the biosynthesis of glycans might be 
common to N- and O-glycans, explaining why some glycosylation defects will affect both the 
biosynthesis of N- and O-glycans. A congenital defect affecting both N- and O-glycans has been 
described previously in patients with CDG-IIe, who have a defect in subunit 7 of the conserved 
oligomeric Golgi complex (COG-7)2, in CDG-IIc14, in a subgroup of patients with cutis laxa15,16 
and in a patient with an as yet unsolved defect (CDG-IIx5).  
In this study, we investigated 19 patients with an unsolved CDG defect found in the selective 
screening with TIEF. This patient group was divided into a CDG-Ix group and a CDG-IIx group 
based on the TIEF profile. ApoC-III IEF and apoC-III sodium dodecyl sulphate-polyacrylamide gel 
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electrophoresis (SDS-PAGE) made it possible to divide the CDG-IIx group into 6 biochemical 
subgroups. The strategy applied in this article narrows down the options for the primary defect in 
the various subgroups especially for CDG-IIx patients. 
 
 
Patients and Methods 
 
 
Patients 
 
Nineteen patients with an unsolved CDG defect were used as study group. The patients were 
found in the selective screening with TIEF. The TIEF profile was found to be abnormal repeatedly 
(two or more samples). Patients 1-7 with increased asialo- and disialotransferrin fractions and 
decreased tetrasialotransferrin were classified as CDG type Ix after excluding CDG-Ia and Ib by 
the phosphomannomutase and phosphomannose isomerase assay in leucocytes or fibroblasts 
according to the method of van Schaftingen et al.17. CDG types Ic-Ih and CDG type Il were 
excluded by lipid-linked oligosaccharide (LLO) analysis according to the method of Imbach et 
al.18. Patients 8-19 with type 2 TIEF profiles (the hyposialylation IEF profiles that are not type 1) 
were classified as CDG-IIx. LLO analysis was normal in these patients. The clinical features of 
patients 8-19 are summarized in Table 1. Patients 17-19 have been described in more detail by 
Morava et al.16. 
 
Table 1. Clinical features in 12 congenital disorders of glycosylation-IIx (CDG-IIx) patients. 
Patients 
Clinical features 8 9 10 11 12 13 14 15 16 17 18 19
 
Dysmorphic facial features - - + + - + + + + + + +
Finger anomalies  
(clino/syndactyly, finger hypoplasia, adducted thumbs) - - + + - + + + + - + +
Motor developmental delay/hypotonia - - + - - + + + + + + +
Microcephaly - - + - - + + + + + + +
Mental retardation - - + - - + + + + + + +
Seizures - - + - - + - + + - + +
Eye anomalies  
(strabismus, myopia, retinis pigmentosa, hypermetropia) - - + + - + + + - + + +
Hepatic dysfunction + + + + + - - + - - - - 
Intracranial anomalies - - + NA - + NA + - - + +
Hearing problems - - + + - + - - - + - +
Cutis laxa - - - - - - - - - + + +
Urogenital anomalies - - - + - - - - - + - +
Club foot - - + - - - + - - - - +
Endocrine anomalies NA - - + - - NA NA + - - - 
Heart anomalies + - - - - + - - - - - - 
Muscle dystrophy 
 
+ - - - - - - - - - - - 
+, clinical feature is present; -, clinical feature is absent; NA, not analyzed 
 
Polymorphisms of transferrin and of apoC-III were excluded by incubation of the samples with 
neuraminidase to remove the negatively charged sialic acid residues. After neuraminidase 
treatment, all transferrin and apoC-III isoforms migrated at the asialo position on IEF, indicating 
that changes in sialic acid content had been responsible for the abnormal profiles. All secondary 
causes for glycosylation abnormalities, such as galactosemia, fructosemia, alcohol abuse and 
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hemolytic uremic syndrome, were excluded by appropriate measures. The IEF profiles of 
thyroxine-binding globulin (TBG), another N-glycosylated protein, were also abnormal in the 19 
patients (data not shown). This indicates that the defect is not restricted to the N-glycans of 
transferrin and affects the glycosylation of other N-glycosylated plasma proteins as well.  
In addition, plasma samples from patients with established CDG subtypes were studied (CDG-Ia, 
n=8; CDG-Ib, n=1; CDG-Ic, n=8; CDG-Ie19, n=1, CDG-If20, n=1; CDG-IIa21, n=1; CDG-IId22, n=1; 
CDG-IIe (P22), n=1).  
  
Samples and sample preparation 
 
Blood samples were obtained from children with unsolved CDG with informed parental consent. 
Plasma was prepared by centrifugation and stored immediately at –80 °C until required for 
analysis.  
 
Transferrin and apoC-III IEF 
 
TIEF was carried out essentially as described by van Eijk and van Noort23. Plasma samples were 
incubated for 30 minutes with a solution of 20 mM ferric citrate and 0.5 mM sodium hydrogen 
carbonate in a ratio of 10:3 (plasma to solution) to saturate the transferrin with iron. The iron-
saturated plasma was diluted 5 times with water and applied to a hydrated immobiline gel (pH 4-
7) on an Ultraphore system (Amersham Biosciences, Piscataway, New Jersey, USA). Transferrin 
isoforms were detected after immunofixation with rabbit anti-human transferrin antibody (Dako, 
Glostrup, Denmark) and Coomassie blue staining. The relative amounts of the transferrin 
isoforms were determined by scanning the stained gel using an Image Master Labscan, Ver. 
3.00 (Amersham Biosciences, Piscataway, New Jersey, USA) and quantified using Image Master 
1D gel analysis, Ver. 4.10, software (Amersham Biosciences, Piscataway, New Jersey, USA). 
IEF of apoC-III was carried out as described by Wopereis et al.5. A dry IEF Phastgel was 
hydrated in a solution of 8 M urea and 60 mL/L Pharmalyte pH 4.2 – 4.9 and Ampholine pH 3.5 – 
5.0 (Amersham Biosciences, Piscataway, New Jersey, USA) in a ratio of 2:1. Plasma samples 
were diluted 10-fold with saline and applied to the hydrated gel on a Phastsystem. After IEF, the 
isoforms of apoC-III were detected by Western blotting using rabbit anti-human apoC-III antibody 
(ANAWA Biomedical Services & Products, Wangen bei Dübendorf, Switzerland), and secondary 
goat anti-rabbit horseradish peroxidase-coupled antibody and visualized by 
electrochemiluminescence. The relative amounts of the apoC-III isoforms were determined by 
densitometry as described above.  
 
SDS-PAGE of apoC-III  
 
Plasma samples used for SDS-PAGE of apoC-III were diluted 10-fold with freshly made sample 
buffer (10 mM Tris/HCl pH 8.0, 1 mM EDTA, 2.5% SDS, 2% DTT and 0.01% bromophenol blue). 
The diluted samples were heated at 100 °C for 5 minutes and applied to a “Phastgel high 
density” on a Phastsystem with a separation time of 300 volthours at the standard running 
 106 
CDG-IIx patients can be subdivided in 6 biochemical groups 
 
conditions for “Phastgel high density”. After SDS-PAGE the apoC-III variants were detected by 
Western blotting using rabbit anti-human apoC-III antibody and secondary goat anti-rabbit 
horseradish peroxidase-coupled antibody and visualized by electrochemiluminescence. 
 
Neuraminidase and O-glycosidase treatment 
 
Negatively charged terminal sialic acid residues were removed from N- and O-linked glycans 
using neuraminidase. Neuraminidase (cat. no. 107590; Boehringer Mannheim, Germany; 1 g/L in 
0.1 M Tris, pH 7.0) and human plasma samples were incubated in a ratio of 2:1 overnight at 
room temperature.  
O-glycosidase can remove the unsubstituted Galβ1-3GalNAc unit from core 1 O-glycans. For 
that purpose O-glycosidase (cat. no. 1347101; Roche Applied Science, Basel, Switzerland; 0.5 
mU/μL) and human plasma samples pretreated with neuraminidase, were incubated in a ratio of 
1:1 overnight at 37 °C. 
 
 
Results 
 
 
IEF of plasma transferrin  
 
Plasma of 19 patients with an unsolved CDG defect were classified as CDG-Ix or as CDG-IIx 
based on their TIEF profile. TIEF of plasma samples from patients with CDG-Ia, -Ib, -Ic, -Ie, and 
–If results in a typical CDG type 1 IEF profile with increased asialo- and disialotransferrin and 
decreased tetra- and pentasialotransferrin (see Figure 1, lane 2). Seven of the 19 patients 
(patients 1-7) with an unsolved CDG defect were classified as CDG-Ix. 
Figure 1. 
Isoelectric focusing (IEF) profiles of plasma 
transferrin (lanes 1-4) and apoC-III (lanes 5-
7). The presence of doublets in the transferrin 
isoelectric focusing (TIEF) profiles of lanes 3 
and 4 is caused by a polymorphism in the 
amino acid sequence of transferrin.   
Lanes 1 + 5, control; lane 2, congenital 
disorders of glycosylation (CDG) type 1 
profile; lane 3, CDG type 2 profile, the “asialo 
TIEF profile” (patient 13); lane 4, CDG type 2 
profile, the “disialo TIEF profile” (patient 15); 
lane 6, the “apoC-III0 IEF profile” (patient 15); 
lane 7, the “apoC-III1 IEF profile” (patient 19). 
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All abnormal TIEF profiles that are not typical CDG type 1 were classified as a CDG type 2 
profile. Twelve of the 19 patients (patients 8-19) were classified as CDG-IIx. The clinical features 
of these 12 CDG-IIx patients are summarized in Table 1. The relative amounts of the transferrin 
isoforms of these 12 CDG-IIx patients and of patients with CDG-IIa, -IId, and –IIe are 
summarized in Table 2. On the basis of the ratio of the transferrin isoforms two different TIEF 
profile types could be distinguished in patients with CDG type II. The “asialo TIEF profile” is 
characterized by highly elevated levels of the asialo- and monosialotransferrin isoforms (Figure 
1, lane 3). TIEF of plasma samples from patients 9,10, 13, and CDG-IId have this asialo TIEF 
profile. The “disialo TIEF profile” is characterized by normal or slightly elevated levels of asialo- 
and/or monosialotransferrin and increasingly higher levels of the disialo- and trisialo-transferrin 
isoforms (Figure 1, lane 4). Patients 8, 11, 12, 14-19, CDG-IIa, and CDG-IIe have this disialo 
TIEF profile.  
 
Table 2 A. Summary of the relative amounts of transferrin isoforms in CDG-IIx patients.  
 T0 (%) T1 (%) T2 (%) T3 (%) T4 (%) T5 (%) 
Reference range  
(of all ages) 
 
0 - 3 
 
0 - 3 
 
2 - 6 
 
3 - 16 
 
51 - 72 
 
12 – 31 
 
Patient 8 3 2 24 21 50 0 
Patient 9 25 17 22 11 19 6 
Patient 10 15 20 19 17 29 0 
Patient 11  0 2 13 29 48 8 
Patient 12  1 2 10 25 45 17 
Patient 13  16 16 20 25 23 0 
Patient 14  0 1 10 29 49 11 
Patient 15 2 9 23 29 32 5 
Patient 16  1 3 26 33 32 5 
Patient 17 3 3 10 28 46 10 
Patient 18 4 5 14 23 39 15 
Patient 19  1 3 12 27 48 9 
CDG-IIa 4 6 73 17 0 0 
CDG-IId 48 38 14 0 0 0 
CDG-IIe 
 
0 6 17 30 42 5 
T, transferrin; 0-5, number of terminal NeuAc 
 
IEF of plasma apoC-III 
 
Patients with CDG-Ia, -Ib, -Ic, -Ie, and –If had a normal apoC-III isoform distribution, just like 
patients 1-7 with CDG-Ix. A normal apoC-III IEF profile was found in patients with CDG-IIa and 
IId, while plasma from a patient with CDG-IIe resulted in an abnormal apoC-III isoform 
distribution (Table 3). Of the 12 CDG-IIx patients, 3 had a normal apoC-III IEF profile (patients 8-
10), whereas 9 had an abnormal apoC-III IEF profile (patients 11-19). The relative amounts of 
the apoC-III isoforms of patients 8-19 are summarized in Table 3. On basis of the ratio of the 3 
apoC-III isoforms, two different IEF profile types could be distinguished. The “apoC-III0 IEF 
profile” is characterized by elevated levels of apoC-III0 (Figure 1, lane 6). Patients 11-15 and the 
patient with CDG-IIe have this apoC-III0 IEF profile. The “apoC-III1 IEF profile” is characterized by 
elevated levels of the monosialo apoC-III form (Figure 1, lane 7).  
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Table 3. Summary of the relative amounts of apoC-III isoforms in CDG-II patients.  
 ApoC-III0 (%) ApoC-III1 (%) ApoC-III2 (%) 
Reference range 
0-1 / 1-18 / >18 yr 
 
0-8 / 0– 12/ 3-19 
 
34-59 / 33 – 67 / 43-69 
 
40-62 / 27 – 60 / 23-50 
 
Patient 8 23 years 3 67 30 
Patient 9 18 years 3 50 47 
Patient 10 6 years 2 58 40 
Patient 11  7 years 14 70 16 
Patient 12  5 years 24 61 15 
Patient 13  9 months 27 53 20 
Patient 14  10 years 36 50 14 
Patient 15 3 years 37 58 5 
Patient 16  20 years 15 75 10 
Patient 17 2 years 11 73 16 
Patient 18 2 years 10 76 14 
Patient 19  3 years 6 86 8 
CDG-IIa Child 4 36 60 
CDG-IId Child 4 61 35 
CDG-IIe 
 
1 month 35 50 15 
 
SDS-PAGE of apoC-III 
 
SDS-PAGE of apoC-III was only performed in cases with abnormal profiles for apoC-III IEF. 
Using SDS-PAGE, two bands of apoC-III could be distinguished; a major band containing apoC-
III1 and apoC-III2 and a minor apoC-III0 band. Two-dimensional electrophoresis (IEF and SDS-
PAGE) has shown that the apoC-III1 and apoC-III2 bands co-migrate on SDS-PAGE (data not 
shown). Plasma from patients 14, 15 and the CDG-IIe patient showed an abnormal apoC-III 
SDS-PAGE pattern (Figure 2A, lanes 4-6), whereas plasma from patients 11-13 and 16-19 had a 
normal apoC-III SDS-PAGE profile (not shown). The apoC-III0 band of plasma from patients 14, 
15 and the CDG-IIe patient migrated further into the gel than the apoC-III0 band of the controls.  
The samples from the patients with abnormal apoC-III SDS-PAGE profiles were sequentially 
treated with neuraminidase and O-glycosidase. Similar results were obtained for plasma from 
patients 14, 15 and the CDG-IIe patient. In Figure 2B, the resulting SDS-PAGE profiles are 
shown of plasma from patient 15 (lanes 4-6) and from a control (lanes 1-3). After the incubation 
of control plasma with neuraminidase, the sialic acid residues of apoC-III2 and apoC-III1 were 
cleaved off, and apoC-III0 with the Galβ1-3GalNAc glycan remained (Figure 2B, lane 2). After 
neuraminidase treatment of plasma of patient 15, the lower band composed of apoC-III2 and 
apoC-III1 disappeared and a new band was visible at the position of apoC-III0 with the Galβ1-
3GalNAc glycan (Figure 2B, lane 5). Clearly, a second band is visible on top of the Galβ1-
3GalNAc glycan, indicating a lower molecular mass. 
After the incubation of desialylated control plasma and of desialylated plasma of patient 15 with 
O-glycosidase, the Galβ1-3GalNAc glycan of apoC-III0 was cleaved off and the protein part of 
apoC-III remained (Figure 2B, lanes 3 and 6). This deglycosylated apoC-III band appears at the 
same position as the “second” band in lane 5. This suggests that the apoC-III0 fraction in plasma 
from patients 14, 15 and CDG-IIe consists of nonglycosylated apoC-III.  
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Figure 2A. 
Sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis (SDS-PAGE) profiles 
of plasma apoC-III. Lanes 1-3, controls; 
lane 4, patient 14; lane 5, patient 15; 
lane 6; patient with congenital disorders 
of glycosylation-IIe (CDG-IIe). The ratio 
of the distance between the apoC-III0
and apoC-III1+2 band of the controls 
compared to patient 14 was 1:2.  
 
 
 
 
 
 
 
 
 
 
Figure 2B. 
SDS-PAGE profiles of enzym-treated 
plasma samples of patient 15 with 
abnormal SDS-PAGE profiles (lanes 4-6) 
compared to control (lanes 1-3). Lanes 1 
and 4, untreated sample; lanes 2 and 5, 
neuraminidase treated sample; lanes 3 
and 6, O-glycosidase treated sample. 
 
 
 
Subdivision of unsolved CDG-II patients in groups 
 
On the basis of the biochemical results, it is possible to divide the 12 unsolved CDG-II patients 
into 6 biochemical different groups (Figure 3). After TIEF, two distinct groups could be 
distinguished based on either the asialo or the disialo profile. Patients 8–10 had normal apoC-III 
IEF profiles, but because of the different TIEF profiles they form two groups in the final 
classification. The patient with CDG-IId is in the same group as patients 9 and 10, whereas the 
patient with CDG-IIa is in the same group as patient 8. 
Nine patients had abnormal apoC-III IEF profiles (cases 11–19). Therefore, they must have 
molecular defects affecting both N- and O-glycosylation. The apoC-III SDS–PAGE profile of 
plasma from patients 14 and 15 was clearly abnormal and similar to the plasma profile of the 
CDG-IIe case. The remaining 7 patients had normal SDS–PAGE profiles and could be divided in 
3 separate groups, based on different combinations of TIEF with apoC-III IEF profile types. 
Therefore, the 12 CDG-IIx cases can be subdivided in a total number of 6 biochemical distinct 
groups. 
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Figure 3.  
Overview of the 6 biochemical groups that result after transferrin isoelectric focusing (TIEF), apolipoprotein C-III (apoC-III) 
IEF, and apoC-III sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS–PAGE) of congenital disorders of 
 
Discussion 
 
 
In this study, we classified 19 patients with unsolved CDG into 7 biochemically distinct patient 
groups based on TIEF, apoC-III IEF, and apoC-III SDS-PAGE. A previous attempt to classify 
CDG-IIx cases was performed by Mills et al. by glycan analysis24. The TIEF profile separates the 
19 patients into a CDG-Ix and a CDG-IIx group. The 7 patients classified as CDG-Ix all had a 
normal apoC-III IEF profile. The same holds for patients with CDG-Ia, -Ib, -Ic, -Ie, and -If. The 
primary defect in these patients is located in the early N-glycan biosynthesis pathway, before the 
transfer of the glycan from the dolichol carrier to the protein by the oligosaccharyl transferase 
complex. This part of the N-glycan biosynthesis is not relevant for the biosynthesis of core 1 O-
glycans. Therefore, the finding of normal apoC-III IEF results is as expected in CDG-Ix cases. 
The CDG-Ix patients present as 1 biochemical group in this study. The methodology used in this 
study is not informative for a further subclassification of this CDG-Ix group.  
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The primary defect in patients 8-19, who had been classified as CDG-IIx, is probably localized in 
the processing of N-glycans, which mainly occurs in the Golgi compartment. The processing of 
N-linked glycans involves the removal of several monosaccharides by glycosidases in the late 
ER and Golgi apparatus and the addition of monosaccharides catalyzed by specific 
glycosyltransferases in the Golgi apparatus. The addition of monosaccharides requires the 
biosynthesis of the nucleotide-sugars UDP-GlcNAc, UDP-Gal and CMP-NeuAc in the cytosol and 
their transport into the Golgi. The biosynthesis of the core 1 O-glycan attached to apoC-III 
requires (1) the biosynthesis of UDP-GalNAc, UDP-Gal, and CMP-NeuAc; (2) their transport into 
the Golgi; and (3) the subsequent transfer by specific glycosyltransferases. CDG-IIx patients with 
normal apoC-III IEF results are likely to have the primary defect in a N-glycan specific processing 
step, while CDG-IIx patients with abnormal apoC-III IEF results are likely to have the defect in an 
enzyme or protein, that plays a role in the biosynthesis of both N- and core 1 O-glycans.  
We hypothesized that IEF profile types provide further information for the localization of the 
primary defect. For example, we found that a CDG-IId patient has the “asialo TIEF profile”, with 
increased amounts of a-, mono- and disialo and decreased amounts of tri-, tetra- and pentasialo 
transferrin fractions, whereas a CDG-IIa patient has the “disialo TIEF profile”, with normal or 
slightly elevated amounts of asialo- and monosialo-, increased amounts of disialo- and 
decreased amounts of tetra- and pentasialotransferrin fractions. Both patients had normal results 
for apoC-III IEF. These results correspond with the biochemical defects in CDG-IIa and CDG-IId. 
Deficiency of β4GalT1 affects both antennae of the N-glycan in patients with CDG-IId. 
Theoretically, this deficiency would result in a TIEF profile with high amounts of the asialo 
fraction. Our CDG-IId patient indeed shows a TIEF profile with elevated levels of asialo- and 
monosialotransferrin. Deficiency of GlcNAcT-II affects only the Man-α1,6-antenna in patients with 
CDG-IIa. As transferrin contains two N-glycans, this deficiency would result in a TIEF profile with 
elevated levels of the disialo fraction. Our CDG-IIa patient indeed shows a TIEF profile with 
elevated levels of disialotransferrin. The defective transferases in CDG-IIa and –IId are not 
required for the biosynthesis of the apoC-III O-glycan. Therefore, the finding of normal apoC-III 
IEF results is as expected in the CDG-IIa and -IId cases. 
Patients 8-10 have a type 2 TIEF profile and normal results for apoC-III IEF. Therefore they are 
likely to have a defect in a protein involved in N-glycan biosynthesis that is not involved in core 1 
O-glycan biosynthesis. A further division could be made on basis of the type of TIEF profile. 
Patients 9 and 10 share the asialo TIEF profile and form biochemical group 1. These patients are 
likely to have the primary defect in ST6Gal I25, β4GalT1, Golgi mannosidase I26, GlcNAcT-I27, or 
in the UDP-GlcNAc transporter. If one of these proteins carries a genetic defect, synthesis of 
both antennae of the N-glycan is hampered. The biosynthesis of core 1 O-glycans would not be 
affected. In contrast, biochemical group 3 with patient 8 has a disialo TIEF profile. This patient is 
likely to have the primary defect in one of the enzymes that acts specifically on 1 antenna of the 
N-glycan. Candidates for the putative defect are GlcNAcT-II and mannosidase II28.  
Seventy-five per cent of the analyzed CDG-IIx patients have an abnormal distribution of the 
plasma apoC-III IEF isoforms. These patients have a defect affecting both the biosynthesis of N-
linked glycans and the core 1 O-glycans and thus have a combined defect in N- and O-
glycosylation. The defect has to be localized in one of the shared biosynthetic steps of both 
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pathways and may involve the biosynthesis of CMP-NeuAc or UDP-Gal or their transporters. As 
UDP-GalNAc is mainly synthesized from UDP-GlcNAc the primary defect could also be situated 
in the biosynthetic route of UDP-GlcNAc29.  
For a further subdivision, we used SDS-PAGE of apoC-III. The abnormal apoC-III SDS-PAGE 
profile with a shift of the apoC-III0 isoform is likely to be caused by nonglycosylated apoC-III 
protein. A patient with CDG-IIe has such a profile. CDG-IIe is caused by mutations in one of the 
subunits of the COG-complex, which affects the regulation, compartmentalization, transport and 
activity of several Golgi enzymes. Defects in the COG complex result in abnormal protein-linked 
N- and O-glycans2.  
Patients 14 and 15 also have an abnormal apoC-III SDS-PAGE profile. Like the CDG-IIe patient, 
they both had the disialo TIEF and apoC-III0 IEF profile types and formed biochemical group 5. 
The abnormal apoC-III SDS-PAGE results could be caused by a defect in the biosynthesis of 
UDP-GlcNAc, in one of the COG subunits, in one of the proteins involved in glycoprotein traffic 
through the Golgi, or in proteins involved in Golgi maintenance and biogenesis. It was found very 
recently that patient 15 indeed has a defect in one of the COG subunits (Prof. G. Matthijs, 
Leuven, Belgium, personal communication). Patient 14 is still under investigation for COG 
subunit defects. 
Patients 11-13 and 16-19 have a combined defect in N- and core 1 O-glycosylation and normal 
apoC-III SDS-PAGE profiles and form biochemical groups 2, 4 and 6 on basis of their TIEF and 
apoC-III IEF profile types. It is likely that the underlying defect in these patients is situated in the 
biosynthesis or transport of CMP-NeuAc or UDP-Gal as these monosaccharides are required for 
the biosynthesis of both N-glycans and core 1 O-glycans, and these deficiencies would result in 
normal apoC-III SDS-PAGE profiles. The differences in TIEF and apoC-III IEF profile types 
suggest a similar defect in patients within 1 biochemical group and a different defect in patients 
between the subgroups. 
Clinically, the 12 CDG-IIx patients have a phenotype with widely variable clinical features as 
central nervous system involvement, hepatic dysfunction, or congenital malformations (Table 1). 
It was not possible to make a classification on basis of the clinical symptoms. For the robustness 
of our methodology, it is encouraging that in biochemical group 6, 3 of the 4 patients (patients 17-
19) have a very similar and peculiar phenotype with cutis laxa, microcephaly, dysmorphy, 
hypotonia, mental retardation and eye anomalies16. These 3 patients may share the same 
primary defect. The observed cutis laxa has not been described in other CDG subtypes so far.  
In conclusion, the combination of the TIEF, apoC-III IEF, and apoC-III SDS-PAGE allowed us to 
subdivide the CDG type II patient group into 6 biochemically distinct groups. This subdivision 
narrows down the options for the position of the primary defect, with a limited number of 
theoretical possibilities for each individual patient.  
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Abstract 
 
 
Background: Apolipoprotein C-III (apoC-III) isoelectric focusing (IEF) can be used to detect 
abnormalities in the biosynthesis of core 1 mucin-type O-glycans.  
Methods: We studied plasma samples from 55 patients with various primary defects in N- and/or 
O-glycosylation, 21 patients with secondary N-glycosylation defects and 9 patients with disorders 
likely to have abnormal glycosylation. Furthermore, we analyzed 500 plasma samples that were 
sent to our laboratory for selective screening on inborn errors of metabolism.  
Results: Plasma samples from patients with CDG types –IIe and –IIf showed a 
hypoglycosyolated apoC-III isoform profile, just like 75% of the patients with an unspecified CDG 
type II. In plasma from 2 patients with hemolytic uremic syndrome hyposialylated O-glycan 
profiles were also obtained. In the 500 plasma samples from the selective screening, 3 patients 
were identified with a possible isolated defect in the biosynthesis of core 1 mucin-type O-glycans. 
ApoC-III isoforms in premature neonates were hyperglycosylated in 6 of 13 cases, suggesting 
abnormal O-glycan biosynthesis possibly due to liver immaturity. 
Conclusions: To our knowledge this is the first time that patients have been identified in which 
only the O-glycan biosynthesis might be affected by use of a plasma marker protein. The primary 
defect(s) remain as yet unknown. Plasma apoC-III IEF is complementary to transferrin 
isofocusing. In conjunction both tests identify biosynthesis defects in N-glycan and mucin-type 
core 1 O-glycan biosynthesis. The apoC-III IEF assay is likely to help metabolic laboratories to 
identify and unravel further subtypes of inborn errors of glycan biosynthesis. 
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Introduction 
 
 
Hyposialylation of glycoproteins is characteristic for congenital disorders of glycosylation (CDG). 
Transferrin isoelectric focusing (TIEF) is generally applied in the screening for inborn errors in the 
biosynthesis of N-glycans, whereas apolipoprotein C-III (apoC-III) isoelectric focusing (IEF) can 
be used in the screening for inborn errors in the biosynthesis of mucin-type core 1 O-glycans1. 
Transferrin is a plasma protein containing two complex type N-glycans with sialic acid (NeuAc) 
residues on their termini. The complex type N-glycan has a common core structure containing 2 
N-acetylglucosamine (GlcNAc) and 3 mannose (Man) residues with heterogeneous antennae 
consisting of GlcNAc, galactose (Gal) and NeuAc residues. Because the terminal residues and 
the branching of N-glycans are variable, several isoforms of transferrin can be distinguished. 
ApoC-III is a plasma protein containing 1 mucin-type core 1 O-glycan. Three isoforms of apoC-III 
can be distinguished, apoC-III0, apoC-III1 and apoC-III2, where the isoform number, like in 
transferrin, represents the number of sialic acid residues that is attached to the mucin-type core 1 
O-glycan2. As sialic acid has a negative charge, the IEF patterns of transferrin and apoC-III show 
a cathodal shift when hyposialylated, which can be caused either by structural glycan changes or 
by a different number of glycans3, whereas the glycoproteins show an anodal shift when 
hypersialylated. TIEF can detect abnormal glycosylation in primary defects that include enzyme 
deficiencies in the N-glycosylation pathway and secondary defects that include genetic diseases 
and conditions that influence the N-glycan biosynthesis. 
In mammals, the most common form of O-glycosylation is the mucin-type O-glycosylation in 
which glycans are attached to the protein via N-acetylgalactosamine (GalNAc). This mucin-type 
O-glycosylation can be subdivided into 8 core structures. The core 1 O-glycan, with Galβ1-
3GalNAc-(Ser/Thr) as the core structure, is the most common subtype and occurs on many 
membrane and secreted proteins4,5. Until now, only 1 disorder with a genetic defect in the 
biosynthesis of mucin-type O-glycans has been described: mutations in polypeptide N-
acetylgalactosaminyl-transferase 3 (GALNT3) cause familial tumoral calcinosis (FTC)6. The O-
glycosylation biosynthesis routing and the different O-glycan biosynthesis defects have recently 
been reviewed by Wopereis et al.7. 
Three years ago, our group has developed apoC-III IEF as a means to study biosynthesis 
defects in mucin-type core 1 O-glycans1. In this paper, we describe our experience with the 
technique when applied to plasma samples from patients with many different disorders. We 
studied samples from patients with primary defects in the N- and/or O-glycosylation, patients with 
secondary N-glycosylation defects and patients with diseases/conditions where abnormal 
glycosylation profiles had been reported. Finally, we have used the apoC-III IEF assay in the 
selective screening for inborn errors of metabolism. In this report, we will summarize these data 
and provide a framework for the use of the apoC-III IEF assay in the detection of congenital 
disorders of glycosylation.  
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Patients, materials and methods 
 
 
Patient group 1; primary defects in the glycosylation 
 
In patient group 1 we collected plasma samples from patients with 1) a specified CDG subtype, 
2) a genetically confirmed other glycosylation disorder and 3) a repeatedly abnormal TIEF profile 
ontained and known within the European consortium on CDG Euroglycanet. We obtained 55 
plasma samples from patients with primary CDG of which 21 from patients with specified CDG 
type I [CDG-Ia, n=8; CDG-Ib, n=3; CDG-Ic, n=8; CDG-Ie, n=1; CDG-If, n=1], 7 from patients with 
unspecified CDG type I (= CDG-Ix8; the patients are in this group, because of the 
characteristically abnormal TIEF profile with asialo- and disialotransferrin markedly increased), 6 
from patients with specified CDG type II [CDG-IIa, n=19; CDG-IId, n = 110; CDG-IIe, n = 3 (P2 in11 
and 2 as yet unpublished cases); CDG-IIf, n = 1(the case from12)], 12 from patients with 
unspecified CDG type II (= CDG-IIx8; the patients are in this group, because of the 
characteristically hypoglycosylated TIEF profile with asialo-, monosialo-, disialo- and 
trisialotransferrin fractions increased to a variable extent), and 9 from other genetically confirmed 
types of glycan biosynthesis disorders [heriditary inclusion body myopathy (HIBM), n = 113; FTC, 
n = 66; and muscle-eye-brain disease (MEB), n = 1].  
The 2 unpublished CDG-IIe patients (one female; 1 month of age, one male; 7 months of age) 
presented with growth retardation, progressive, severe microcepahly, hypotonia, adducted 
thumbs, feeding problems by gastrointestinal pseudoobstruction, failure to thrive, cardiac 
anomalies, wrinkled skin and episodes of extreme hyperthermia. In both patients the same 
homozygous, intronic plice site mutation (c.169+4A>C) of the COG7 gene was identified as in 
the patients described by Wu et al.11. Clinical signs and symptoms of these 2 CDG-IIe patients 
will be described in more detail seperately by Morava et al.  
 
Patient group 2; secondary defects in the N-glycosylation  
 
In patient group 2 we collected plasma samples from patients proven to have a secondary defect 
in the N-glycosylation. These were patients with 1) genetically confirmed secondary diseases, 
and 2) confirmed syndromes found to have abnormal TIEF profiles. We obtained 21 plasma 
samples from patients with secondary N-glycosylation alterations [fructosemia due to aldolase B 
deficiency, n = 2; galactosemia due to galactose-1-phosphate uridyltransferase deficiency, n = 5; 
chronic alcohol abuse, n = 12; and hemolytic uremic syndrome (HUS), n = 2]. The plasma 
samples from the patients with fructosemia and galactosemia were obtained before dietary 
treatment. The plasma samples from the HUS cases were obtained in the acute phase of the 
disease prior to or soon after the start of the appropriate treatment.  
 
Patient group 3; possible glycosylation abnormalities 
 
In patient group 3 we collected plasma samples from patients with 1) a genetic confirmed defect 
suspectible of influencing the biosynthesis of glycans or 2) a syndrome described in literature 
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with abnormal glycosylation patterns. We studied 6 plasma samples from patients with disorders 
suspected to have an abnormal glycosylation [Hutchinson Gilford progeria syndrome (HGPS), n 
= 2; and a combined deficiency of factor V and factor VIII (F5F8D), n = 4]. In HGPS abnormal N-
glycosylation has been reported14. Patients with F5F8D have a defect in component 53 of the 
endoplasmic reticulum (ER)-Golgi intermediate compartment (ERGIC-53), which could influence 
the biosynthesis and trafficking of glycoproteins. 
 
Patient group 4; selective screening for inborn errors of metabolism 
 
In patient group 4 we collected samples that were sent to our laboratory for selective metabolic 
screening. In a prospective study, we analyzed 500 different plasma from patients presented 
either with psychomotor retardation –isolated or with additional symptoms-, muscle diseases, 
encephalopathy and other symptoms compatible with metabolic disorders.  
Based on a preliminary observation of a severe hyperglycosylation in a premature baby, 13 
plasma samples of premature neonates (gestational age was less than 36 weeks) were 
investigated. Samples used for the apoC-III IEF reference intervals for premature neonates were 
obtained between the second week of life and 6 months after birth. Samples used for the 
reference interval for babies born at full term were from 17 children obtained between the first 
week of life and 6 months of age.  
 
Samples and sample preparation 
 
Blood samples were obtained from patients with informed parental consent. Plasma was 
prepared by centrifugation and stored immediately at –80 °C until required for analysis.  
 
Isoelectric focusing of apoC-III 
 
IEF of apoC-III was carried out as described by Wopereis et al1. A dry IEF Phastgel was hydrated 
in a solution of 8 M urea and 60 mL/L Pharmalyte pH 4.2 – 4.9 and Ampholine pH 3.5 – 5.0 in a 
ratio of 2:1. Plasma samples were diluted 10-fold with saline and applied to the hydrated gel on a 
Phastsystem (Amersham Biosciences, Piscataway, New Jersey, USA). After IEF, the isoforms of 
apoC-III were detected by Western blotting using polyclonal rabbit anti-human apoC-III antibody 
(ANAWA trading SA, Wangen, Switzerland) and goat anti-rabbit horseradish peroxidase-coupled 
antibody. After visualizing the results by electrochemiluminescence, the relative amounts of the 
apoC-III isoforms were determined by scanning the film using an Image master Labscan (Version 
3.00, Amersham Biosciences, Piscataway, New Jersey, USA) and quantified using Image master 
1D gel analysis software (Version 4.10, Amersham Biosciences, Piscataway, New Jersey, USA). 
The apoC-III IEF profile was defined as abnormal when the ratio of the 3 apoC-III isoforms was 
found outside the described reference ranges in at least two different plasma samples from 1 
patient in duplicate1. In general, 2 abnormal apoC-III IEF profile types can be differentiated; the 
apoC-III0 IEF profile characterized by elevated levels of apoC-III0 and the apoC-III1 profile 
characterized by elevated levels of the monosialo apoC-III form8. The between-run 
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reproducibility, assessed by performing the test on the same plasma sample on 6 different days, 
showed a standard deviation below 2% for the 3 isoforms1. 
 
Isoelectric focusing of transferrin 
 
TIEF was carried out essentially as described by van Eijk and van Noort15. Equal volumes of a 
plasma sample and a solution of 20 mM ferric citrate and 0.50 mM sodium hydrogen carbonate 
were incubated for 30 minutes to saturate the transferrin with iron. The iron-saturated plasma 
was diluted 10 times with water and applied to a hydrated dry Phastgel (2.5% Ampholines pH 5-7 
solution) and run on a PhastSystem. After IEF the transferrin isoforms were detected by 
precipitating with rabbit anti-human transferrin antibody (Dako, Glostrup, Denmark) and the gels 
were washed overnight in saline and stained with Coomassie blue. The relative amounts of the 
transferrin isoforms were determined by densitometry as described under isoelectric focusing of 
apoC-III. 
  
Neuraminidase treatment 
 
Neuraminidase from Clostridium Perfringens (cat. no. 1585886; Roche, Basel, Switzerland; 5U in 
0.5 ml 0.1 M Tris, pH 7.0), catalyzes the hydrolysis of α2-3-, α2-6-, and α2-8-linked NeuAc 
residues from glycoproteins and oligosaccharides. Polymorphisms of apoC-III and transferrin 
were excluded by incubation of the samples with neuraminidase removing the negatively 
charged sialic acid residues. After neuraminidase treatment, all apoC-III and transferrin isoforms 
migrated to the asialo position on IEF, indicating that any observed abnormal profiles were due to 
changes in the sialic acid content. Human plasma was incubated with the enzyme (5U/ml) 
overnight at room temperature. Samples for transferrin IEF were diluted 30 times with water and 
samples for apoC-III IEF were diluted as described. Samples were analysed as the plasma 
samples described. 
 
 
Results 
 
 
To identify the causes of abnormal apoC-III IEF profiles we selected 4 groups of patients. The 
results are presented below. 
 
Patient group 1; primary congenital disorders of glycosylation 
 
All plasma samples from 28 patients with CDG type I (CDG-Ia, -Ib, -Ic, -Ie, -If and CDG-Ix) 
showed a normal apoC-III isoform distribution. The plasma sample from 3 CDG-IIe patients 
showed an apoC-III0 IEF profile with increased amounts of the apoC-III0 isoform (35%, 27% and 
23% respectively; reference range 0-8%) and decreased amounts of the apoC-III2 isoform (15%, 
20% and 22% respectively; reference interval 40-62%, see Figure 1, lane 2). The plasma sample 
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from the CDG-IIf patient showed a different isoform profile, the apoC-III1 IEF profile with 
increased amounts of the apoC-III1 isoform (78%, reference interval 33-67%) and decreased 
amounts of the apoC-III2 isoform (16%, reference range 27-60%; see Figure 1, lane 3). Of the 12 
CDG-IIx patients, 3 had a normal apoC-III IEF profile, whereas 9 had an abnormal apoC-III 
profile. Of the 9 patients with abnormal apoC-III IEF results, 5 had an apoC-III0 IEF profile and 4 
had the apoC-III1 profile. Table 1 summarizes the relative amounts of the apoC-III isoforms in the 
patients with abnormal apoC-III IEF profiles. Clinical signs and biochemical results of the 12 
CDG-IIx patients have been described in more detail by Wopereis et al.8. The plasma samples 
from 1 CDG-IIa, 1 CDG-IId, 1 HIBM, 1 MEB and 6 FTC patients showed a normal apoC-III 
isoform distribution. Table 2 summarizes the apoC-III IEF and TIEF results from patients with 
primary congenital disorders of glycosylation.  
 
Table 1. Summary of the relative amounts of apoC-III isoforms in patients with an abnormal apoC-III profile.  
ApoC-III0 (%) ApoC-III1 (%) ApoC-III2 (%) 
Reference Range 0-1/1-18/>18* 
Mean (SD) 0-1/1-18/>18 
0-8 / 0-12 / 3-19 
4(2)/5(3)/9(4) 
34-59 / 33-67 / 43-69
47(6)/53(9)/55(6) 
40-62 / 27-60 / 23-50 
49(6)/42(8)/36(7) 
ApoC-III profile type
 
CDG-IIe11 1 month 35 50 15 ApoC-III0
CDG-IIe 9 month 27 53 20 ApoC-III0
CDG-IIe 1 month 23 55 22 ApoC-III0
CDG-IIf  4 month 6 78 16 ApoC-III1
CDG-IIx*1 7 years 14 70 16 ApoC-III0
CDG-IIx*2 3 years 37 58 5 ApoC-III0
CDG-IIx*3 2 years 11 73 16 ApoC-III1
CDG-IIx*4 3 years 6 86 8 ApoC-III1
HUS 1 year 18 56 26 ApoC-III0
HUS 1 year 23 53 24 ApoC-III0
HGPS + LMNA 10 years 4 76 20 ApoC-III1
HGPS - LMNA Child 1 70 29 ApoC-III1
Patient 1 9 years 7 80 13 ApoC-III1
Patient 2 18 years 2 17 81 Hyper 
Patient 3 5 years 18 70 11 ApoC-III0
Patient 4 16 years 2 79 19 ApoC-III1
Mother of patient 4 
 
45 years 3 75 22 ApoC-III1
* As published in ref. 1; *1: Patient 11 in ref. 8; this patient has the mildest apoC-III0 IEF profile of the patients investigated, *2: 
Patient 15 in ref. 8, this patient has the most severe apoC-III0 IEF profile of the patients investigated, *3: Patient 17 in ref 8; 
this patients has the mildest apoC-III1 IEF profile of the patients investigated, *4: Patient 19 in ref. 8; this patient has the most 
severe apoC-III1 IEF profile of the patients investigated. 
 
Patient group 2; secondary N-glycosylation alterations 
 
Several disorders and/or conditions are known to cause N-glycan abnormalities, such as 
galactosemia16, fructosemia17, chronic alcohol abuse18 and hemolytic uremic syndrome (HUS) 
due to a Streptococcus pneumoniae infection19. Plasma samples from 2 patients in the acute 
phase of HUS resulting from a Streptococcus pneumoniae infection showed an apoC-III0 profile 
with increased relative amounts of apoC-III0 (18 and 23% respectively, reference range 0-12%) 
and slightly decreased amounts of apoC-III2 (26 and 24% respectively, reference range 27-60%; 
see Figure 1, lane 4). Table 1 summarizes the relative amounts of the apoC-III isoforms in the 
HUS patients. The profiles normalized soon after the start of appropriate treatment. The plasma 
samples from 12 chronic alcohol abuse, 2 fructosemia and 5 galactosemia patients all had 
normal plasma apoC-III isoform profiles (Table 2).  
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Figure 1. 
Plasma apoC-III isofocusing profiles from patients 
with primary and secondary mucin-type core 1 O-
glycan abnormalities. Lane 1, control; lane 2, 
CDG-IIe; lane 3, CDG-IIf; lane 4, HUS; lane 5, 
Hutchinson Gilford progeria. 
 
Patient group 3; possible glycosylation abnormalities 
 
In the third group, we investigated 2 different disorders that were suspected to have an abnormal 
glycan biosynthesis, namely Hutchinson Gilford progeria syndrome (HGSP), and a combined 
deficiency of factor V and VIII (F5F8D). Robinson et al.14 reported that proteome analysis in 
HGPS showed an abnormal glycosylation in patients with and without mutations in the lamin A/C 
gene. Our HGPS patient with a mutation in the LMNA gene showed an apoC-III1 profile with 
increased amounts of apoC-III1 (76%, reference range 33-67%), and decreased amounts of 
apoC-III2 (20%, reference interval 27-60%; see Figure 1, lane 5). The apoC-III isoform 
distribution in a HGPS patient without a mutation in the LMNA gene (the underlying defect is still 
unknown) was slightly and not convincingly abnormal. The apoC-III1 isoform was just above the 
reference range (70%, reference range 33-67%). The results for TIEF were normal in both HGPS 
patients. Lamins are structural protein components of the nuclear lamina, a protein network 
underlying the inner nuclear membrane that determines nuclear shape and size. It is unlikely that 
lamin A/C itself is a glycoprotein, as it is a nuclear protein and thus not synthesized in the 
secretory pathway. The only connection between the nucleus and the biosynthesis of core 1 O-
glycans is the final step in the biosynthesis of CMP-NeuAc localized in the nucleus20. Table 1 
summarizes the relative amounts of the apoC-III isoforms of the apoC-III isoforms in the HGPS 
patients.  
F5F8D is a second disorder potentially leading to glycosylation abnormalities. As is seen in 
patients with a defect in subunit 7 of the conserved oligomeric Golgi complex (COG7) or CDG-
IIe, defects in Golgi trafficking can influence the biosynthesis of glycoproteins. Patients with 
F5F8D have a defect in component 53 of the ER-Golgi intermediate compartment (ERGIC-53). 
This is thought to function as a molecular chaperone for ER to Golgi transport of a specific 
subset of secreted proteins, including factor V and VIII21. Therefore, we considered that this 
defect might lead to a disturbance of glycosylation. The plasma samples from patients with 
F5F8D, however, gave normal results for both apoC-III IEF and TIEF.  
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Patient group 4; selective screening for inborn errors of metabolism 
 
ApoC-III IEF was performed in 500 plasma samples that were sent to our laboratory for selective 
screening on inborn errors of metabolism. Four samples were found to have an abnormal apoC-
III IEF profile (Table 1). All patients had normal results for TIEF.  
Patient 1: Patient 1 is a 9-year-old boy with pronounced developmental regression at age 2 
years with deterioration of verbal communication. ApoC-III IEF repeatedly showed an apoC-III1 
profile with increased amounts of apoC-III1 (80%, reference interval 33-67%), and decreased 
amounts of apoC-III2 (13%, reference interval 27-60%). 
Patient 2: Patient 2 is an 18-year-old woman with psychomotor retardation, rhabdomyolysis and 
kidney insufficiency. The plasma sample was obtained in the acute phase of the rhabdomyolysis. 
ApoC-III IEF showed a hyperglycosylated apoC-III profile with decreased amounts of apoC-III1 
(17%, reference range 43-69%), and increased amounts of apoC-III2 (81%, reference range 23-
50%). 
Patient 3: Patient 3 is a boy of 5 years with psychomotor retardation and dysmorphic features. 
His apoC-III IEF profile was repeatedly abnormal and showed an apoC-III0 profile with increased 
amounts of apoC-III0 (18%, reference interval 0-12%), slightly elevated amounts of apoC-III1  
(70%, reference range 33-67%),and decreased amounts of apoC-III2 (11%, reference interval 27-
60%). 
Patient 4: Patient 4 is a 16-year-old woman with muscle cramps of unknown cause and 
excessive sweating. ApoC-III IEF repeatedly showed an apoC-III1 profile with increased amounts 
of apoC-III1 (79%, reference interval 33-67%), and decreased amounts of apoC-III2 (19%, 
 
Table 2. Overview of apoC-III IEF and TIEF results on samples from patients with primary and secondary disorders in the 
glycosylation. +, IEF profile is abnormal; -, IEF profile is normal; nd, not determined 
CDG type MIM Gene Protein TIEF ApoC-III IEF 
 
Primary glycan biosynthesis defect 
 
CDG-I (a,b,c,e,f,x)    + - 
IIa 212066 MGAT2 GlcNAc transferase II + - 
IIb 606056 GLS1 Glucosidase I - 29 nd 
IIc 266265 SLC35C1 GDP-fucose transporter - 30 nd 
IId 607091 B4GALT1 Galactosyltransferase + - 
IIe 608779 COG7 COG7 + + 
IIf  SLC35A1 CMP-NeuAc transporter - + 
IIx    + + or –8
FTC 211900 GALNT3 Protein GalNActransferase - - 
MEB 253280 POMGNT1 O-mannosyl-β-1,2-GlcNAc transferase - - 
HIBM 600737 GNE UDP-GlcNAc 2-epimerase/ 
ManNAc kinase - - 
 
Secondary glycosylation disturbance 
 
Galactosemia 230400 GALT Galactose-1-phosphate 
uridyltransferase 
+ - 
Fructosemia 229600 ALDOB Aldolase B + - 
HUS    + + 
Chronic Alcohol 
abuse  
   + - 
HGPS 
 
176670 LMNA Lamin A/C - + 
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reference interval 27-60%). Interestingly, her mother with similar clinical symptoms showed also 
an apoC-III1 profile with increased amounts of apoC-III1 (75%, reference interval 43-69%), and 
decreased amounts of apoC-III2 (22%, reference interval 23-50%). Serum creatine kinase was 
normal and a quadriceps muscle biopsy showed no morphological or enzyme histochemical 
abnormalities. Fiber size and fiber type proportions were normal. There were no ragged red 
fibers. Enzyme histochemistry showed no abnormal mitochondrial staining and also PAS-staining 
was normal. Biochemical investigations of the muscle biopsy showed normal overall oxidation 
rates and normal activity of respiratory chain complexes. 
 
ApoC-III pattern in premature babies 
 
Based on a preliminary observation of an obvious hypersialylation in a sample from a premature 
baby, 13 plasma samples from premature neonates were investigated. The results are 
summarized in Table 3. In 6 of the 13 cases (cases nr. 2, 4, 5, 8, 9, and 13 in Table 3) the apoC-
III isoform distribution was different from the reference range for children 0-1 year, published by 
Wopereis et al.1. Plasma samples from neonates (n = 17) born full term all showed values within 
this reference range published (data not shown). ApoC-III1 levels were significantly lower and 
apoC-III2 levels were significantly higher in samples from the premature neonates than in 
samples from babies born at full term. No correlation could be found between gestational age 
and the degree of the hypersialylation. O-glycan abnormalities in premature infants may relate to  
liver immaturity or due to the ratio of α2,6 and α2,3 sialyltransferase activities. The 
hypersialylation found in premature neonates may hamper the interpretation of apoC-III IEF 
profiles.  
 
Table 3. Plasma apoC-III isoform distribution in 13 premature neonates. 
nr Gestational age (weeks + days) ApoC-III0 (%) ApoC-III1 (%) ApoC-III2 (%) 
 
1 24 + 0 0 55 45 
2 26 + 0 2 18 80 
3 26 + 0 1 60 39 
4 27 + 0 1 12 87 
5 27 + 0 1 34 65 
6 28 + 3 5 37 58 
7 28 + 3 2 59 39 
8 29 + 1 3 11 86 
9 29 + 1 1 21 78 
10 32 + 0 2 53 45 
11 33 + 2 10 40 50 
12 34 + 5 2 48 50 
13 
 
35 + 0 0 12 88 
 
Mean (SD) – Range ‘prematurity’ 2 (3) 0 - 10 35 (18) 12 - 61 62 (19) 39-88 
Mean (SD) – Range ‘born at full term’* 
 
4 (2) 0 - 8 47 (6) 34 - 59 49 (6) 40-62 
* As published in ref. 1. 
 
ApoC-III polymorphisms 
 
In the 500 samples, we found 2 individuals who had a polymorphism in the protein backbone of 
apoC-III. Plasma of the person with polymorphism 1 showed 4 apoC-III isoforms, whereas 
plasma of the person with polymorphism 2 showed 6 apoC-III isoforms (Figure 2, lanes 2 and 3 
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respectively). After treatment with neuraminidase, plasma from a control showed 1 band in the 
position of apoC-III0 (Figure 2, lane 4). Plasma of the person with polymorphism 1 showed 2 
bands of equal intensity at the positions of apoC-III0 and apoC-III1 (Figure 2, lane 5). This 
illustrates that this person has the wild type apoC-III allele and a mutated allele leading to apoC-
III isoforms with a more negative net charge than the wild type isoforms. The asialo form of the 
mutated protein exactly coincides with the monosialo form of the wild type protein (Figure 2, lane 
2). Plasma of the person with polymorphism 2 showed 2 bands of equal intensity at the position 
of apoC-III0 and at a position below the apoC-III0 isoform (Figure 2, lane 6). This person also has 
2 different apoC-III alleles. The mutated allele leads to apoC-III isoforms with a more positive net 
charge than the wild type isoforms. Remarkably, the ratio between the 3 apoC-III isoforms was 
not equal for both forms of the protein. The relative amount of apoC-III0 was significantly higher in 
the mutated form of the protein. This form therefore is hyposialylated suggesting that the 
polymorphism interferes with normal O-glycosylation. Polymorphisms in the apoC-III protein may 
hamper the interpretation of apoC-III IEF profiles. 
 
Figure 2. 
Plasma apoC-III isofocusing profiles from individuals 
with a protein polymorphism. The numbers on the 
right side of a lane represent the original isoform 
height from allele 1. The numbers on the left side of a 
lane represent the isoform height from allele 2. Lane 
1, control; lane 2, polymorphism 1; lane 3, 
polymorphism 2; lane 4, control after treatment with 
neuraminidase; lane 5, polymorphism 1 after 
treatment with neuraminidase; lane 6, polymorphism 
2 after treatment with neuraminidase. 
 
 
Discussion 
 
 
In the group with primary glycan biosynthesis defects we tested several patients with CDG-I 
subtypes (CDG-Ia, -Ib, -Ic, -Ie, and –If) and with CDG-Ix. The primary defect in these patients is 
located in the early N-glycan biosynthesis pathway in the cytoplasm or in the ER. This part of the 
N-glycan biosynthesis is not relevant for the biosynthesis of mucin-type core 1 O-glycans. 
Therefore, the finding of normal apoC-III IEF results is as expected in CDG type I.  
Subsequently, we tested several patients with CDG-II subtypes (CDG-IIa, -IId, -IIe and –IIf), 
CDG-IIx, and further primary defects in glycosylation (HIBM, FTC, and MEB). Samples from 
patients with CDG-IIe and –IIf showed an abnormal apoC-III IEF profile. CDG-IIe is caused by 
mutations in subunit 7 of the COG-complex11. The COG-complex is involved in retrograde 
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trafficking processes through the Golgi and the defect affects the regulation, 
compartmentalization, transport and activity of several Golgi enzymes11,22. Wu et al.11 reported a 
defective N-glycosylation, and subsequently showed an altered biosynthesis of mucin-type core 
1 O-glycans in the patients’ fibroblasts by lectin staining. ApoC-III IEF resulted in an apoC-III0 IEF 
profile8 with increased amounts of apoC-III0 and decreased amounts of apoC-III2 in plasma of a 
CDG-IIe patient. The altered mucin-type core 1 O-glycosylation in CDG-IIe can thus be picked up 
with apoC-III IEF.  
The patient with CDG-IIf has a deficient cytidine 5’monophospho-N-acetylneuraminic acid (CMP-
NeuAc) transporter12. Martinez-Duncker et al. found that the sialylation pattern of several N-
glycosylated plasma proteins was normal, but showed a defective sialylation of core 1 mucin-
type O-glycans by lectin staining12. ApoC-III IEF showed an apoC-III1 profile8 with increased 
amounts of the apoC-III1 isoform and decreased amounts of apoC-III2. The patient with CDG-IIf 
can be picked up with apoC-III IEF, whereas TIEF gave normal results. A comparison with other 
sialylation defects shows that in all cases mainly mucin-type O-glycosylation is affected, rather 
than the N-glycosylation. Three defects affecting sialylation are known to date: CDG-IIf (CMP-
NeuAc transporter defect), HIBM and Sialuria. Sialuria patients have a defect in uridine-5’-
diphosphate-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase (GNE/MNK) 
leading to an overproduction of CMP-NeuAc. The patients have a clear hypersialylation of 
plasma core 1 O-glycans as shown in the apoC-III IEF assay, while only minor changes were 
found in the sialylation pattern of the N-glycans23 (Chapter 8, this thesis). Patients with HIBM, 
also called distal myopathy with rimmed vacuoles (OMIM 600737 and 605820), have a defect in 
the gene coding for the enzyme uridine diphosphate-N-acetylglucosamine-2-epimerase/N-
acetylmannosamine kinase (GNE / MNK). GNE / MNK is a bifunctional enzyme that catalyzes 
the first 2 steps in the biosynthesis of CMP-NeuAc. The theoretical decrease in CMP-NeuAc 
biosynthesis leads to hyposialylated muscle core 1 O-glycans as shown by lectin staining24 and 
to a decrease of muscle α-dystroglycan staining suggestive for hyposialylation of O-
mannosylglycans13. The sialylation level of N-glycans, however, seems to be unaffected13,24. 
ApoC-III IEF resulted in a normal sialylation pattern in plasma of a HIBM patient and does not 
confirm the hyposialylation of core 1 O-glycans that was found in muscle tissue. The disturbance 
in mucin-type core 1 O-glycan biosynthesis may be tissue specific leading to abnormal O-glycans 
in muscle, thus possibly not affecting the hepatic synthesis of apoC-III.  
The primary defect in 12 CDG-IIx patients, most probably presenting a genetic heterogeneous 
group, is probably localized in the processing of N-glycans, which mainly occurs in the Golgi 
compartment. The 3 CDG-IIx patients with normal apoC-III IEF are likely to have the primary 
defect in an N-glycan specific processing step, whereas the 9 CDG-IIx patients with abnormal 
apoC-III IEF are likely to have the defect in an enzyme or protein, that plays a role in the 
biosynthesis of both N- and core 1 O-glycans. Of the analyzed CDG-IIx patients, 75% has an 
abnormal distribution of the plasma apoC-III IEF isoforms (see also8).  
In patients with other glycosylation disorders, patients with FTC have the only genetically defined 
defect in the biosynthesis of mucin-type O-glycosylation identified so far. The defective GALNT3 
gene encodes UDP-GalNAc transferase 3 (GALNT3), responsible for the transfer of UDP-
GalNAc to Thr/Ser to the protein backbone. GalNT3 is highly expressed in human pancreas, 
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skin, kidney and testis and weakly expressed in prostate, ovary, intestine and colon25. The 
results of a normal apoC-III IEF profile reflected this expression pattern, as GalNT3 is not 
expressed in liver tissue where apoC-III is synthesized6. The normal results in CDG-IIa, -IId and 
MEB are explained by the fact that the defective transferases in these disorders are not involved 
in the biosynthesis of the apoC-III O-glycan.  
The second patient group tested for abnormalities in the biosynthesis of mucin-type core 1 O-
glycans, were diseases/conditions leading to secondary N-glycan abnormalities. Among these 
are galactosemia, fructosemia, alcohol abuse and HUS. Plasma apoC-III was hyposialylated in 
the acute phase of S. pneumoniae associated HUS of 2 patients. S. pneumoniae excrete 
neuraminidase, which catalyzes the hydrolysis of NeuAc residues from glycoproteins. This 
explains the apoC-III hyposialylation profile. Plasma from patients with galactosemia, fructosemia 
(all before dietary treatment) and from individuals who are alcohol abusive showed normal 
results for apoC-III IEF. The 3 conditions result in a transferrin type 1 profile17,18,26, which 
suggests that these conditions have an influence on the early N-glycan biosynthesis pathway, 
localized in the ER or cytoplasm. As the biosynthesis of mucin-type core 1 O-glycans is situated 
in the Golgi, these results were as expected.  
Finally, we analyzed 500 plasma samples that were sent to our laboratory for the selective 
screening of inborn errors of metabolism. We found 4 patients with an abnormal apoC-III IEF 
profile. Three of the 4 patients had a hypoglycosylated apoC-III IEF profile, whereas 1 patient 
had a hypersialylated apoC-III IEF profile. The sample from patient 2 was taken in the acute 
phase of the rhabdomyolysis and apoC-III isoforms showed a hypersialylated profile. The 
rhabdomyolysis in our patient caused secondary renal failure. It is unlikely that the kidney failure 
in this patient caused the hyperglycosylation, as 6 additional patients with kidney failure showed 
normal apoC-III IEF profiles (data not shown). Unfortunately, the patient was lost for follow-up. 
Therefore, it remains unclear whether this patient also has an abnormal apoC-III IEF profile after 
this rhabdomyelytic phase. The mechanism behind the hypersialylation remains unknown.  
The other 3 patients showed a hyposialylated apoC-III isoform distribution on several occasions 
(patients 1, 3 and 4). Patients 1 and 4 showed an apoC-III1 profile with increased amounts of 
apoC-III1 and decreased amounts of apoC-III2. The mother of patient 4 has similar symptoms as 
her daughter and turned out to have an abnormal apoC-III1 IEF pattern as well, suggesting 
dominant or X-linked inheritance. Patient 3 had an apoC-III0 profile with increased amounts of 
apoC-III0 and apoC-III1 and decreased amounts of apoC-III2. The results for TIEF were normal in 
all 3 patients. They are likely to have the primary defect situated in one of the steps involved in 
the biosynthesis of mucin-type core 1 type O-glycans. To our knowledge this is the first time that 
patients have been identified in which only the O-glycan biosynthesis might be affected, while N-
glycan biosynthesis is unaffected.  
In conclusion, the apoC-III IEF test is helpful especially in patients with congenital disorders of 
glycosylation type II and should be considered complementary to the selective screening with 
TIEF. The reference range of the apoC-III isoforms in any age-cohort is broad. In some 
patients only slightly abnormal values are found for apoC-III isoforms (as in case CDG-
IIx*1 in Table 1). When such slight abnormalities are confirmed in a second sample they 
may be meaningful. However, as long as the primary defect in these patients has not 
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been determined the significance of slight abnormalities remains uncertain. At the 
moment, no alternative techniques for the screening of O-glycan biosynthesis disorders 
are present, although newly developed mass spectrometric techniques look 
promising27,28.  
In patients with an abnormal TIEF profile, but normal results for apoC-III IEF, it is likely that the 
primary defect is situated in one of the N-glycan specific biosynthetic steps, not shared by the 
biosynthesis routing of core 1 O-glycans. This is for example shown in plasma samples from 
patients with CDG-IIa and –IId. Patients with a combined deficiency in the biosynthesis of N- and 
mucin-type core 1 O-glycans have abnormal results for both TIEF and apoC-III IEF. In these 
patients, the primary defect is situated in one of the shared biosynthetic steps of N- and core 1 
O-glycosylation. This is the case in patients with CDG-IIe. Patients with normal results for TIEF 
and abnormal results for apoC-III IEF might have a primary defect in one of the mucin-type core 
1 O-glycan specific synthesis steps, or in the biosynthesis or transport to the Golgi of UDP-
GalNAc and CMP-NeuAc. Although NeuAc is a monosaccharide shared by N- and mucin-type 
core 1 O-glycans, apoC-III IEF seems to be more sensitive for changes in CMP-NeuAc levels 
than TIEF. This is illustrated in a plasma sample of a patient with CDG-IIf. The apoC-III IEF test 
is pivotal to pick up inborn errors in the mucin-type core 1 O-glycan biosynthesis. The assay is 
likely to help metabolic screening laboratories to identify and unravel a further series of inborn 
errors of glycan biosynthesis.  
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Abstract 
 
 
Congenital cutis laxa is a genetically heterogeneous condition presenting with loose and 
redundant skin folds, decreased elasticity of the skin, connective tissue involvement and a highly 
variable spectrum of associated features. The most common forms are inherited in an autosomal 
recessive or dominant fashion. Fibulin 5 and elastin mutations were detected in a limited number 
of patients, but in most cases the etiology is not known. Based on a previous observation of an 
abnormal transferrin isoelectric focusing pattern in a patient with cutis laxa indicating an N-
glycosylation defect, we performed a screening for disorders of protein glycosylation in unrelated 
children with cutis laxa syndrome, including a recently developed test for defective O-
glycosylation. Here, we describe 5 patients from consanguineous marriages with a cutis laxa 
syndrome with skeletal and joint involvement, developmental delay and neurological findings. 
Three of these 5 children have an inborn error of glycan biosynthesis affecting the synthesis of 
both N-linked and O-linked glycans. Two patients had normal glycosylation patterns. All known 
causes of secondary glycosylation disorders were excluded in the children. No mutations were 
found in the FBLN5 gene. 
In conclusion, we have identified a new combined glycosylation defect with a distinct clinical 
phenotype. Our results suggest that a combined defect of glycosylation might be a causative 
factor in congenital cutis laxa. This is the first report where abnormal N- and O-linked 
glycosylation is implicated in the etiology of cutis laxa syndrome. 
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Introduction 
 
 
Cutis laxa syndrome is a rare, genetically heterogeneous condition1-4 presenting in the early 
months of life with loose and redundant skin folds mostly on the trunk and the extremities, and 
decreased elasticity of the skin1,5,6. A highly variable spectrum of associated features7-11 has 
been reported. The skin histology characteristically demonstrates abnormal elastic fiber structure 
with a significantly decreased amount of elastin5,6,12. The most common forms are inherited in an 
autosomal recessive or dominant fashion (MIM 219200, 219100, MIM 123700, MIM 150240).  
Two distinct clinical types of autosomal recessive cutis laxa (ARCL) have been described in 
detail. In ARCL type I (MIM 219100), congenital cutis laxa presents with a generalized disorder of 
the elastic tissue with diaphragmatic or other hernias, diverticula of the gastrointestinal or urinary 
tract and infantile emphysema. The disease is often fatal within the first year. In this severe form, 
missense mutations have been detected in the fibulin-5 gene1,3. The phenotypic features 
observed in a fibulin-5 knockout mouse model are similar to those of the human ARCL type I12.  
In patients with ARCL type II (MIM 219200), the cutis laxa is combined with widely patent anterior 
fontanel, a variety of malformations, retarded growth and abnormal development7,8,11,13,14. Central 
nervous system anomalies and ophthalmologic findings are rare findings in ARCL type II9,10. So 
far, the genetic etiology of ARCL type II is not known.  
Congenital defects of glycosylation (CDG) are a group of phenotypically diverse, multisystemic 
disorders caused by various enzyme defects of the N-glycan synthesis. The generally used 
screening method for CDG is transferrin isoelectric focusing (TIEF)15. In some of these patients, 
the underlying enzyme defect is not yet known. During a systemic screening program for CDG in 
patients with multisystem disorders without a known etiology, we observed an abnormal TIEF 
pattern, indicating an N-glycosylation defect (classified as CDG type IIx) in a patient with cutis 
laxa. Based on this observation, we performed a metabolic evaluation for disorders of protein 
glycosylation (including N-glycan and O-linked glycan biosynthesis) in further unrelated patients 
with cutis laxa and developmental delay.  
Apolipoprotein C-III (ApoC-III) isoelectric focusing (IEF) has recently been described as a new 
screening method for “core 1 mucin-type O-glycans”16. Defects of the O-glycan biosynthesis may 
also lead to clinically very distinct disorders. Muscle-eye-brain disease and Walker-Warburg 
syndrome17 have been identified as O-mannosylation disorders. The progeroid type of Ehlers 
Danlos18 and multiple exostoses syndrome19 are due to biosynthesis defects in O-xylosyl-
proteoglycans. The gene underlying familial tumoral calcinosis encodes a glycosyltransferase 
responsible for initiating mucin-type O-glycosylation20.  
Here, we present 5 patients with a cutis laxa syndrome associated with skeletal and joint 
involvement, muscle hypotonia, and developmental delay. Some of these patients had epilepsy 
and congenital brain malformations as well. Three of the 5 children were found to have a defect 
affecting the biosynthesis of both the N- and the O-linked glycans.  
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Case reports 
 
 
The clinical and laboratory findings of 5 patients with cutis laxa syndrome are summarized in 
Table 1. Here we describe in details the phenotype of the 3 patients (patients 1-3) with an inborn 
error of glycosylation.  
 
Table 1: Clinical features and laboratory findings in 5 patients with cutis laxa 
Clinical features∗ Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
 
Consanguinity + + +  + + 
Cutis laxa + ++ + + + 
Microcephaly ++ + + + - 
Large fontanel ++ ++ + - - 
Dysmorphic features + + + + + 
Motor developmental delay/hypotonia + ++ + + + 
Mental retardation + + + + + 
Seizures - ++ + - + 
Intracranial malformation - ++ + ++ - 
Congenital joint anomaly (deformation) + + + - - 
Hypermobile joints + + + + + 
Eye anomalies (strabismus, myopia) + + ++ + + 
Urogenital anomalies  + - + - - 
Characteristic skin histology for cutis 
laxa 
+ + + + + 
Abnormal result of TIEF screening + + + - - 
Abnormal results of ApoC III screening + + + - - 
Fibulin-5 mutation 
 
- - - NA NA 
∗None of the patients had growth retardation, cardiac anomalies, lung emphysema, liver disease, endocrine or coagulation 
anomalies.+: feature is present ; -: feature is absent; ++: feature is present in a pronounced form; NA: not analyzed. 
 
Patient 1  
 
Patient 1 (Figure 1a) was born as the second child of healthy parents of Turkish origin, who were 
first cousins. The third offspring had nonimmune fetal hydrops and died at the 20th week of the 
pregnancy. Our patient presented at term with a birth weight of 2730g (-2SD), a birth length of 47 
cm (-2SD), microcephaly (HC: 31.0 cm, -3.0SD), large fontanel (5.5x7 cm), brachycephaly, flat 
face, midfacial hypoplasia, anteverted nares, long philtrum, neonatal teeth (left incisor), down-
slanting palpebral fissures, strabismus, blue sclera, generalized cutis laxa, and single umbilical 
artery. Additionally, hyperflexible joints, muscle hypotonia, cryptorchidism, and swallowing 
difficulties were reported. Cranial and abdominal ultrasound, EEG and a cranial MRI were 
normal. VEP and BAEP were both abnormal showing decreased conduction velocities. A skeletal 
survey showed luxated hypoplastic femur heads with hip dysplasia. Chromosome analysis, Hb, 
Htc, MCV, MCH, MCHC, cell counts, serum creatinine, BUN, uric acid, electrolytes, calcium, 
phosphorus, ALP, ASAT, ALAT, γGT, LDH, CK, cholesterol, TG, serum proteins, 
immunoglobulins, lactic acid, glucose, blood gas (ASTRUP), coagulation studies (APT, APTT, 
factor VII, VIII, IX, X, XI, XII, protein C and S), alpha1-antitrypsin, endocrine evaluation (TSH, 
freeT4, thyroxine binding globulin (TBG), ACTH, GH, cortisol), markers for a possible infection 
and initial metabolic studies (serum amino-acid profile, acyl-carnitin profile, homocysteine, 
studies on cholesterol synthesis, phytanic acid, lysosomal enzymes, urine organic acid pattern, 
urine amino-acids, purines/pyrimidines) were all normal. The skin histology showed a normal 
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epidermis, homogeneous staining of the collagen bundles, with somewhat shorter collagen 
fibers, and the elastic fiber staining detected a rarefaction of elastic fibers, which were severely 
fragmented. The electromicroscopy showed a decreased elastic material. Intact elastic fibers 
could not be observed. 
The fontanel was closed at the age of 3 years (length: 101 cm, +1SD; weight: 18 kg; 0SD; HC: 
46.5 cm, -2.5SD). At the age of 10 years the patient (Figure 2a) had a normal growth with 
microcephaly (length: 146 cm, +1SD; weight: 31 kg, -1SD; HC: 49 cm, -2.5SD). He wore hearing 
aids, showed a developmental delay (IQ 69), and followed special education. He had mild 
hypotonia and a minimal hyperlaxity of the joints (the hip luxation was successfully operated). He 
showed a gradual improvement of the skin disease, he continued to have a very dry skin, but at 
10 years of age the cutis laxa was localized only in the abdominal region (Figure 2d).  
Figure 1. 
Family tree of the 3 patients (patients 1-3) with a combined glycosylation disorder 
 
 
Patient 2  
 
Patient 2 (Figure 1b) was born premature at 36 weeks of gestation as the first child of healthy 
parents of European origin, who were second cousins. She presented with a birth weight of 
2250g (-2SD), length of 44 cm (-2SD), microcephaly (HC: 29cm, -2.5SD), large fontanel (5 x 6 
cm), brachycephaly, flat face, midfacial hypoplasia, anteverted nares, long philtrum, down-
slanting palpebral fissures, strabismus, a generalized, severe cutis laxa, dry skin, sparse hair, 
pes adductus, hyperflexible joints, muscle hypotonia and feeding difficulties. Abdominal 
ultrasound and echocardiography were normal. From the age of 5 months (Figure 3a), she 
received anticonvulsive medication due to a West syndrome and abnormal EEG. A cranial MRI 
at the age of 2.5 years showed bilateral pachygyria (Figure 4a). VEP and BAEP were normal. A 
skeletal survey showed a large, open fontanel, narrow pelvis and generalized osteopenia. She 
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had recurrent urinary infections and a gastro-esophageal reflux. Chromosome analysis and blood 
and urine analysis including initial metabolic analysis (see patient 1) were all normal. The skin 
histology showed a normal epidermis, increased subcutaneous fat and homogeneous staining of 
the collagen bundles; the Weigert elastic fiber technique detected a rarefaction of elastic fibers, 
which were short and fragmented. Intact elastic fibers could not be observed. The Western 
blotting for collagens and procollagens were normal. Electromicroscopy showed decreased 
elastic material. 
The patient had no significant feeding problems at the age of 3 years (Figure 3c) and showed a 
normal growth with a microcephaly (HC: 45.5 cm, -2.5SD). Her fontanel was closed at the age of 
2.5 years. At the age of 7.5 years our patient (Figures 2b and 3d) was severely retarded, but able 
to communicate and very social. Her growth was age appropriate (length: 122.5 cm, -1SD; 
weight: 22.5 kg, -1 SD) with a microcephaly (HC: 47, -2.5 SD) and psychomotor developmental 
delay (IQ 52) She walked clumsy but without help. She had a significant improvement of the cutis 
laxa since birth with a mostly abdominal localization (Figure 3b-d), a very dry skin, and gluteal 
fad-pads (Figure 2e). 
 
 Figure 2. 
 
Patient 1: facial features with down-slanting palpebral fissures, midfacial hypoplasia, long philtrum (a) and mild abdominal 
cutis laxa (d) at the age of 10 years. Patient 2: characteristic facial features with high forehead, down-slanting palpebral 
fissures, midfacial hypoplasia (b) and gluteal fat-pads (e) at the age of 7 years. Patient 3: facial features with down-slanting 
palpebral fissures, midfacial hypoplasia and facial cutis laxa at the age of 3 years (c), and cutis laxa on the extremities at the 
age of 3.5 years (f). 
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Patient 3 
 
Patient 3 (Figure 1c) was born as the first child of healthy parents of Turkish origin, who were first 
cousins. The patient presented at term with a birth weight of 3605 g (+1SD), length of 53 cm 
(+1SD), microcephaly (HC: 31.5 cm, -2.5SD), large fontanel (4.5 x 5 cm), flat face, midfacial 
hypoplasia, anteverted nares, down-slanting palpebral fissures, strabismus, generalized cutis 
laxa, clubfeet, bilateral clinodactyly of the IVth fingers, hyperflexible joints and muscle hypotonia. 
She had recurrent urinary tract infections. A mild bilateral hydronephrosis was found by an 
abdominal ultrasound. Further studies detected bilateral pyelo-urethral stenosis. The 
echocardiography was normal. From as early as the second day of life, she suffered from tonic 
clonic seizures, the EEG was abnormal and she was started on anticonvulsive therapy. A cranial 
MRI showed a partial, bilateral fronto-temporal pachygyria (Figure 4b). She was diagnosed with a 
myopia of 5.5 diopters. VEP showed decreased conduction velocities. BAEP was normal. A 
skeletal survey showed a large, open fontanel, and hypoplastic iliac wings and acetabulae. 
Chromosome analysis and blood and urine analysis including initial metabolic analysis (see 
patient 1) were all normal. The skin histology showed a slight hyperkeratosis; the Gleason 
staining detected shorter and thin collagen fibers and the elastic fibers were short, scattered and 
severely fragmented. Electromicroscopy showed a severe decrease in the amount of elastic 
fibers. The fibers present were all abnormal in structure. 
The patient at the age of 3 years had no feeding problems, showed a normal growth and 
microcephaly (length: 98 cm, +0.5SD; weight: 16 kg, +1SD; HC: 46.0 cm, -2SD). Her fontanel  
Figure 3.
Evolving phenotype in patient 2 showing an 
improvement of the skin symptoms at the age of 5 
months (a), 18 months (b), 3.5 years (c), and 7 
years (d). 
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Figure 4. 
Cranial MRI picture of patient 2 with bilateral pachygyria (a) and patient 3 with mild partial fronto-temporal pachygyria in the 
sagittal and vertical view (b). 
 
was closed at the age of 2 years. She had a developmental delay and speech delay; she started 
to walk at 15 months of age but could not speak till the age of 22 months, and she had muscle 
hypotonia, significant hyperlaxity of the joints and cutis laxa. At the age of 4 years (Figure 2c), 
she still had generalized cutis laxa (Figure 2f), hyperelastic joints, hypotonia and a 
developmental delay (IQ 59). 
 
Patient 4 
  
The clinical phenotype of Patient 4 (see Table 1) has been described in detail earlier9.  
 
Patient 5  
 
Patient 5 had a mild intrauterine growth retardation, severe congenital generalized cutis laxa with 
joint hyperlaxity, psychomotor retardation, hypotonia, epilepsy, transient feeding problems, and 
normal growth after the 1st year of life. He had no microcephaly or brain malformations (Table 1). 
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Methods 
 
 
Patient selection 
 
Metabolic screening for inborn errors of protein glycosylation was performed in 5 patients with 
cutis laxa syndrome, consecutively diagnosed in the neonatal period. These unrelated patients 
were all born from consanguineous marriages. The clinical features are summarized in Table 1. 
 
Sample preparation for IEF of  apoC-III, transferrin, and TBG 
  
After centrifugation for cell separation, plasma and/or serum samples were stored without delay 
at –80 °C until analysis. Samples used for IEF of apoC-III were diluted 10-fold with saline. 
Samples used for TIEF were saturated with a 10 mM ferric citrate and 0.5 mM sodium hydrogen 
carbonate solution (2:1) in a ratio of 10:3 for 30 min. This saturated plasma sample is diluted 5 
times with water. 
 
IEF of apoC-III 
 
ApoC-III is a mucin-type core 1 O-glycosylated plasma protein. In control samples, equal 
amounts of disialo and monosialo isoforms are present with only a very small amount of asialo-
apoC-III. 
IEF of apoC-III was carried out as described by Wopereis et al16. Plasma was separated on a 
hydrated dry IEF gel (pH 3.5 – 5.0 and 8 M urea) on a PhastSystem. After IEF, a Western blot 
was performed. The apoC-III isoforms were specified by adding rabbit anti-human apoC-III 
antibody and visualized by electrochemiluminescence. The relative amounts of apoC-III isoforms 
were determined using densitometry. 
 
IEF of transferrin 
 
Transferrin is an N-glycosylated protein. Multiple isoforms occur in plasma with the tetrasialo-
isoform being the most abundant. TIEF is used as a screening method for the detection of 
abnormally high amount of asialo, monosialo, disialo, and trisialo isoforms in N-glycan biosynthesis 
defects. 
TIEF was carried out essentially as described21. Iron-saturated plasma or serum was separated on 
a hydrated immobiline gel (pH 4-7) on a Ultraphore system (Amersham Pharmacia Biotech). After 
IEF, the isoforms were visualized by adding rabbit anti-human transferrin antibodies (Dako, 
Glostrup, Denmark) and stained with Coomassie blue. The relative amounts of isoforms were 
scanned using an Image master Labscan, Ver. 3.00 (Amersham Pharmacia Biotech) and 
quantified using Image master 1D gel analysis, Ver. 4.10, software (Amersham Pharmacia 
Biotech).  
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IEF of TBG 
 
Pure plasma was applied to a Phastgel (pH 4 - 6.5) (Amersham Pharmacia Biotech) and 
analyzed using the PhastSystem. After addition of rabbit TBG antibody (Dako), the TBG pattern 
was detected by silver staining. 
 
Mutation analysis of FBLN5 
 
Genomic DNA was isolated from cultured dermal fibroblasts of patients 1 and 2 and from 
leukocytes of patient 3. Mutation analysis of the FBLN5 gene was performed as described by 
Loeys et al3. 
 
 
Results 
 
 
Transferrin and TBG isofocusing 
 
Plasma samples of patients 1 - 3 showed reproducibly an abnormal transferrin isofocusing 
pattern with a decrease of the tetrasialotransferrin isoforms but increase of hypoglycosylated 
transferrin isoforms (tri-, di- and monosialylated isoform) (Figure 5a). TBG isoforms were also 
abnormal, confirming a generalized defect in N-glycosylation (data not shown). All known causes 
of secondary glycosylation disorders were excluded in the 3 children. These 3 patients were 
classified as having an unidentified CDG type II, suggesting a defect in glycan biosynthesis in the 
Golgi. The IEF patterns in patients 4 and 5 were repeatedly normal. 
 
ApoC-III isofocusing 
 
Plasma and/or serum samples of patients 1 - 3 showed an abnormal isofocusing profile for apo 
C-III (Figure 5b) in duplicate over a period of a year. All 3 patients had increased  
apoC-III1, decreased apoC-III2 and normal apoC-III0. (patient 1: ApoC-III1: 73%, controls: 33-
67%;  ApoC-III2: 16%, controls: 27-60%; ApoC-III0: 11%, controls: 0-12%; patient 2: ApoC-III1: 
76%, controls: 33-67%; ApoC-III2: 14%, controls: 27-60%; ApoC-III0: 10%, controls: 0-12%; 
patient 3: ApoC-III1: 86%, controls: 33-67%; ApoC-III2: 8%, controls: 27-60%; ApoC-III0: 6%, 
controls: 0-12%). The ApoC-III IEF patterns in patients 4 and 5 were normal.  
 
Mutation analysis of FBLN5 
 
No mutations were found in the FBLN5 gene in the cutis laxa patients with abnormal 
glycosylation profiles. 
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Figure 5. 
IEF results: abnormal transferrin patterm with decreased tetrasialotransferrin and increased tri-, di-, and monosialylated 
ansferrin isoforms (a) in patient 1 (lane 2), patient 2 (lane 3), and patient 3 (lane 4). Abnormal apoC-III pattern with 
creased levels op apoC-III1, decreased levels of apoC-III2 and normal apoC-III0 (b) in patients 1 (lane 2), patient 2 (lane 3), 
nd patient 3 (lane 4). Lanes 1 in (a) and (b) represents a control. 
 
 
Discussion 
 
 
We performed a metabolic evaluation for glycosylation disorders in 5 unrelated patients with cutis 
laxa syndrome. We found 3 patients out of the 5 with the clinical presentation of cutis laxa 
syndrome and developmental delay who were diagnosed with an inborn error of metabolism 
affecting N- and O-glycan synthesis. All known causes of secondary CDG forms were excluded 
by appropriate measures.  
The patients with the combined glycosylation defect presented with a phenotype similar to that of 
ARCL type II (generalized cutis laxa, mental retardation, microcephaly, late closure of the 
fontanel, joint laxity). However, some features, like the bilateral urethral-pelvic stenosis and 
vesico-urethral reflux in patient 3, support the presence of urethral wall involvement, which is 
more characteristic for ARCL type I.  
The presence of seizures, found in 2 of these 3 patients with glycan abnormalities and in 1 with 
normal IEF patterns, is not characteristic in cutis laxa syndrome, but common in CDG 
syndrome15. Structural abnormalities of the brain occur frequently in CDG as well. The finding of 
pachygyria as in patients 2 and 3 is a rare observation in cutis laxa patients. However, 
pachygyria have been reported in children with O-glycan biosynthesis defects17 supporting the 
importance of glycosylation in normal brain development.  
There was an obvious difference observed in the severity of the cutis laxa at birth (with the most 
severe phenotype in patient 2), but all of the 5 children showed a significant improvement of the 
skin symptoms at an older age. Based on some of the phenotypical overlap observed in these 
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children with a glycosylation defect and in patients with known fibulin mutations, our findings 
further support the presence of genetic heterogeneity in cutis laxa syndrome.  
Cutis laxa syndrome is a congenital disorder with major structural and functional defects of the 
elastic fiber system. Elastin is a nonglycosylated extracellular matrix (ECM) protein found in 
vasculature, lung, skin and connective tissue. Crosslinked elastin can be found in association 
with several microfibril-associated glycoproteins like fibrillin-1, fibrillin-2, fibronectin or fibulin-1 
and fibulin-5 suggesting that these proteins contribute to elastic fiber assembly, structure and 
function22,23,24. In the ECM, the final structure and adequate function of collagen and elastin fibers 
are dependent on the perfect function and anchoring of these essential matrix glycoprotein 
molecules. 
Fibulins are widely expressed secretory glycoproteins with a complex structure including N- and 
O-glycosylated sites and are present in the basement membranes and the stroma of most 
tissues12,24-26 22,25. Their roles have been implicated in organogenesis and vasculogenesis . In 
fibuline knockout mice, fragmented elastin can be detected in different tissues without an 
increase of elastase activity, indicating a defective development of elastic fibres, similar to that in 
cutis laxa syndromes12. In some patients with ARCL type I and in a large family with a dominant 
form of cutis laxa, mutations have been detected in the fibulin-5 gene1-3.  
An inborn error of metabolism leading to a combined defect of N- and O-glycosylation might alter 
the structure and therefore the function of several ECM glycoproteins, like fibulin-5. This may 
cause developmental defects already in the early embryonic period and lead to abnormal 
structure and malfunction of different tissues and organs. In the 3 patients described here with a 
cutis laxa syndrome, the combined N- and O-linked glycosylation defect might explain the 
presence of the characteristic phenotype without a fibulin-5 gene mutation, and the presence of 
features overlapping with other syndromes with N- or O-glycosylation defects.  However, in the 
absence of an evident enzyme deficiency, the primary defect remains speculative27.  
Recently Wu et al28. described patients with a lethal form of CDG syndrome and a defect in the 
COG7 subunit of the COG complex (conserved oligomeric Golgi complex). Disruption of this 
complex caused by COG7 deficiency leads to abnormal localization of enzymes and transporters 
resulting in severe hypoglycosylation of glycoproteins. The defect also affects both N- and O-
glycosylation. These patients had a multisystem disease with neurological involvement, and 
wrinkled skin. The partial phenotypic overlap with the 3 cutis laxa cases further delineates the 
importance of O-linked protein glycosylation in the normal skin structure and brain development. 
The subunits of COG complex and other proteins, associated with the cytoplasmic surface of the 
Golgi apparatus, and involved in intracellular trafficking, are among the candidate proteins for the 
primary defect in our cutis laxa patients. 
Our findings support the presence of a new cutis laxa syndrome, based on an inborn error of 
glycan biosynthesis. We suggest that all patients with cutis laxa syndrome, especially with 
microcephaly, late closure of the fontanels and associated features of the central nervous 
system, should be screened for glycosylation defects. 
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Abstract 
 
 
Based on our preliminary observation of abnormal glycosylation in a cutis laxa patient, 9 cutis 
laxa patients were analyzed for congenital defects of glycosylation (CDG). Isoelectric focusing of 
plasma transferrin and apolipoproteinC-III showed that 3 out of 9 patients had a defect in the 
biosynthesis of N-glycans and core 1 mucin-type O-glycans, respectively. Mass spectrometric N-
glycan analyses revealed a relative increase of glycans lacking sialic acid and glycans lacking 
sialic acid and galactose residues. Mutation analysis of the fibulin-5 gene (FBLN5), which has 
been reported in cases of autosomal recessive cutis laxa, revealed no mutations in the patients’ 
DNA. Evidence is presented that extracellular matrix (ECM) proteins of skin are likely to be highly 
glycosylated with N- and/or mucin-type O-glycans by using algorithms for predicting 
glycosylation. The conclusions in this study were that the clinical phenotype of autosomal 
recessive cutis laxa seen in 3 patients is not caused by mutations in the FBLN5 gene. Our 
findings define a novel form of CDG with cutis laxa and neurological involvement due to a defect 
in the sialylation and/or galactosylation of N- and O-glycans. Improper glycosylation of ECM 
proteins of skin may form the pathophysiological basis for the cutis laxa phenotype. 
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Introduction 
 
 
The congenital disorders of glycosylation (CDG) represent a group of autosomal recessive 
metabolic disorders caused by defects in the biosynthesis of protein-linked glycans. Glycans are 
usually covalently linked to human proteins by either an N-glycosidic linkage to the amide group 
of an asparagine side chain (N-glycosylation) or by an O-glycosidic linkage to an OH-group of a 
serine, threonine or lysine side chain (O-glycosylation). In 1987, Jaeken was the first to describe 
an inborn error of metabolism in the N-glycan biosynthetic pathway1. CDG has been divided into 
CDG-I, which includes all defects from the assembly of dolichol-phosphate to the transfer of the 
oligosaccharide to the protein and CDG-II, which includes all defects that are localized in the 
processing of glycans on the protein. At present, 17 genetically distinct defects in N-glycan 
biosynthesis have been described: CDG-Ia through to -Il, CDG-IIa through to -IId2,3. Recently, a 
new type of CDG caused by a deficiency in one of the proteins of the conserved oligomeric Golgi 
complex, COG7, has been described4. Isoelectric focusing of plasma transferrin (TIEF) is 
generally used in the screening for defects of N-linked glycan biosynthesis5.  
At least 7 different types of O-glycosylation occur in mammals and currently there is not a 
general screening method for detecting defects in the biosynthesis of all O-linked glycans. 
However, isoelectric focusing (IEF) of apolipoproteinC-III (ApoC-III) has recently been described 
as a new screening assay for defects in the biosynthesis of  “core 1 mucin-type O-glycans”6. The 
main types of protein-linked O-glycosylation in mammals include the attachment of 
glycosaminoglycans by a xylosyl-serine linkage, short “mucin”-type oligosaccharide chains by N-
acetylgalactosamine (GalNAc) and oligosaccharides with mannose linked to serine or threonine, 
the disaccharide glucosylgalactose to hydroxylysine residues in collagen and a single N-
acetylglucosamine residue linked to serine or threonine in nuclear and cytoplasmic proteins. The 
most common form of O-glycosylation in mammals is the mucin-type O-linked glycan, which is 
subdivided into 8 core structures based on the second sugar(s) and/or sugar binding7,8. The core 
1 mucin-type O-linked glycan, which has Galβ1–3GalNAc-Ser/Thr as the core, is the most 
common subtype and occurs on many membrane and secreted proteins, especially in brain and 
neural tissue9. It is also the precursor for the branched core 2 mucin-type O-glycan10,11. At least 
15 N-acetylgalactosaminyltransferases that catalyze the formation of the N-acetylgalactosaminyl-
Ser/Thr linkage are known12. Recently, mutations in N-acetylgalactosaminyltransferase 3 
(GALNT3), which is highly expressed in human skin, bone marrow, pancreas and kidney, were 
shown to be the cause of familial tumoral calcinosis (FTC)13. This is the first genetically defined 
defect in the biosynthesis of mucin-type O-glycans. Other inborn errors of metabolism that affect 
O-glycosylation are defects in proteoglycan biosynthesis (the progeroid variant of Ehlers Danlos 
syndrome14 and the multiple exostoses syndrome15) and defects in the biosynthesis of O-
mannosylglycans (Muscle-Eye-Brain disease16 and Walker-Warburg syndrome17). Until now, 
defects in the biosynthesis of O-glycans have not been classified as CDG.  
As there are some common precursors and enzymatic steps in the biosynthesis of N- and O-
linked glycans, some glycosylation defects will affect both N- and O-glycosylation. Congenital 
defects affecting both N- and O-linked glycosylation have been described previously. CDG-IIc 
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patients have hypofucosylated N- and O-linked glycans18 and patients with the COG7 deficiency 
have abnormal core 1 mucin-type O-glycans and aberrant N-glycosylation4. Interestingly, these 
patients also have a loose and wrinkled skin, although not so prominent as in cutis laxa patients. 
As far as we know, a phenotype of cutis laxa has not been observed in any of the glycosylation 
disorders described.  
Congenital cutis laxa is a rare condition characterized by inelastic, loose, hanging skin that gives 
the appearance of premature aging. The skin histology characteristically demonstrates an 
abnormal elastic fiber structure with a significantly decreased amount of elastin19. Autosomal 
recessive, dominant, and X-linked forms have been observed, but the genetic etiology of cutis 
laxa is unknown in most cases. Mutations in the fibulin-5 gene (FBLN5) have been detected in 
some cases of autosomal recessive20 and autosomal dominant forms of cutis laxa21. Mutations in 
the elastin gene have also been found in cases of the autosomal dominant form of cutis laxa22.  
We studied 9 patients with cutis laxa, of which 3 were found to have a defect affecting the 
biosynthesis of both N-linked glycans and core 1 mucin-type O-linked glycans. None had 
mutations in the FBLN5 gene. The clinical phenotypes of these 3 patients were very similar 
presenting with cutis laxa, skeletal and joint involvement, developmental delay, and neurological 
findings. To our knowledge these are the first patients described that have a congenital disorder 
of glycosylation with cutis laxa as clinical feature. 
 
 
Patients and Methods 
 
 
Patients  
 
Nine patients with cutis laxa syndrome and dysmorphic features from 8 families were 
investigated for defects in glycosylation (patients 1-9). Patients 1-3 were offspring from unrelated 
consanguineous marriages (patients 1 and 3 with Turkish and patient 2 with German 
background) with healthy parents suggesting an autosomal recessive cutis laxa syndrome. They 
had normal birth weight, significant microcephaly with a large open fontanel, dysmorphic features 
and muscle hypotonia at birth. All 3 had a motor developmental delay, mild to severe mental 
retardation, strabismus, hyperelastic joints, and congenital joint anomalies. Two of the 3 patients 
had intracranial anomalies (partial pachygyria) and suffered from seizures. All 3 patients had 
generalized cutis laxa in a different degree of severity (mild to severe). The skin histology 
showed fragmented, short and thin collagen fibers. Elastic fibers were fragmented and severely 
decreased in quantity, which was confirmed by electron microscopy. Clinical signs and 
symptoms of patients 1-3 will be described in more detail separately23. Patient 4 has been 
described by Litzman et al24. Patient 5 had normal birth weight, severe generalized cutis laxa, a 
large open fontanel, facial dysmorphic features, severe hypotonia, epilepsy and mild 
developmental delay. Predominant features of patient 6, the brother of patient 5, were moderate 
cutis laxa, a large open fontanel, hyperelastic joints, arachnodactyly and severe developmental 
delay. Patient 7 had low birth weight, moderate generalized cutis laxa, characteristic facial 
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features, extreme microcephaly, a tetralogy of Fallot, severe failure to thrive and profound 
developmental delay. Patient 8 had low birth weight, progeroid facial features, ventricular septal 
defect, arachnodactyly, gluteal fat pads, mild cutis laxa, severe muscular hypotonia, hyperelastic 
joints and profound developmental delay. Patient 9 had mild to moderate generalized cutis laxa, 
microcephaly, hyperelastic joints, hypotonia, cerebellar hypoplasia, broad thumbs and moderate 
developmental delay. Patients 1, 6 and 9 are male and patients 2-5 and 7-8 are female. Patients 
4-9 were from European ancestry. 
Routine metabolic screening on body fluids of the patients showed normal results, including 
analysis of urinary oligosaccharides, which did not show the oligosaccharide characteristic for 
CDG-IIb25. 
 
Samples and sample preparation  
 
Blood samples were obtained from children with cutis laxa with informed parental consent. 
Plasma was prepared by centrifugation and stored immediately at –80 °C until required for 
analysis.  
 
IEF of plasma transferrin  
 
IEF of plasma transferrin (TIEF) was carried out essentially as described by van Eijk and van 
Noort26. Plasma samples were incubated for 30 min with 10 mM ferric citrate and 0.5 mM sodium 
hydrogen carbonate (2:1) in a ratio of 10:3 (plasma to solution) to saturate the transferrin with 
iron. The iron-saturated plasma was diluted 5 times with water and applied to a hydrated 
immobiline gel (pH 4-7) on an Ultraphore system (Amersham Pharmacia Biotech). After IEF, the 
transferrin isoforms were detected by adding rabbit anti-human transferrin antibody (Dako, 
Glostrup, Denmark) and the gels were stained with Coomassie blue. The relative amounts of the 
transferrin isoforms were determined by scanning the stained gel using an Image master 
Labscan, Ver. 3.00 (Amersham Pharmacia Biotech) and quantified using Image master 1D gel 
analysis, Ver. 4.10, software (Amersham Pharmacia Biotech).  
 
IEF of plasma thyroxine-binding globulin  
 
Undiluted plasma was applied to a Phastgel pH 4-6.5 (Amersham Pharmacia Biotech) and 
analyzed on a Phastsystem (Amersham Pharmacia Biotech). After addition of rabbit anti-human 
TBG antibody (Dako) the TBG pattern was detected by silver staining.  
 
IEF of plasma apoC-III 
 
IEF of apoC-III was carried out as described by Wopereis et al6. A dry IEF Phastgel was hydrated 
in a solution of 8M urea and 60 mL/L Pharmalyte pH 4.2 – 4.9 (cat. no. 17-0560-01; Amersham 
Pharmacia Biotech) and Ampholine pH 3.5 – 5.0 (cat. no.80-1125-89; Amersham Pharmacia 
Biotech) in a ratio of 2:1. Plasma samples were diluted 10-fold with saline and applied to the 
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hydrated gel on a Phastsystem (Amersham Pharmacia Biotech). After IEF the isoforms of apoC-
III were detected by Western blotting using rabbit anti-human apoC-III antibody (ANAWA 
Biomedical Services & Products) and goat anti-rabbit horseradish peroxidase-coupled antibody 
as the secondary antibody and visualized by electrochemiluminescence. The relative amounts of 
the apoC-III isoforms were determined by densitometry as described above.  
 
Mass spectrometric analysis of N-linked glycans released from total plasma proteins 
 
Analysis of N-linked glycans released from plasma glycoproteins was carried out by matrix-
assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as 
described by Mills et al27. Analysis of acidic and neutral N-linked glycans was performed in 
negative and positive linear ion mode, respectively. The total N-linked glycans from plasma 
proteins were released enzymatically as described by Mills et al27. The reference samples were 
anonymous plasma samples from non-CDG and non-lysosomal patients in an age category of 0-
5 years. 
 
Mutation analysis of FBLN5  
 
Genomic DNA was isolated from cultured dermal fibroblasts of patients 1 and 2 and from 
leukocytes of patient 3. Genomic DNA was extracted by the method of Miller et al28. Mutation 
analysis of the FBLN5 gene was performed as described by Loeys et al20.  
 
Glycosylation of extracellular matrix proteins of the skin 
 
The likelihood that an extracellular matrix (ECM) protein of the skin carries a mucin-type O-
glycan was predicted according to Hansen et al29 [significance level >0.5]. The presence of a N-
glycan derives from the Expasy protein database (http://www.expasy.org/sprot/). 
Figure 1.
Isoelectric focusing profiles of plasma transferrin (lanes 1 and 2) 
and apoC-III (lanes 3 and 4). Lanes 1 and 3 represent a control, 
lanes 2 and 4 represent a cutis laxa patient with abnormal 
glycosylation (patient 3). 
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Results 
 
 
IEF of plasma transferrin 
 
Three of the 9 patients with cutis laxa (patients 1-3) had an abnormal TIEF profile (Figure 1, lane 
2). The other 6 patients had normal patterns. The relative amounts of the transferrin isoforms of 
the 3 patients with the abnormal IEF profiles are summarized in Table 1. All 3 patients had 
increased relative proportions of mono-, di- and trisialotransferrin but decreased relative amounts 
of tetra- and pentasialotransferrin. Patient 2 also had an elevated amount of asialotransferrin. 
Interestingly, patient 3 showed a normal TIEF profile at an age of 3 months. TIEF became 
abnormal in this patient at the age of 10 months (no samples were obtained in the meantime; 
data not shown). TIEF profiles of patients 1 and 2 were not investigated at that age. On the basis 
of the undersialylation of transferrin and the specific presence of mono- and trisialotransferrin, 
the 3 patients were classified as having an unidentified form of CDG type II (CDG-IIx). The IEF 
patterns of TBG, another N-glycosylated protein, were also abnormal in patients 1-3, indicating 
that the glycosylation defect was not restricted to transferrin but more general.  
 
Table 1. Summary of the relative amounts of transferrin isoforms. 
Patient 1 Patient 2 Patient 3   
Reference interval (%) 2 years 2 years 3 months  3 years 
 
T0 0 – 2.6 2.6 4.0 1.4 1.2 
T1 0 – 2.6 3.2 5.3 0.9 2.7 
T2 1.6 – 6.1 10.4 14.1 5.6 11.8 
T3 2.5 – 15.6 28.5 23.3 12.2 27.4 
T4 51.2 – 72.2 45.7 39.0 65.4 47.6 
T5
 
12.1 – 30.8 9.6 11.9 14.6 9.3 
Abbreviations and symbols: T, transferrin; 0 to 5, number of terminal NeuAc. 
 
IEF of plasma apoC-III 
  
The 3 patients with an abnormal TIEF profile also showed an abnormal IEF profile for plasma 
apoC-III, indicating an abnormal biosynthesis of core 1 mucin-type O-glycan (Figure 1, lane 4). 
The relative amounts of the apoC-III isoforms of patients 1-3 are summarized in Table 2. 
Polymorphisms in the amino acid sequence causing abnormal apoC-III isoelectric focusing 
profiles were excluded by incubation of the samples with neuraminidase to remove the negatively 
charged terminal sialic acid residues. After neuraminidase treatment all apoC-III isoforms 
migrated to the apoC-III0 position, indicating that changes in sialic acid content had been 
responsible for the abnormal profiles (data not shown). The apoC-III profile showed an increase 
in the relative distribution of apoC-III1 and a decrease of apoC-III2 in the 3 patients. Whilst the 
transferrin IEF profile for patient 3 had been normal at the age of 3 months, abnormalities in the 
glycosylation of apoC-III were already evident at this age. The other 6 patients were found to 
have normal IEF profiles for apoC-III. 
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Table 2. Summary of the relative amounts of apoC-III isoforms. 
Reference interval (%) Patient 1 Patient 2 Patient 3  
0 – 1 year 1 – 18 years 2 yr 2 yr 3 mth 3 yr 
 
ApoC-III0 0 – 8 0 – 12 11 10 1 6 
ApoC-III1 34 – 59 33 – 67 73 76 78 86 
ApoC-III2
 
40 - 62 27 - 60 16 14 21 8 
 
Mass spectrometric analysis of total N-glycans released from plasma proteins 
 
Differences in the relative amounts of the N-linked glycans released from total plasma proteins 
between controls and the 3 patients with abnormal glycosylation were detected by MALDI-TOF 
MS (Table 3). In normal controls, the fully sialylated biantennary (m/z 2223) and triantennary 
(m/z 2879) glycans are the most abundant structures. We observed a decrease in the amount of 
both in all 3 patients (Table 3A). Analysis of the acidic (i.e., sialic acid containing) N-linked 
glycans revealed an increase in the relative amounts of glycan structures lacking 1 or more 
terminal sialic acid (NeuAc) residues in the 3 patients (e.g., m/z 1932, 2297, 2588 and 2734 in 
Table 3A). The most prominent and consistent abnormality among the cutis laxa patients is 
observed in the glycan with m/z 1932. The ratio of fully sialylated biantennary glycans (m/z 2223) 
to biantennary glycans lacking 1 NeuAc (m/z 1932) was approximately 2 in the cutis laxa cases, 
while approximately 4 in controls. Between the 3 patients, subtle differences were found in the 
expression patterns of N-glycans lacking 1 or more sialic acids. Patient 1, for instance, had an 
elevated amount of the triantennary N-glycans lacking 1 NeuAc (m/z 2588), patient 3 had an 
elevated amount of the fucosylated triantennary N-glycans lacking 1 NeuAc (m/z 2734), while in 
patient 2 both structures occurred in normal amounts. Also the triantennary N-glycan lacking 2 
NeuAc (m/z 2297) was not detected in patient 3, while increased in the other 2 patients. Glycan 
structures that lacked both galactose (Gal) and NeuAc were found to be increased in the 3 
patients (m/z 1769). This increase was most marked in patient 3. 
The most abundant glycans found in normal samples when the released glycans were analyzed 
in the positive linear ion mode were a fucosylated (Table 3B, m/z 1649) and a non-fucosylated  
(Table 3B, m/z 1503) biantennary structure lacking 2 sialic acid residues and a single galactose 
residue. Therefore, results in Table 3B are presented relative to the major ion of m/z 1649. 
Patient 1 and 2 showed almost normal amounts of neutral glycans, while patient 3 was slightly 
abnormal for some. 
 
Mutation analysis of FBLN5 
 
Patients 1-3 were heterozygous for the base change 945 T>C (Ile315Ile) in exon 9 of the fibulin-5 
gene. In patient 3, 2 additional heterozygous base changes were found, the 1122C>T 
(Tyr374Tyr) in exon 10 and an intronic mutation IVS10-46g/a. The 2 exonic mutations are 
conservative and do not affect the amino acid sequence and all 3 base changes have been 
detected in healthy volunteers. Therefore, they are likely to be polymorphisms. 
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Table 3. Summary of the relative changes in amounts of N-linked glycans released from total plasma proteins and detected 
by MALDI-TOF.  
 
A. Controls are expressed as range. Amounts of each acidic N-glycan presented as percentage of total N-linked glycans (in 
negative mode) and relative to the ion of mass 2223 in parentheses. All m/z values correspond to pseudomolecular ions 
resulting from the loss of 1 hydrogen. 
  
Incomplete glycans 
 
 
Complete glycans 
m/z 1769 1932 2297 2588 2734 2223 2879 
structure  
 
 
 
 
      
 
control 
n = 6 
 
0-1 
(0-2) 
 
8-14 
(14-27) 
 
0-1 
(0-2) 
 
3-5 
(5-12)  
 
1-2 
(2-3) 
 
41-53 
(100) 
 
14-21 
(29-50) 
patient 1 
2 years 
2 
(4) 
15 
(48) 
6 
(2) 
8 
(25) 
2 
(6) 
31 
(100) 
10 
(32) 
patient 2 
2 years 
2 
(7) 
14 
(40) 
3 
(1) 
4 
(11) 
2 
(5) 
35 
(100) 
9 
(25) 
patient 3 
3 years 
 
5 
(17) 
14 
(44) 
n.d. 
(n.d.) 
2 
(7) 
4 
(12) 
32 
(100) 
5 
(17) 
 
B. Summary of the relative changes in amounts of N-linked glycans released from total plasma proteins and detected by 
MALDI-TOF. Amounts of neutral N-glycans presented as percentage of total N-linked glycans (in positive mode) and the 
amounts of each glycan relative to the ion of mass 1649 in parentheses. All m/z values correspond to the sodium adduct of 
the molecular ion (M[Na+]+). 
m/z 1503 1649 1690 1852 2014 
structure  
 
 
 
    
 
control 
n = 8 
 
1-4 
(14-27) 
 
14-28 
(100) 
 
0-4 
(0-19) 
 
0-4 
(0-17) 
 
0-1 
(0-6) 
patient 1 
2 years 
6 
(24) 
22 
(100) 
3 
(18) 
3 
(16) 
1 
(4) 
patient 2 
2 years 
4 
(21) 
21 
(100) 
3 
(18) 
3 
(13) 
1 
(3) 
patient 3 
3 years 
 
6 
(33) 
20 
(100) 
6 
(30) 
5 
(25) 
1 
(8) 
 
 
Glycosylation of extracellular matrix proteins of the skin 
 
The presence of mucin-type O-glycans and N-glycans on selected ECM proteins of skin was 
investigated by analysis of protein sequences using predictive software and database searching 
(Table 4). All of the ECM proteins investigated, except elastin, are predicted to be glycoproteins. 
The analysis suggests that all forms of collagen are heavily glycosylated with mucin-type O-
glycans and all but collagen α1 (XIX) have at least 1 N-linked glycan. Fibulin-3 and fibulin-5 
appear to have both N- and mucin-type O-glycans. All of the laminins have potential N-
glycosylation sites but only laminins α-2, α-3 and γ-3 have potential sites for mucin-type O-
glycans. It is probable that many of the ECM proteins of skin are highly glycosylated. This may 
provide a clue to the pathogenesis of the cutis laxa in patients 1-3.  
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Discussion 
 
 
In this study, 9 patients with cutis laxa were investigated for defects in glycosylation. An 
abnormal distribution of plasma transferrin isoforms was found in 3 of the 9 patients on several 
occasions. The relatively high proportions of asialo-, mono- and disialotransferrin isoforms were 
consistent with designation of the patients with CDG-IIx, due to an unknown genetic defect(s) in 
the processing of N-linked glycans. All 3 patients also had an abnormal distribution of TBG 
isoforms on IEF, suggesting a generalized defect in N-glycosylation. On O-glycosylation studies, 
the 3 patients also had an abnormal distribution of apoC-III isoforms, with an increase in the 
proportion of apoC-III1, a decrease in apoC-III2 and normal amounts of apoC-III0. This indicates 
that patients 1-3 have a defect in core 1 mucin-type O-linked glycan biosynthesis. Thus, the 3 
patients have a defect affecting the biosynthesis of both N-linked glycans and core 1 mucin-type 
O-linked glycans. The other 6 cutis laxa patients had normal IEF profiles for all the plasma 
glycoproteins analyzed. To understand the structural basis of this altered glycosylation, the N-
linked glycans on plasma proteins from the 3 patients were analyzed by MALDI-TOF MS. 
Increases of N-linked glycans lacking terminal NeuAc residues and of N-linked glycans lacking 
Gal and NeuAc residues, relative to controls, were detected in all 3 patients. These results 
suggest that there is a defect in the addition of galactose or neuraminic acid in the late stages of 
N-glycan processing in the Golgi apparatus.  
 
Table 4. The estimated number of N- and mucin-type O-glycans per molecule in  extracellullar matrix proteins of the skin. The 
number of mucin-type O-glycans was estimated using algorithms for predicting mucin-type O-glycosylation29,30. The number 
of estimated N-glycans derives from the Expasy protein database (http://www.expasy.org/sprot/). 
Human protein Mucin-type O-glycan N-glycan 
 
collagen alpha 1 (I) 20 0 
collagen alpha 1 (III) 24 0 
collagen alpha 1 (V) 28 0 
collagen alpha 1 (VII) 13 3 
collagen alpha 1 (XVII) 17 1 
collagen alpha 1 (XIX) 8 0 
collagen alpha 2 (I) 14 0 
collagen alpha 2 (IV) 7 1 
collagen alpha 2 (V) 22 0 
collagen alpha 3 (IX) 8 1  
elastin 0 0  
fibulin-3 4 3  
fibulin-5 2 2  
laminin alpha-1 0 34 
laminin alpha-2 7 10 
laminin alpha-3 1 10 
laminin beta-3 0 3  
laminin gamma-2 0  4  
laminin gamma-3 
 
1 9  
 
The processing of N-linked glycans involves the removal of monosaccharides by glycosidases in 
the endoplasmic reticulum and Golgi apparatus and the addition of monosaccharides catalyzed 
by glycosyltransferases in the Golgi apparatus. The addition of monosaccharides requires the 
biosynthesis and transport into the Golgi of adequate supplies of nucleotide sugars, such as 
uridine 5’diphospho-N-acetyl-glucosamine (UDP-GlcNAc), uridine 5’diphosphogalactose (UDP-
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Gal), guanosine 5’diphospho-fucose (GDP-Fuc) and cytidine-5’-monophospho-N-
acetylneuraminic acid (CMP-NeuAc). The biosynthesis of the core 1 mucin-type O-glycan 
attached to apoC-III requires the biosynthesis and the transport into the Golgi of adequate 
supplies of the nucleotide sugars uridine 5’diphospho-N-acetylgalactosamine (UDP-GalNAc), 
UDP-Gal and CMP-NeuAc, as well as the expression of the relevant glycosyltransferases. CMP-
NeuAc and UDP-Gal are the only nucleotide sugars required for the biosynthesis of both the N-
glycans and the core 1 mucin-type O-glycans. Therefore, it is likely that the underlying defect in 
our 3 cutis laxa patients is in the biosynthesis, transport or transfer of CMP-NeuAc or UDP-Gal. 
This is consistent with the glycan analysis results. The transfer of CMP-NeuAc and UDP-Gal is 
catalyzed by sialyl- and galactosyltransferases specific for the N-glycosylation and for the core 1 
mucin-type O-glycosylation routing31,32. This suggests that the primary defect is situated in the 
biosynthesis or transport of CMP-NeuAc or UDP-Gal, rather than in a glycosyltransferase.  
Previously described forms of CDG-II can be excluded in the 3 patients for the following reasons. 
Patients with CDG-IIa (N-acetylglucosaminyltransferase II deficiency) and CDG-IId (UDP-Gal:N-
acetylglucosamine β-1,4-galactosyltransferase I or β4GalT1 deficiency) have normal apoC-III 
profiles6. This indicates that defects in these enzymes do not affect the biosynthesis of core 1 
mucin-type O-glycans. CDG-IIb, which is due to a deficiency of glucosidase I, is characterized by 
the presence of an abnormal tetrasaccharide in urine33. This oligosaccharide was not found in 
the urine of patients 1-3. Furthermore, glucose residues do not play a role in the biosynthesis of 
core 1 mucin-type O-glycans. CDG-IIc is caused by a defect in a fucose transporter18. As fucose 
is not present in core 1 mucin-type O-glycans and also on clinical grounds, it seems unlikely that 
our patients suffer from CDG-IIc. Therefore, it is concluded that a novel type of CDG-II affects 
our patients, which is in line with the fact that the clinical signs and symptoms of patients 1-3 
have not been reported for CDG patients previously. 
Clinically, the 3 patients present with a phenotype comparable with the autosomal recessive form 
of cutis laxa. The children were offspring from unrelated consanguineous marriages and in 2 out 
of the 3 families siblings were unaffected (the family of the third case has no other children), 
which further supports that these children have an autosomal recessive cutis laxa syndrome. 
Mutations in the gene encoding for fibulin-5 have been described in the autosomal recessive 
form of cutis laxa20. However, the fibulin-5 gene was screened for mutations but only polymorphic 
changes were found.  
Patient 3 had a normal TIEF profile at the age of 3 months, whereas at the age of 3 years his 
profile was clearly abnormal. In contrast, his apoC-III IEF profile was already abnormal at the age 
of 3 months and became more markedly abnormal at 3 years. This shows that TIEF screening 
may not reveal an abnormal pattern of glycosylation in the first months of life for this type of 
CDG, as has been observed in other forms34. 
The clinical phenotypes of patients 1-3 are very similar, showing microcephaly, a large open 
fontanel, dysmorphic features and central nervous system involvement (pachygyria and 
deafness). Patient 2 is the most affected and patient 1 has the mildest presentation of the 
disease. Patients 2 and 3 had the unique combination of microcephaly, a large open fontanel, 
pachygyria and moderate to severe generalized cutis laxa. These features were not present in 
such a combination in patients 4-9. However, patient 1 was clinically comparable to patients 5 
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and 6. Similar IEF profiles were obtained for the plasma proteins transferrin, apoC-III and TBG in 
the patients 1-3. MALDI-TOF MS analysis of total plasma N-glycans in patients 1-3 also revealed 
very similar structural expression patterns. All 3 had a relative increase of N-glycans lacking 
NeuAc and glycans lacking NeuAc and Gal residues, although the results suggested that the 
defect in patient 3 was more severe than in patients 1 and 2. No direct correlation could be 
drawn between the clinical spectrum and the biochemical results. It is concluded that patients 1-3 
have a similar primary defect, which is situated in the biosynthesis or transport of UDP-Gal or 
CMP-NeuAc. However, our current data cannot fully exclude that different genes in the 
biosynthesis or transport of these 2 nucleotide sugars are involved in the 3 patients. 
The clinical phenotypes of the various forms of CDG and of the known defects in O-glycan 
biosynthesis are very diverse. Severe skin problems comparable with cutis laxa have not been 
observed in any of the known N-glycosylation defects. Skin abnormalities do occur in the 
progeroid variant of Ehlers Danlos syndrome, but are less pronounced than in the cutis laxa 
patients with a combined defect in the biosynthesis of N- and O-glycans. Besides loose, elastic 
skin these Ehlers Danlos patients have other clinical similarities like failure to thrive, joint laxity, 
psychomotor retardation and hypotonia. The main phenotypic differences with patients 1-3 are 
the macrocephaly and the characteristic progeroid appearance, which do not occur in the cutis 
laxa patients with a glycosylation biosynthesis defect. Patients with the progeroid variant of 
Ehlers Danlos have a deficiency of galactosyltransferase I (β4GALT7), which prevents the 
transfer of galactose residues to the xylosyl-serine linkage in the linker region of proteoglycans14. 
As proteoglycans are important structural components of the ECM of connective tissues, these 
patients suffer from skin, cartilage, and bone problems. The ECM, which incorporates the 
attached cells into tissues, is a well-preserved structure involved in the evolution of multicellular, 
highly structured organisms. The ECM is composed of macromolecules, like glycosaminoglycans 
(GAGs) and structural glycoproteins35. The theoretical analysis of the potential glycosylation of 
skin proteins of the ECM (Table 4) predicted that they all carry N- and/or mucin-type O-glycans 
except for elastin. The different collagen types of skin seem to be heavily glycosylated with 
predominantly mucin-type O-glycans, while the different laminin types of skin seem to be heavily 
glycosylated with predominantly N-linked glycans. Fibulin-5 is also highly likely to be glycosylated 
with N- and mucin-type O-glycans. Recently, the core 1 β-1,3-galactosyltransferase was knocked 
out in mice to produce the nonsialylated Tn antigen, with only a GalNAc residue linked to the 
protein. These mice died (14 day old embryos) of a fatal brain hemorrhage, due to insufficient 
binding of endothelial cells to the ECM of the blood vessels in the developing brain 
parenchyma36. It appears that core 1 mucin-type O-glycans are involved in cell-matrix 
interactions, which could lead to disturbances in anchoring the final structure of skin. As most 
ECM proteins are likely to be highly glycosylated with N- and/or mucin-type O-glycans this could 
explain the pathophysiology of cutis laxa in patients 1-3.  
The combined defect in the biosynthesis of N- and core 1 mucin-type O-glycans is highly likely to 
cause the characteristic phenotype in the 3 cutis laxa patients. Our findings suggest a new type 
of CDG, in which the primary defect is situated in the biosynthesis or transport of CMP-NeuAc or 
UDP-Gal.  
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Abstract 
 
 
Sialuria is an inborn error of metabolism characterized by coarse face, hepatomegaly and 
recurrent respiratory tract infections. The genetic defect in this disorder results in a loss of 
feedback control of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine-kinase by 
CMP-N-acetylneuraminic acid (CMP-NeuAc) resulting in a substantial overproduction of 
cytoplasmic free sialic acid. This study addresses fibroblast CMP-NeuAc levels and N- and O-
glycan sialylation of plasma proteins from Sialuria patients.  
CMP-NeuAc levels were measured with HPLC in fibroblasts. Isoelectric focusing (IEF) of plasma 
transferrin and of apolipoprotein C-III (apoC-III) was performed on plasma of 3 Sialuria patients. 
Isoforms of these proteins can be used as specific markers for the biosynthesis of N- and core 1 
O-glycans. Furthermore, total N- and O-linked glycans from plasma proteins were analyzed by 
HPLC.  
HPLC showed a clear overproduction of CMP-NeuAc in fibroblasts of a Sialuria patient. Minor 
changes were found for plasma N-glycans and hypersialylation was found for core 1 O-glycans 
on plasma apoC-III and on total plasma O-glycans in Sialuria patients. HPLC showed an 
increased ratio of disialylated over monosialylated core 1 O-glycans. The hypersialylation of core 
1 O-glycans is due to the increase of NeuAcα2,6-containing structures (mainly NeuAcα2-3Galβ1-
3[NeuAcα2-6]GalNAc). This may relate to KM differences between GalNAc-α2,6-sialyltransferase 
and α2,3-sialyltransferases. 
This is the first study demonstrating that the genetic defect in Sialuria results in a CMP-NeuAc 
overproduction. Subsequently, increased amounts of α2,6-linked NeuAc were found on plasma 
core 1 O-glycans from Sialuria patients. N-glycosylation of plasma proteins seems largely 
unaffected. Sialuria is the first metabolic disorder presenting with hypersialylated O-glycans. 
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Introduction 
 
 
Sialuria (OMIM 269921), formerly called French type Sialuria, is an autosomal dominant inborn 
error of metabolism in which the feedback control mechanism in the biosynthesis of cytidine-
monophosphate-N-acetylneuraminic acid (CMP-NeuAc) is lost. This is caused by a defect in the 
gene coding for the enzyme uridine diphosphate-N-acetylglucosamine-2-epimerase/N-
acetylmannosamine kinase (GNE / MNK, EC 5.1.3.14)1,2. Heterozygous mutations in the region 
of codons 263 to 266 of GNE / MNK have been found3. GNE / MNK is the rate-limiting enzyme in 
the biosynthesis of CMP-NeuAc. It is a bifunctional enzyme that catalyzes the first 2 biosynthetic 
steps of CMP-NeuAc formation. These are the epimerization of UDP-N-acetylglucosamine (UDP-
GlcNAc) to N-acetylmannosamine (ManNAc) and the phosphorylation of ManNAc to ManNAc-6-
phosphate by the kinase part of the enzyme4. The epimerase and the kinase domain work 
independently of each other5. The epimerization is feedback-inhibited by CMP-NeuAc, the end 
product of the pathway6,7. The lack of feedback inhibition of GNE / MNK results in an extreme 
overproduction of free sialic acid in the cytoplasm8. To date, 7 patients have been reported with 
Sialuria presenting clinical features that include mild psychomotor delay, coarse facies, recurrent 
upper respiratory tract infections and hepatomegaly9-13,3. The pathophysiology of the disease is 
poorly understood. 
The presence of sialic acid on glycans is crucial for their function in numerous physiological 
processes including cell recognition and adhesion, cell migration and antigenicity14. The 
congenital disorders of glycosylation (CDG) form a group of autosomal recessive metabolic 
disorders caused by defects in the biosynthesis of protein-linked glycans. The glycoproteins of 
CDG patients often show hypoglycosylation. This group of disorders has shown that changes in 
the glycan structure may lead to severe multisystem disease15,16. Transferrin isofocusing on 
plasma is generally used in the screening to diagnose patients suffering from a defect in the N-
glycan biosynthesis17. Apolipoprotein C-III isofocusing can be used as a screening method for 
defects in the biosynthesis of core 1 O-glycans18. The core 1 O-glycan, which has Galβ1-
3GalNAc-Ser/Thr as the core, is the most common O-linked glycan type and occurs on many 
membrane and secreted proteins.  
In the current study, we analyzed nucleotide sugar levels in fibroblasts with HPLC to study CMP-
NeuAc levels in a Sialuria patient. Subsequently, apoC-III IEF, transferrin IEF and HPLC of total 
plasma protein glycans were used to investigate plasma protein glycosylation in Sialuria patients. 
It was shown that CMP-NeuAc levels were clearly increased in a Sialuria patient. Furthermore, 
these patients were shown to have hypersialylated O-glycans due to increased levels of α2,6-
linked NeuAc in core 1 O-glycans. These findings offer a new perspective for studying Sialuria 
pathogenesis. To our knowledge this is the first report that shows an overproduction of CMP-
NeuAc in Sialuria, which results in increased protein O-glycan sialylation. This is also the first 
time that hypersialylation of plasma proteins is demonstrated in an inborn error of metabolism. 
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Patients and Methods 
 
 
Patients 
 
A unique feature in Sialuria is a relatively benign clinical course with a significant improvement in 
adulthood. Blood samples from patients A; patient 1 in3, B; patient 2 in3 and C; the patient 
described in10,19 have been used for the current study. Patient B is the mother of patient A. Only 
a slight mental delay is reported in the mother. Patient B and her son, patient A, carry the same 
heterozygous R266Q mutation in the GNE / MNK gene3. 
  
Samples and sample preparation  
 
A skin biopsy was obtained from patient C and blood samples were obtained from Sialuria 
patients A, B and C with informed parental consent. Plasma was prepared by centrifugation and 
stored immediately at –80 °C until required for analysis. Fibroblasts used for the reference range 
of nucleotide sugar analysis were obtained from 7 healthy controls after written informed 
consent. 
 
HPLC of nucleotide sugars 
 
Analysis of nucleotide sugars with HPLC was carried out essentially as described by Räbina et 
al.20. Fibroblasts were cultured in medium 199 (cat. no. 041-94259; Gibco) containing 10% fetal 
calf serum and 1% Penicillin-Streptomycin at 37 °C. The fibroblast cells (between 10.106 6 – 20.10  
cells) were harvested by trypsinization and washed 4 times with PBS. The pellet was stored in –
20 °C until further use. The pellet was resuspended in 600 μl 20 mM NH4HCO3 (pH 10.6) and 
sonicated for 6 x 8 s on ice. After sonication, 600 μl of 2M NH4HCO3 (pH 7) was added and the 
sample was applied to an Envi-Carb carbon column (Supelco) for the isolation of the nucleotide 
sugars according to the method of Räbina et al20 with minor modifications. Prior to use, the Envi-
Carb carbon column was conditioned with 3 ml 80% (v/v) acetonitrile in 0.1% (v/v) trifluoroacetic 
acid, followed by 2 ml of water. The sample was subsequently applied to the column and washed 
with 2 ml water, 2 ml 25% (v/v) acetonitrile, and 2 ml 50 mM triethylammonium acetate buffer 
(TEAA buffer) (pH 6.7). Nucleotide sugars were then eluted with 2 ml 25% (v/v) acetonitrile 
containing 50 mM TEAA buffer (pH 6.7), dried in a vacuum centrifuge and stored at –20°C until 
further use. The sample was redissolved in 600 μl 20 mM TEAA buffer (pH 4.0) and 250 μl 
sample was injected on a Discovery C18 column (0.46 x 25 cm; Supelco). Nucleotide sugars 
were eluted isocratically with 20 mM TEAA buffer (pH 4.0) at a flow rate of 1 ml/min. The 
reference mixture contained 1 μM CMP-NeuAc, tyrosine, UDP-Gal, UDP-Glc, GDP-Man, and 
UDP-GalNAc (Sigma Aldrich). The effluent was monitored with a UV detector (Applied 
Biosystem, nr. 785 A) at 255 nm and the nucleotide sugars were quantified with PC1000 
software (Spectra-Physics). 
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Isoelectric focusing of Transferrin 
 
21TIEF was carried out essentially as described by van Eijk and van Noort . Plasma samples were 
incubated for 30 minutes with 20 mM ferric citrate and 0.5 mM sodium hydrogen carbonate in a 
ratio of 10:3 (plasma to solution) to saturate the transferrin with iron. The iron-saturated plasma 
was diluted 5 times with water and 1 μl was applied to a hydrated dry Phastgel (2.5% ampholines 
pH 5-7 solution) on a PhastSystem (Amersham Pharmacia Biotech). After IEF the transferrin 
isoforms were detected by adding rabbit anti- human transferrin antibody (Dako, Glostrup, 
Denmark) and the gels were stained with Coomassie blue. The relative amounts of the 
transferrin isoforms were determined by scanning the stained gel using an Image master 
Labscan, Ver. 3.00 and quantified using Image master 1D gel analysis, Ver. 4.10, software 
(Amersham Pharmacia Biotech).  
 
Table 1. Relative percentages of nucleotide sugars presented as percentage of total nucleotide sugars measured in human 
fibroblasts. Amounts of each nucleotide sugar presented as percentage of total nucleotide sugars (peaks 1 + 3-6 = 100%). 
The reference values for nucleotide sugars are from 7 healthy volunteers. The corresponding RP-HPLC chromatogram is 
shown in Figure 1. 
Control ranges Patient C Peak 
no. 
Name Retention time 
(min)   
Relative amounts (%) Relative amounts (%) 
 
1 CMP-NeuAc 5.8 3 - 12 70 
2 Tyrosine 6.0 - - 
3 UDP-Gal 8.8 12 - 38 27 
4 UDP-Glc 9.4 10 - 29 1 
5 UDP-HexNAc  
(UDP-GalNAc+UDP-GlcNAc) 
11.0 25 - 53 1 
GDP-Man 12.5 5 - 24 1 6 
 
 
Isoelectric focusing of apolipoprotein C-III 
 
IEF of apoC-III was carried out as described by Wopereis et al18. A dry IEF Phastgel was 
hydrated in a solution of 8M urea and 60 mL/L Pharmalyte pH 4.2 – 4.9 (cat. no. 17-0560-01; 
Amersham Pharmacia Biotech) and Ampholine pH 3.5 – 5.0 (cat. no.80-1125-89; Amersham 
Pharmacia Biotech) in a ratio of 2:1. Plasma samples were diluted 10-fold with saline and applied 
to the hydrated gel on a Phastsystem (Amersham Pharmacia Biotech). After IEF the isoforms of 
apoC-III were detected by Western blotting using rabbit anti-human apoC-III antibody (ANAWA 
Biomedical Services & Products) and goat anti-rabbit horseradish peroxidase-coupled antibody 
as the secondary antibody and visualized by electrochemiluminescence. The relative amounts of 
the apoC-III isoforms were determined by densitometry as described above.  
 
HPLC analysis of N- and O-linked glycans released from total plasma proteins 
 
The total N-linked glycans were released enzymatically from plasma proteins by PNGaseF 
(Roche Applied Sciences) digestion. Hydrazine release of O-glycans was carried out as 
described by Royle et al.22. Glycans were fluorescently labeled using 2-aminobenzamide (2AB) 
by reductive amination according to the method of Bigge et al.23 using an LudgerTag 2-AB 
labeling kit (Ludger Ltd, Oxford, UK). NP-HPLC was performed on a TSK Amide-80 250 x 4.6 
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mm column (Anachem, Luthon, UK) according to the low-salt buffer system described by Guile et 
al.24. The HPLC system was calibrated using an external standard of 2-AB labeled glucose 
oligomers. Retention times were converted to glucose units (GU) by comparison to the standard 
glucose oligomer ladder using a fifth order polynomal fit. Structures were allocated by matching 
experimental GU values obtained from exoglycosidase enzymes arrays and MALDI mass 
spectrometry with standard values in a database22. This database is publically available. 
 
 
Results 
 
 
Separation and quantification of nucleotide sugars by HPLC 
 
In Figure 1 the HPLC chromatograms are shown of fibroblast nucleotide sugars of a control and 
Sialuria patient C. A standard run shows the positions of the different nucleotide sugars in the 
chromatogram. The relative amounts of the nucleotide sugars are listed in Table 1. The relative 
amount of CMP-NeuAc (peak 1) is approximately 5 times the upper reference range in Sialuria 
patient C, whereas the amounts of UDP-Glc (peak 4), UDP-HexNAc (peak 5) and GDP-Man 
(peak 6) are clearly decreased. 
 
Isoelectric focusing of plasma transferrin 
 
In the 3 Sialuria patients, a slight hypersialylation profile was found for plasma transferrin (Figure 
2, lanes 1 - 4). The relative amounts of the transferrin isoforms of the 3 patients with Sialuria are  
 
Table 2A. Relative amounts of transferrin isoforms presented as percentage of total transferrin. The corresponding TIEF 
profiles are shown in Figure 2 (lanes 1-4). There is no difference in the reference interval between adults and children. T, 
Transferrin; 0 to 7, number of terminal sialic acid 
Reference interval (n = 28)  Patients Transferrin 
Mean (SD) Range A B C 
 
T 1 (2) 0 – 3 0 0 0 0
T 1 (2) 0 – 6 0 0 3 1
T 6 (2) 2 – 10 4 5 6 2
T 9 (3) 3 – 14 7 11 13 3
T 54 (13) 44 – 68 44 49 48 4
T 21 (4) 15 – 27 24 26 21 5
T 5 (2) 3 – 12 15 8 8 6
T 0 (0) 0 6 1 1 7 
 
 
Table 2B. Relative amounts of apoC-III isoforms presented as percentage of total apoC-III. ApoC-III0, apoC-III1 and apoC-III2 
correspond to asialo, monosialo and disialo fraction of the protein, respectively. The corresponding apoC-III IEF profiles are 
shown in Figure 2 (lanes 5-8). 
Reference intervals Patients ApoC-III 
Children (n = 30) Adults (n = 30) A B C 
    
Mean (SD) Range Mean (SD) Range Child Adult Adult 
 
ApoC-III 5.1 (2.7) 0 – 12 8.5 (4.1) 3 – 19 3 4 1 0
ApoC-III 53.2 (9.1) 33 – 67 55.5 (6.5) 43 – 69 19 24 36 1
ApoC-III 41.6 (8.3) 27 - 60 36.0 (7.2) 23 - 50 78 72 63 2 
 
 175
Chapter 8 
 
Figure 1. 
RP-HPLC profiles of nucleotide sugar analyses of control 
versus Sialuria patient C. The standard shows the 
retention times of the different nucleotide sugars. The 
relative amounts and the corresponding structures of the 
peaks 1-6 are listed in Table 1. 
 
 
 
 
Figure 2.  
Isoelectric focusing profiles of plasma transferrin (lane 1- 4) and apoC-III (lane 5 - 8). Lanes 1 and 5, Control; Lanes 2 and 6, 
Patient A; Lanes 3 and 7, Patient B; Lanes 4 and 8, Patient C; Lane 9, Sialidase treated sample from patient A; 0-7 in the 
TIEF profiles corresponds with the number of terminal sialic acid residues on the N-glycans of transferrin; 0-2 in the apoC-III 
profile correspond with the number of terminal sialic acid residues on the core 1 O-glycan on apoC-III. The relative amounts 
of the bands are listed in Table 2.  
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summarized in table 2A. Patient A had increased relative amounts of hexa- and heptasialo 
transferrin and in patients B and C the heptasialo transferrin isoform was only very slightly 
increased. Polymorphisms in the amino acid sequence changing the isoelectric point of 
transferrin isoforms (thus causing an abnormal TIEF profile) were excluded by incubation of the 
samples with sialidase25. This removes the negatively charged terminal sialic acid residues. After 
sialidase treatment all transferrin isoforms migrated to the asialo position, indicating that changes 
in sialic acid content had been responsible for the abnormal profiles (data not shown). 
 
Isoelectric focusing of plasma apoC-III 
 
In all 3 Sialuria patients, a clear hypersialylation profile was found for plasma apoC-III (Figure 2, 
lanes 5-8 and table 2B). The 3 apoC-III isoforms, apoC-III0, apoC-III1 and apoC-III2, correspond 
to the asialo, the monosialo and disialo fraction of the protein respectively. The apoC-III profiles 
showed an increase of the relative proportions of apoC-III2 and a decrease of the relative amount 
of apoC-III1 in all 3 patients. Polymorphisms in the amino acid sequence causing abnormal apoC-
III profiles were excluded by incubation of the samples with neuraminidase to remove the 
negatively charged terminal sialic acid residues18. After neuraminidase treatment all apoC-III 
isoforms migrated to the apoC-III0 position, indicating that changes in sialic acid content had 
been responsible for the abnormal profiles (data not shown).  
 
HPLC of total plasma N-glycans 
 
In Figure 3A the normal phase HPLC (NP-HPLC) chromatograms are shown of total plasma N-
glycans for a control versus the 3 Sialuria patients. Peaks 1 - 10 are neutral N-glycans lacking 
terminal sialic acid residues. Peaks 11 - 22 correspond to sialic acid containing N-glycans. No 
increase was observed in the total sialylation level of N-linked glycans in plasma of the 3 Sialuria 
patients. The relative amounts and the corresponding structures of the peaks detected with NP-
HPLC are listed in Table 3A. There were some differences in relative amounts of some of the 
individual N-glycan structures in comparison to controls. Patients A and B for example showed 
increased amounts of the fully sialylated biantennary N-glycan structure (peak 16), while patient 
C had an increase of the fully sialylated fucosylated biantennary N-glycan structure (peak 17). 
For all 3 Sialuria patients, however, the relative amounts of total fully sialylated biantennary N-
glycan structures were within the control range. 
 
HPLC of total plasma O-glycans 
 
In Figure 3B the NP-HPLC chromatograms of total plasma O-glycans are shown for a control and 
for the 3 Sialuria patients. A blank run shows the contamination peak at the position of the asialo 
core 1 O-glycan (Galβ1-3GalNAc). This contamination peak is consistent in all samples and 
accounts maximally for about 20% of peak 1. The relative amounts and the corresponding 
structures of the peaks detected with NP-HPLC are listed in Table 3B. Peak 2 (NeuAcα2-3Gal) is 
the peeling product induced by the O-glycan hydrazinolysis. In the 10 controls, the 
monosialylated fractions (peaks 2, 3 and 4) accounted for the majority of the O-glycans with a  
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Figure 3A.  
NP-HPLC profiles of total plasma N-
glycans of control versus Sialuria 
patients A, B and C. The relative 
amounts and the corresponding 
structures of the peaks are listed in 
Table 3A. 
 
 
Figure 3B.  
NP-HPLC profiles of total plasma O-
glycans of control versus Sialuria 
patients A, B and C. The blank run 
shows a small contamination peak 
(peak assigned with *1) with similar 
retention time as peak 1 in total 
plasma chromatograms. The relative 
amounts and the corresponding 
structures of the peaks are listed in 
Table 3B. *2 represents an aspecific 
peak. 
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Table 3A. Summary of the relative percentages of neutral N-linked glycans from total plasma proteins detected by NP-
HPLC.Amounts of each N-glycan presented as percentage of total N-linked glycans (peaks 1-22 = 100%). The reference 
values for total plasma N-glycans are from 10 healthy volunteers (adults and children). The corresponding NP-HPLC 
chromatogram is shown in Figure 3A. 
Percentage area 
Control Patients 
Peak no. Name Structure GU 
 
Mean (SD) Range A B C 
  5.9 2.1 (1.0) 0.9 – 4.1 1.5 0.7 1.6 1 FcA2
 
  2 FcA2B 6.2 0.8 (0.7) 0.1 – 1.9 2.6 2.2 2.0 
 
  
3 FcA2[6]G 6.6 2.7 (1.0) 1.8 – 4.8 4.5 1.1 2.8 1
 
  4 FcA2[3]G1
 6.8 1.7 (0.4) 1.2 – 2.5 0.7 0.5 1.1 
  5 FcA2B[6]G1
 
  
6 FcA2B[3]G 6.9 1.4 (0.4) 1.0 – 2.0 1.4 1.1 1.4 1
 
  
7.1 2.7 (0.8) 1.0 – 3.4 4.0 4.0 2.3 7 A2G2
 
 
8 A2BG 7.3 1.2 (0.4) 0.5 – 2.0 2.6 0.8 0.1 2
 
  9 FcA2G 7.5 4.8 (1.2) 3.4 – 7.0 4.0 4.2 6.7 2
 
  10 FcA2BG 7.6 2.9 (0.9) 1.8 – 4.7 1.1 0.9 1.1 2
 
Name abbreviations: all N-glycans have 2 core GlcNAcs and 3 Man; Fc, core fucose linked α 1-6 to inner GlcNAc; Ax, 
number of antenna on core; B, bisecting GlcNAc linked β 1-4 to inner mannose; Gx, number of galactose on antenna; Sx, 
number of sialic acids on antenna; GU, glucose units.  
* These are presumed structures. Exoglycosidase digestions did not fully confirm these structures. 
 
Symbols: GlcNAc; Gal;Man; NeuNAc; Fuc
 
mean percentage of 74.2 % of total O-glycans; the disialo core 1 O-glycan (peak 5) is 13.2% of 
total O-glycans, while only small amounts of Galβ1-3[NeuAcα2-6]GalNAc (peak 4) and 
disialylated core 2 O-glycan (peak 6) were detected. In the 3 Sialuria patients, the relative 
amounts of the disialylated core 1 O-glycan (peak 5) is clearly increased, while the relative 
11.5% in the 3 Sialuria patients. This results in a ratio disialylated / monosialylated core 1 O-
glycans of approximately 1.5 – 1.9 times the upper reference range in the 3 Sialuria patients and 
corresponds to the hypersialylation that we found by apoC-III IEF. A more closer look at the 
relative values of the individual monosialylated structures shows clearly that peak 3 is decreased 
in patients A and B, while peak 4 with an α2,6-linked NeuAc residue is 1.4 – 2 times increased in 
all Sialuria patients. This suggests that an increased α2,6-sialylation mainly causes the increase 
of the disialylated core 1 O-glycan. The relative amounts of the asialo core 1 O-glycan and also 
of the disialylated core 2 O-glycan seems to be at about the same level in the Sialuria patients.  
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Discussion 
 
 
Sialuria patients have an increased sialylation of the core 1 O-glycan on plasma apolipoprotein 
C-III. Increased sialylation was also found for total plasma O-glycans after hydrazinolysis. 
Hypersialylation of plasma proteins in this inborn error of metabolism may be readily explained  
by increased intracellular CMP-NeuAc levels. The bifunctional enzyme GNE / MNK, defective in 
Sialuria, is the rate-limiting enzyme of CMP-NeuAc biosynthesis. CMP-NeuAc is formed from 
NeuAc. An enormous overproduction of NeuAc is the biochemical hallmark of the disease. It is 
therefore conceivable that this will result in increased amounts of intracellular CMP-NeuAc, the 
donor substrate for the sialylation of glycans. Our study shows that the relative amount of CMP-
NeuAc was indeed clearly increased in fibroblasts of patient C. CMP-NeuAc is synthesized in the 
nucleus from cytosolic NeuAc. It enters the lumen of the Golgi via specific antiporters. Inside the 
Golgi, specific sialyltransferases use CMP-NeuAc to attach NeuAc at the termini of N- and O-
glycans26,27. Our data show a clear hypersialylation of O-glycans, but only minor changes on N-
glycans. For apoC-III, which carries a core 1 O-glycan, the disialylated apoC-III2 amounted to 63 
and 72% in the Sialuria adults and to 78% in the Sialuria child, while this isoform accounts for 23-
50% in healthy adults and for 27-60% in healthy children, respectively. The analysis of total 
plasma O-glycans showed a similar overrepresentation of disialylated core 1 O-glycans with a 
clearly abnormal ratio of disialylated over monosialylated core 1 O-glycans. Especially the 
amounts of core 1 O-glycans carrying the α2,6- bound NeuAc were clearly increased.  
The pathogenesis of Sialuria is largely unknown. Until this study, the only biochemical 
abnormalities detected have been the extremely high levels of free sialic acid in the cytoplasm of 
cells and in urine. CMP-NeuAc levels were found to be normal as analyzed by Seppala et al.1 
and Thomas et al.28. Analysis of total protein-bound sialic acid levels were determined before by 
Seppala et al. and Thomas et al.1,28 and were then found to be normal. Our study now indicates 
an increase of CMP-NeuAc levels in an assay for detecting isolated nucleotide sugars and a 
specific increase of α2,6-linked NeuAc residues in plasma protein-linked O-glycans. In previous 
studies these subtle effects could have been overlooked since only total protein sialylation was 
investigated. The total effect of the increase in protein O-glycan sialylation, however, is not as 
pronounced as the increase of free NeuAc. Seemingly, the biosynthesis of core 1 O-glycans and 
specifically of N-glycans is highly controlled. The biosynthesis routing from free NeuAc to bound 
NeuAc involves many steps. Firstly, NeuAc has to be converted to CMP-NeuAc, subsequently 
CMP-NeuAc has to be transported to the Golgi by a specific CMP-NeuAc transporter with a 
probable limited transport rate and finally specific sialyltransferases with their own KM have to 
attach the sialic acid residue to the protein. Subsequently, the CMP-NeuAc transporter is an 
antiporter, which means that CMP-NeuAc import into the Golgi is coupled to the equimolar export 
of CMP-residues. Because CMP is an inhibitor for sialyltransferases, the sialylation rate itself 
also has an influence on the influx of CMP-NeuAc and consequently on the concentration of this 
substrate in the Golgi29. 
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Table 3B. Summary of the relative percentages of sialylated N-linked glycans from total plasma proteins detected by NP-
HPLC. Amounts of each N-glycan presented as percentage of total N-linked glycans (peaks 1-22 = 100%). The reference 
values for total plasma N-glycans are from 10 healthy volunteers (adults and children). The corresponding NP-HPLC 
chromatogram is shown in Figure 3A. 
Percentage area 
Control Patients 
Peak 
No. Name Structure GU 
 
Mean (SD) Range A B C 
11 A2G2S1
 
 
 
8.0 10.2 (3.5) 6.4 – 16.4 15.1 17.8 12.2 
12 A2BG2S1
 
8.2 2.2 (1.5) 0.5 – 4.1 1.8 0.5 1.2 
13 FcA2G2S1
 
8.4 8.4 (2.3) 5.5 – 12.2 4.7 8.6 11.7 
14 FcA2BG2S1
 
8.6 4.8 (0.9) 3.3 – 5.9 3.6 1.2 3.9 
15 A2G2S2
 
16 A2BG2S2
  
 
8.9 27.5 (3.0) 24.0 – 33.1 34.9 37.8 29.5 
17 FcA2G2S2
 
 
9.2 5.7 (0.9) 4.4 – 7.4 5.4 7.6 11.3 
18 FcA2BG2S2
 
 
9.3 7.8 (2.2) 4.2 – 10.9 3.5 3.2 4.6 
19* A3G3S2
 
 
9.8 4.6 (2.5) 1.3 – 8.2 1.6 1.6 1.1 
20 A3G3S3
 
 
10.1 4.2 (1.6) 1.5 – 6.3 4.7 3.8 3.3 
21* FcA3G3S3
  
 
10.4 1.4 (1.3) 0.2 – 4.3 1.0 0.7 0.8 
22* FcA3BG3S3
  
 
10.7 2.8 (0.9) 1.2 – 4.0 1.3 1.7 1.2 
Total sialylation (%) 79.5 (3.9) 72.8 – 85.0 77.5 84.5 80.7 
Total mono-sialylated biantennary (%) 25.6 (4.4) 20.6 – 33.2 25.3 28.2 29.0 
Total di-sialylated biantennary (%) 40.9 (4.1) 33.6 – 48.6 43.8 48.6 45.4 
Total sialylated tri-antennary (%) 13.0 (4.7) 6.0 – 19.3 8.5 7.7 6.3 
Name abbreviations: all N-glycans have 2 core GlcNAcs and 3 Man; Fc, core fucose linked α 1-6 to inner GlcNAc; Ax, 
number of antenna on core; B, bisecting GlcNAc linked β 1-4 to inner mannose; Gx, number of galactose on antenna; Sx, 
number of sialic acids on antenna; GU, glucose units.  
* These are presumed structures. Exoglycosidase digestions did not fully confirm these structures. 
Symbols: GlcNAc; Gal;Man; NeuNAc; Fuc
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The genetic defect in Sialuria mainly influences the incorporation of NeuAc in core 1 O-glycans 
and not so much into N-glycans. The opposite has been observed before in another inborn error 
in this pathway. A decrease in CMP-NeuAc biosynthesis in hereditary inclusion body myopathy 
(hIBM, OMIM 600737) leads to hyposialylated core 1 O-glycans, while also the sialylation level of 
N-glycans is seemingly unaffected30. Hypersialylation of O-glycans has been described before in 
relation to cancer, due to the increase of both α2,3- and α2,6-linked sialic acid residues31. To our 
knowledge Sialuria is the first example of an inborn error of metabolism resulting in the 
hypersialylation of plasma O-linked glycans.  
 
The specific increase in core 1 O-glycan α2,6-sialylation and not in core 1 O-glycan α2,3-
sialylation or in N-glycan sialylation, may relate to individual KM for CMP-NeuAc of 
sialyltransferases. The human sialyltransferase family consists of at least 15 members. So far, 3 
members of the human GalNAc-α2,6-sialyltransferases (ST6GalNAc I, II and IV) have been 
cloned and characterized. These transferases specifically catalyze the formation of α2,6-linkages 
onto GalNAc residues in mucin-type O-glycans. Human ST6GalNAc I exhibits the broadest 
specificity reacting with the Tn- and T-antigens and the α2,3-sialylated core 1 O-glycan. 
ST6GalNAc II only acts on the T-antigen and α2,3-sialylated core 1 O-glycan, whereas 
ST6GalNAc IV activity is restricted to α2,3-sialylated core 1 O-glycan as substrate. ST6GalNAc II 
and ST6GalNAc IV are known to be expressed in many tissues including the liver, whereas for 
ST6GalNAc I the tissue expression has not been examined26. The Gal-α2,3-sialyltransferases 
(ST3Gal transferases) in the liver act specifically on type 1 (Galβ1-3GalNAc) or type 2 (Galβ1-
4GlcNAc) epitopes. Thus, it is unlikely that the ST3Gal transferases involved in plasma protein 
N-glycan sialylation are involved in α2,3-sialylation of plasma protein core 1 O-glycans26. So, 
different sialyltransferases are responsible for N-glycan sialylation, O-glycan α2,3-sialylation and 
O-glycan α2,6-sialylation. It is known that the 2 ST6GalNAc transferases in liver tissue have a 
nearly 10 fold higher KM value for CMP-NeuAc than the ST3Gal I32-34. This higher KM could be the 
explanation for the increased α2,6-sialylation in Sialuria.  
The number of acceptor sites available for α2,6-sialic acid compared to the number of acceptor 
sites available for α2,3-sialic acid could also be an explanation for the specific increase of α2,6-
sialylation. For O-glycans, most acceptor sites are available for α2,6 sialylation (i.e. structure 3 is 
most abundant, Table 3B). However, if α2,3-sialylation would be increased, a decrease would be 
expected of the asialo core 1 O-glycan (structure 1, Table 3B). Subsequently, despite the fact 
that roughly 50% of the N-glycan structures have one or more NeuAc acceptor sites, no increase 
in total sialylation is observed. The decrease of the α2,3-monosialylated core 1 O-glycan 
(structure 3, Table 3B) and the increase of the α2,6-monosialylated core 1 O-glycan (structure 4, 
Table 3B) also suggest a specific increase of O-glycan α2,6-sialylation. 
Another possible explanation for the differential influence of the Sialuria defect on N-glycan and 
O-glycan sialylation may derive from differences in the transport of CMP-NeuAc to the Golgi. The 
Golgi localization of N-glycan sialyltransferases differs from the localization of core 1 O-glycan 
sialyltransferases. The N-glycan sialyltransferases are localized in the trans Golgi network 
(TGN), while the core 1 O-glycan sialyltransferases are distributed in a separate Golgi 
compartment proximal to the TGN35. It is not known how CMP-NeuAc is delivered to the sites  
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Table 3B. Summary of the relative percentages of O-linked glycans from total plasma proteins and detected by NP-HPLC. 
Amounts of each O-glycan presented as percentage of total O-linked glycans. The reference values for total plasma O-
glycans are from 10 healthy volunteers (adults and children). Structures were assigned by reference to a GU database 22 in 
conjunction with a range of exoglycosidase digestions. The corresponding NP-HPLC chromatogram is shown in Figure 3B. 
Percentage area 
 
Children (n=5) Adults (n=5) Patients Peak 
no. GU Name Structure Mean (SD) Range Mean (SD) Range A3 B4 C4
Core 1 O-glycans  
 1 1.801 9 (1) 9 – 11 11 (2) 8 – 14 8 8 10Galβ1-3GalNAc
 
 2 2.30 11 (4) 6 - 18 16 (2) 14 – 18 17 12 5 NeuAcα2-3Gal
 
 
61 (3) 59 – 64 57 (3) 54 – 61 46 47 563 2.98 NeuAcα2-3Galβ1-3GalNAc
 
 
1.6 (0.3) 1.3 – 2.0 1.4 (0.1) 1.3 – 1.6 2.3 3.1 2.94 3.28 Galβ1-3[NeuAcα2-6]GalNAc
 
 
NeuAcα2-3Galβ1-3[NeuAcα2-
6]GalNAc5 4.44
2 14 (2) 11 – 17 12 (1) 11 – 13 25 28 24
 
Core 2 O-glycans  
 
6 5.42 NeuAcα2-3Galβ1-4GlcNAcβ1-6  2.7 (0.3) 2.4 – 3.1 1.9 (0.3) 1.5 – 2.1 2.1 1.7 3.0  [NeuAcα2-3Galβ1-3]GalNAc
Ratio disialylated / monosialylated core 1 O-glycans  
0.20 0.15-0.24 0.16 0.14-0.18 0.38 0.45 0.37(peak 5 / (peak 2+3+4)) 
 
1 This peak also contains about 20% background contamination (see bottom panel of Figure 3B); 2 Small amounts of 
monosialylated core 2 will be obscured by this large peak of disialylated core 1; 3This patient is a child; 4This patient is an 
adult;  
Symbols:  GalNAc Gal NeuAc GlcNac 
 
where sialylation occurs. The different Golgi compartments may share the same CMP-NeuAc 
transporter that functions differently in the distinct compartments. Alternatively, the different Golgi 
compartments could have specific CMP-NeuAc transporters. Both models could help to explain 
the different susceptibility of N- and O-glycan biosynthesis for decreased CMP-NeuAc levels (as 
seen in hIBM;36) and for increased CMP-NeuAc levels as seems to be the case in Sialuria. 
Separate CMP-NeuAc transporters for the different Golgi compartments would also explain the 
normal plasma N-glycan sialylation levels and abnormal sialylated core 1 O-glycan levels 
observed in plasma from CDG-IIf patients who have a deficient CMP-NeuAc transporter37.  
We prefer the ‘affinity model’ as it can explain both the difference between N- and core 1 O-
glycan sialylation as well as the increased amounts of α2,6-linked NeuAc residues in O-glycans 
observed in plasma of the 3 Sialuria patients. Subsequently, only 1 CMP-NeuAc transporter has 
been described to date and no literature is known that describes a nucleotide sugar transporter 
that functions differentially in distinct locations.  
In summary, the genetic defect in Sialuria results in an overproduction of free cytoplasmic NeuAc 
and may also result in an overproduction of cytoplasmic CMP-NeuAc shown in fibroblast of 
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patient C. The genetic defect led to increased α2,6-linked NeuAc in plasma core 1 O-glycans, 
whereas the sialylation of N-glycans only showed minor changes. The reported abnormalities 
may offer a new perspective for investigating the pathogenesis of the clinical phenotype in 
Sialuria patients.  
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Summary 
 
 
Glycosylation is the enzymatic addition of carbohydrates to proteins and lipids. It is a common 
and complex type of post-translational modification. The 2 most abundant mammalian protein 
glycan types are N-glycans, linked by a beta linkage between the anomeric carbon of N-
acetylglucosamine and the amido-group of L-asparagine, and O-glycans, linked to the hydroxy 
group of serine, threonine or lysine. Defects in the N-glycan biosynthesis pathway are known as 
Congenital Disorders of Glycosylation (CDG) and are grouped as CDG-I and CDG-II according to 
the localization of the deficient protein. IEF of the glycoprotein transferrin is generally used as a 
screening assay for defects in the biosynthesis of N-linked glycans. N-glycosylation has been 
studied extensively in health and disease, whereas defects in the biosynthesis of protein-linked 
O-glycans were largely ignored in the field of inborn errors of metabolism. This thesis deals with 
the role of protein-linked mucin-type O-glycans in inborn errors of metabolism. Mucin-type O-
glycans, initiated by attachment of an N-acetylgalactosamine residue, are the most common type 
of O-linked glycans in mammals. 
An introduction on N-glycosylation and CDG is given in chapter 1 of this thesis. Chapter 2 deals 
with the general mechanisms of protein O-glycan biosynthesis and reflects our current 
knowledge about diagnosis, clinical manifestations and molecular genetic aspects of known 
protein O-glycan biosynthesis defects. The rest of the thesis is divided into 2 parts. In Part I 
(chapters 3-5) methodological studies are described that have been performed to improve the 
biochemical diagnosis of biosynthesis defects in protein-linked O-glycans. In part II (chapters 6-
8) studies are described that highlight the clinical aspects of defects in the biosynthesis of 
protein-linked (N- and) mucin-type core 1 O-glycans. 
 
Part I: Methodological studies 
 
In chapter 3 of this thesis, we describe the development of a first approach to screen for 
biosynthesis defects in mucin-type core 1 O-glycans. The technique relies on isoelectric focusing 
of plasma apolipoprotein C-III, a glycoprotein that carries a single O-glycan (core 1 mucin-type 
O-glycan containing N-acetylgalactosamine, galactose and sialic acid residues). We show that 
the test is helpful in the elucidation of patients with an unsolved CDG defect. We provide 
evidence that a patient in this study has an unsolved primary genetic defect affecting both N- and 
O-glycosylation. The options for the primary defect in this patient are narrowed down to those 
steps that are shared by the N- and mucin-type core 1 O-glycan biosynthesis pathways. Plasma 
apolipoprotein C-III isofocusing may play a role in the laboratory screening for mucin-type core 1 
O-glycan biosynthesis defects, similar to the role of transferrin isofocusing in the biochemical 
diagnosis of N-glycan biosynthesis defects. 
Chapter 4 describes the use of TIEF in combination with SDS-PAGE and IEF of apoC-III to 
provide a biochemical classification for CDG patients. We studied plasma material from 22 
patients with 8 different and well characterized CDG-I and CDG-II subtypes and 19 cases with 
unsolved CDG-I and CDG-II and show that CDG-II patients can be subdivided in 6 biochemical 
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subgroups. The robustness of the methodology is supported by the fact that 3 patients with 
similar clinical features ended up in the same subgroup. Also another patient with an unsolved 
CDG type was checked for the COG protein complex, because the patient ended up in the same 
subgroup as a patient with CDG-IIe (with deficiency of subunit 7 of the COG-complex). Finally, 
this patient could be diagnosed with a similar defect as the CDG-IIe patient (deficiency of another 
subunit of the COG complex). Dividing the patients with an unsolved CDG-II in subgroups 
narrows down drastically the options for the primary defect in each of the subgroups and will be 
helpful to define new CDG type II defects.  
Chapter 5 gives an overview of the use of the apoC-III IEF assay in the detection of congenital 
disorders of glycosylation. It investigates different patient groups (patients with primary defects in 
the glycosylation, patients with secondary N-glycosylation defects, patients expected to have 
glycosylation abnormalities and 500 plasma samples that have been sent to the laboratory for 
the selective screening on inborn errors of metabolism). The study shows specific primary and 
secondary glycosylation defects that cause alterations in the core 1 mucin-type O-glycan 
structure. Furthermore, we provide evidence that 3 patients found in the selective screening on 
inborn errors of metabolism are likely to have an isolated biosynthesis defect in core 1 mucin-
type O-glycans. This is the first study diagnosing patients with an isolated O-glycan biosynthesis 
defect by making use of an O-glycan marker protein in blood plasma. It shows the usefulness of 
the apoC-III IEF technique and demonstrates that it is complementary to the transferrin IEF test 
in the detection of patients with congenital disorders of glycosylation.  
 
Part II: Clinical studies 
 
Using the apoC-III IEF assay, new categories of patients could be identified with a congenital 
disorder of glycosylation. In chapter 6, we have identified a novel form of CDG with a combined 
defect in the biosynthesis of N- and O-glycosylation. We describe 3 children with a distinct 
clinical phenotype presenting with a cutis laxa syndrome, skeletal and joint involvement, 
developmental delay and neurological findings. For the first time, an abnormal glycosylation is 
implicated in the etiology of cutis laxa.  
In chapter 7, we illustrate the biochemical characteristics of the 3 patients with autosomal 
recessive cutis laxa described in chapter 6. Transferrin IEF and apoC-III IEF showed that these 
patients have a defect in the biosynthesis of N- and mucin-type core 1 O-glycans. By application 
of mass spectrometric N-glycan analyses we demonstrate a relative increase of glycans lacking 
sialic acid and glycans lacking sialic acid and galactose residues. Evidence is presented that 
extracellular matrix proteins of skin are likely to be highly glycosylated with N- and mucin-type O-
glycans. Mutation analysis excluded a defect in the FBLN5 gene as an underlying cause for the 
disease in our patients. We conclude that the clinical phenotype of the described cutis laxa 
patients is likely caused by a defect localized in the sialylation and/or galactosylation of N- and 
O-glycans. Improper glycosylation of extracellular matrix proteins may form the 
pathophysiological basis of the cutis laxa phenotype.  
In chapter 8, we investigated the role of fibroblast CMP-sialic acid levels and N- and O-glycan 
sialylation of plasma proteins from Sialuria patients. Sialuria patients have a genetic defect 
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localized in the biosynthesis routing of CMP-sialic acid. The defect results in a loss of feedback 
control of the defective protein by CMP-sialic acid, which results in a substantial overproduction 
of cytoplasmic free sialic acid. We show that CMP-sialic acid is also overproduced in fibroblasts 
of a Sialuria patient, resulting in hypersialylated plasma core 1 O-glycans, but normal sialylation 
levels of plasma N-glycans in 3 Sialuria patients. The hypersialylation of core 1 O-glycans is due 
to the increase of NeuAcα2,6-containing structures. Sialuria is the first metabolic disorder 
presenting with hypersialylated O-glycans. The hypersialylation may contribute to the 
pathophysiology in Sialuria. 
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Samenvatting 
 
 
Glycosylering is de enzymatische aanhechting van oligosacchariden aan eiwitten en lipiden. Het 
is een veel voorkomende en complexe post-translationele modificatie. De 2 glycosyleringstypes 
die het meest voorkomen op eiwitten in zoogdieren zijn N-glycanen, die via een bètabinding van 
N-acetylglucosamine aan de amidogroep van asparagine gebonden zijn, en O-glycanen, die via 
de hydroxygroep van serine, threonine of lysine gebonden zijn. Defecten in de N-glycosylering 
staan bekend als ‘Congenitale Defecten in de Glycosylering’ (CDG) en kunnen verdeeld worden 
in CDG-I en CDG-II op basis van de locatie van het defecte eiwit. In het algemeen wordt 
isoelektrische focusering (IEF) van het glycoproteïne transferrine toegepast als 
screeningstechniek voor het opsporen van defecten in de biosynthese van N-glycanen. Binnen 
het veld van erfelijke stofwisselingsziekten is de rol van N-glycanen uitgebreid onderzocht in 
relatie tot gezondheid en ziekte, dit in tegenstelling tot O-glycosyleringsdeficiënties. In dit 
proefschrift wordt de rol van eiwitgebonden mucine-type O-glycanen bestudeerd in erfelijke 
stofwisselingsziekten. Mucine-type O-glycanen, waarbij een N-acetylgalactosamine als eerste 
aan het eiwit gebonden wordt, vormen het type O-glycaan dat het meest voorkomt in zoogdieren.  
Hoofdstuk 1 van dit proefschrift introduceert de N-glycaan biosynthese en CDG. Hoofdstuk 2 
beschrijft de algemene mechanismen van de O-glycaan biosynthese en reflecteert onze huidige 
kennis over diagnose, klinische manifestatie en moleculair genetische aspecten van bekende O-
glycaan biosynthese defecten. Het overige deel van dit proefschrift is onderverdeeld in 2 delen. 
In deel I (hoofdstukken 3-5) worden methodologische studies beschreven die uitgevoerd zijn ter 
verbetering van de diagnostiek van eiwitgebonden O-glycaan biosynthese defecten. Deel II 
(hoofdstukken 6-8) beschrijft klinische studies waarbij de nadruk ligt op de klinische aspecten 
van defecten in de biosynthese van eiwit gebonden (N- en) mucine-type core 1 O-glycanen.  
 
Deel I: Methodologische studies 
 
In hoofdstuk 3 van dit proefschrift beschrijven we de ontwikkeling van een eerste 
screeningsmethode voor defecten in de biosynthese van mucine-type core 1 O-glycanen. De 
techniek is gebaseerd op isoelectrische focusering van het plasmaeiwit apolipoproteïne C-III, een 
glycoproteïne dat één O-glycaan bevat (een mucine-type core 1 O-glycaan bestaande uit N-
acetylgalactosamine, galactose en siaalzuur residuen). We laten zien dat de test kan bijdragen 
aan het oplossen van het primaire gendefect in patiënten met een onopgelost CDG. We tonen 
aan dat het primaire defect van een patiënt, onderzocht in deze studie, zowel de N- als de O-
glycosylering aantast. De opties voor het primaire defect worden in deze patiënt gereduceerd tot 
stappen die gedeeld worden door zowel de biosynthese route van N- als van de mucine-type 
core 1 O-glycaan. Binnen het metabole laboratorium zou de plasma apoC-III IEF bepaling een 
gelijkwaardige rol kunnen gaan spelen in de screening van defecten in de biosynthese van 
mucine-type core 1 O-glycanen als transferrine IEF in de huidige biochemische diagnose van N-
glycaan biosynthese defecten.  
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Hoofdstuk 4 beschrijft het opzetten van een biochemisch classificatie systeem voor CDG 
patiënten met behulp van transferrine IEF in combinatie met SDS-PAGE en IEF van apoC-III. 
Daarvoor hebben we plasma materiaal geanalyseerd van 22 patiënten met 8 verschillende CDG-
I en CDG-II subtypes, aangevuld met plasma afkomstig van 19 patiënten met onopgelost CDG-I 
en CDG-II. We tonen aan dat CDG-II patiënten in 6 verschillende biochemische groepen 
onderverdeeld kunnen worden. De robuustheid van de methode wordt ondersteund door het feit 
dat 3 patiënten met soortgelijke klinische symptomen in dezelfde subgroep onderverdeeld 
worden. Tevens hebben we bij een patiënt met onopgelost CDG-II type het COG eiwitcomplex 
na laten kijken, omdat deze patiënt in dezelfde subgroep eindigde als een CDG-IIe patiënt 
(deficiëntie van subunit 7 van het COG-complex). In deze patiënt werd een soortgelijk defect 
gevonden als in de CDG-IIe patiënt (deficiëntie van een ander subunit van het COG 
eiwitcomplex). Het onderverdelen van CDG-IIx patiënten in 6 verschillende biochemische 
subgroepen reduceert drastisch het aantal opties voor het primaire defect in elke subgroep. Deze 
methode zal bruikbaar zijn bij het definiëren van nieuwe CDG-II defecten. 
Hoofdstuk 5 geeft een overzicht van het gebruik van de apoC-III IEF bepaling in de detectie van 
congenitale defecten in de glycosylering. Hierin worden verschillende patiëntengroepen 
onderzocht (patiënten met primaire defecten in de glycosylering, patiënten met secondaire N-
glycosyleringsdeficiënties, patiënten die verdacht worden van glycosyleringsafwijkingen en 500 
plasma monsters die naar het laboratorium zijn gestuurd voor de selectieve screening op 
erfelijke stofwisselingsziektes). Specifieke primaire en secundaire glycosyleringsdeficiënties zijn 
gevonden die veranderingen veroorzaken in de mucine-type core 1 O-glycaan structuur. Uit de 
selectieve screening van 500 plasma monsters vinden we 3 patiënten die waarschijnlijk een 
‘geïsoleerd’ defect hebben in de mucine-type core 1 O-glycaan. Voor het eerst worden patiënten 
diagnosticeerd met een ‘geïsoleerd’ O-glycaan biosynthese defect via het onderzoeik van een O-
geglycosyleerd plasma markereiwit. Het onderzoek toont aan dat de apoC-III IEF techniek nuttig 
en complementair is aan de transferrine IEF test in de detectie van patiënten met een 
congenitaal defect in de glycosylering.  
 
Deel II: Klinische studies 
 
Met behulp van de apoC-III IEF bepaling kunnen nieuwe patiëntencategorieën worden 
geïdentificeerd met een congenitaal defect in de glycosylering. Hoofdstuk 6 beschrijft een 
nieuwe vorm van CDG waarbij patiënten een gecombineerde deficiëntie hebben in de N- en O-
glycosylering. De 3 kinderen met een duidelijk onderscheidend klinisch fenotype vertonen een 
cutis laxa syndroom met betrokkenheid van het skelet en de gewrichten, een 
ontwikkelingsachterstand en neurologische afwijkingen. Het is de eerste keer dat een afwijkende 
glycosylering betrokken is in de etiologie van cutis laxa. 
Hoofdstuk 7 illustreert de biochemische karakteristieken van de 3 cutis laxa patiënten 
beschreven in hoofdstuk 7. IEF van transferrine en apoC-III toont de gecombineerde deficiëntie 
in de biosynthese van N- en mucine-type core 1 O-glycanen in de 3 patiënten. 
Massaspectrometrische analyses van plasma N-glycanen demonstreren een relatieve toename 
van zowel glycanen waarbij siaalzuur residuen ontbreken als glycanen waarbij siaalzuur en 
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galactose residuen ontbreken. Extracellulaire matrix eiwitten van de huid zijn waarschijnlijk in 
hoge mate geglycosyleerd met N- en mucine-type O-glycanen. Met behulp van mutatie analyse 
is het uitgesloten dat een defect in het FBLN5 gen de onderliggende oorzaak is van de 
aandoening in onze patiënten. We concluderen dat het klinische fenotype van de beschreven 
cutis laxa patiënten waarschijnlijk veroorzaakt wordt door een defect dat gelokaliseerd is in de 
sialylering en/of galactosylering van N- en O-glycanen. Een afwijkende glycosylering van 
extracellulaire matrix huideiwitten zou de pathofysiologische basis kunnen vormen van het cutis 
laxa fenotype. 
In hoofdstuk 8 onderzoeken we de rol van CMP-siaalzuur en de sialylering van plasma 
glycoproteïnes in de erfelijke stofwisselingsziekte Sialurie. Sialurie patiënten hebben een 
genetisch defect dat gelokaliseerd is in de biosynthese route van het CMP-siaalzuur. Het 
gendefect resulteert in het verlies van de feedback controle van het defecte eiwit door CMP-
siaalzuur, met als gevolg een overproductie van vrij siaalzuur in het cytoplasma. Wij laten zien 
dat ook CMP-siaalzuur wordt overgeproduceerd in fibroblasten van een Sialurie patiënt. Dit 
resulteert in hypergesialyleerde plasma core 1 O-glycanen, terwijl de sialylering van N-glycanen 
nagenoeg gelijk blijft. De hypersialylering van core 1 O-glycanen is het gevolg van een toename 
van O-glycaan structuren die α2,6 gebonden siaalzuur bevatten. Sialurie is de eerste metabole 
ziekte waarbij sprake is van hypergesialyleerde O-glycanen. De hypersialylering zou kunnen 
bijdragen aan de pathofysiologie van Sialurie.  
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